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The E3 ubiquitin ligase MDM2 is the most well-known physiological antagonist of the tumor 
suppressor P53. P53 induces cell cycle arrest or apoptosis in the case of DNA damage, 
whereas MDM2 targets it for proteasomal degradation during unstressed conditions. Loss of 
MDM2 in the murine organism is embryonically lethal but can be rescued by a concomitant 
loss of P53, which led to the assumption that MDM2’s only function is based on P53 
regulation. Still, several tumor species have been identified which are supported by high 
levels of MDM2 even in the absence of P53. 
In this project, we have analyzed a P53-independent and stemness maintaining function of 
MDM2 which supported the de-differentiation process of induced pluripotent stem (iPS) cells. 
It furthermore inhibited differentiation of mesenchymal stem cells (MSCs) into osteoblasts 
and accelerated clonogenic cancer cell survival in the absence of P53. In each system, loss 
of MDM2 resulted in the deregulation of Polycomb group (PcG) family target genes. The PcG 
consists of the two protein complexes, PRC1 and PRC2, and silences gene expression 
through methylation of histone H3K27 (PRC2) and ubiquitination of H2AK119 (PRC1), which 
is often essential for stemness maintenance and cancer cell survival. MDM2 directly 
interacted with the PRC2 proteins EZH2 and SUZ12 and was recruited to PcG target gene 
promoters through EZH2. On the chromatin, MDM2 enhanced H3K27me3 and H2AK119ub1 
which correlated to its gene regulatory function. H2AK119 is mainly ubiquitinated by the 
PRC1 protein RING1B. Loss of both E3 ligases, MDM2 and RING1B, decreased 
H2AK119ub1 levels and induced target gene expression further than the loss of each factor 
alone. Moreover, loss of RING1B and MDM2 was synthetically lethal in primary mouse- and 
cancer cells. 
A close homolog of the MDM2 protein is MDM4. MDM2 and MDM4 support each other in the 
regulation of P53 but they cannot compensate each other according to in vivo loss of function 
studies. Preliminary data in our setting indicated a similar gene regulatory and H3K27me3 
stabilizing function of MDM4 as detected for MDM2. 
Taken together, MDM proteins enhanced the repression of lineage specific genes in 
cooperation with the PcG family, in the absence of P53. Thus, the oncogenic function of 
MDMs is not limited to controlling P53, but extended to chromatin modification and a stem-





2.1 The MDM family – evolution, structure and functions 
Murine double minute 2 or MDM2 is one of the most frequently studied oncoproteins worldwide. 
In the following paragraphs MDM2 evolution and structure will be discussed and it will be 
explained how MDM2 got one of the most important targets of the pharmaceutical industry to 
fight cancer. 
2.1.1 MDM family structure and evolution 
As its full name already suggests, MDM2 was originally identified on double minute 
chromosomes from transformed mouse 3T3DM cells roughly 30 years ago (Cahilly-Snyder et al, 
1987). Double minutes are extrachromosomal DNA fragments that result from DNA 
amplification processes. MDM2 is not the only MDM protein; MDM4 (also known as MDMX) is a 
paralog of MDM2 that emerged from a gene duplication event around 440 M years ago 
(Momand et al, 2011; Shvarts et al, 1996). Both proteins are expressed in most vertebrate 
organisms whereas Drosophila and Caenorhabditis genomes do not encode any MDM 
sequences. This absence was long taken as reverse evidence that MDM proteins just classify to 
the vertebrates. However, recent studies identified coding sequences in several invertebrate 
organisms that resemble up to 27% of the human MDM2 (Momand et al, 2011). This makes it 
possible to trace back the MDM family for 1.5 billion years (Lane & Verma, 2012; Momand et al, 
2011). 440 M years of evolution caused some independent development, but overall, the 
structures of MDM2 and MDM4 are quite similar. Since my project mainly focused on MDM2, 
the upcoming chapters will address mostly MDM2 but some specific features of MDM4 will be 
highlighted as well. 
In jawed vertebrates the domain structure of MDM2 is highly conserved. In general, an acidic 
and a zinc finger domain are flanked by the aminoterminal P53-binding domain (Chen et al, 
1993; Kussie et al, 1996) and a carboxyterminal RING (really interesting gene) domain (cf. 
Figure 2-1) (Fang et al, 2000; Honda et al, 1997) Among these domains, the RING domain is 
the most conserved (Momand et al, 2011). In MDM2, the RING domain encodes the E3 
ubiquitin ligase function which is responsible for the mono- or polyubiquitination of several target 
proteins (cf. paragraphs 2.1.2.2 and 2.1.5.1) as well as MDM2 itself (Fang et al, 2000; Honda et 
al, 1997). Nuclear export and localization signal (NES/NLS) domains located between the P53-




finger domain are necessary for the interaction of MDM2 with multiple partners, influencing 
MDM2 posttranslational modifications, activity and function (cf. paragraph 2.1.3.2). 
The MDM proteins differ by length in only one amino acid (aa) (Figure 2-1) and share 31 % 
amino acid identity. Highest conservation between the two proteins was detected in the P53-
binding domain and the RING domain. MDM4 does not have intrinsic ubiquitin ligase activity. 
Instead, the RING domain promotes dimerization with MDM2 and was found to influence MDM2 









Figure 2-1 Domain structure of MDM2 and MDM4.  
The different domains of MDM2 and MDM4 are shown together with the respective flanking 
amino acids (Wienken et al, under review). 
 
2.1.2 P53 regulation by the MDM proteins 
 
MDM2 and MDM4 are the main physiological antagonists of the tumor suppressor P53. The 
following paragraphs will introduce the MDM-P53 network and explain its importance. 
2.1.2.1 The tumor suppressor P53 
The P53 tumor suppressor, encoded by the TP53 gene on chromosome 17p13.1, is one of the 
most studied proteins worldwide because of its significant role during tumor development and 
progression. Originally described in 1979 by Levine et al and Lane and colleagues as a 54 kDa 
protein which interacts with the SV40 large T antigens (Lane & Crawford, 1979; Linzer & Levine, 
1979), P53 reactivation in a tumor is now the common goal of most future cancer therapies 
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(Wade et al, 2013). Together with its family member p73 and p63, P53 is the main mediator of 
cell cycle arrest and apoptosis in any case of cellular stress. It ensures proper heritage of the 
genomic information onto arising daughter cells and protection against accumulation of 
oncogenic mutations (Levrero et al, 2000).  
In unstressed cells, P53 levels and activity are tightly controlled via numerous mechanisms, 
including the regulation by the MDM protein family as outlined in 2.1.2.2 (Gu & Zhu, 2012). 
Upon genotoxic stress e.g. via UV radiation, P53 is posttranslationally modified especially via 
phosphorylation and acetylation, leading to its stabilization, accumulation and activation (for 
illustration see also Gu et al, 2012). When activated, P53 can assemble as a homo-tetramer 
and bind to specific DNA binding sites, leading to the transactivation of genes involved in cell 
cycle arrest-, DNA repair, senescence and apoptosis (cf. Figure 2-2). The classic and probably 
most well-known target of P53 is the CDKN1A gene encoding the cyclin dependent kinase 1A 
(also known as p21), which mediates induction of G1 cell cycle arrest (El-Deiry et al, 1993). 
Several outstanding reviews have tried to gather published data (22,000 publications on 
PubMed only in the last 5 years) on the functions of P53 (Oren, 2003; Vogelstein et al, 2000; 
Vousden, 2000).  
 
Figure 2-2 The regulation of P53 by MDM2 and its potential for cancer drug development.  
MDM2 targets P53 for proteasomal degradation in an unstressed cell. Upon cell stress, P53 
gets activated leading to the induction of target genes. Reactivation of wt p53 functions in 





2.1.2.2 P53 regulation by MDM2 and MDM4 
5 years after the first description of MDM2, a paper published by Arnold Levine and colleagues 
described the first interaction of MDM2 with the tumor suppressor P53. To that point, P53 had 
gained a lot of scientific interest but a major associated regulatory pathway was still lacking. 
Levine targeted this question by analyzing interaction partners of P53 and came across the p90 
protein. Purification processes revealed that p90 was already described as the MDM2 protein 
important in murine fibroblast transformation and further analyzes identified its ability to 
abrogate P53 mediated cell cycle regulation functions (Momand et al, 1992). It took yet another 
5 years to understand the main function of this interaction and new aspects of the P53 
regulation by the MDM family are still getting published.  
Haupt and Oren published in 1997 that MDM2 directly mono- and polyubiquitinates P53 and 
therefore targets it for proteasomal degradation (cf. Figure 2-2) (Haupt et al, 1997). As most 
embryonic and adult cells do not produce high wt P53 protein levels, proteasomal degradation 
explained the considerably high levels of P53 mRNA (Marine et al, 2006). Less well defined in 
the scientific community is the extent of MDM2 specific ubiquitination of P53. Degradation by 
the proteasome is dependent on Lysine 48-linked polyubiquitination of multiple lysines in the 
P53 C-terminus (amongst them are e.g. K370, K372, K373, K381, K382, and K386) (Michael & 
Oren, 2003). Depending on its expression levels, MDM2 is able to both, mono- and 
polyubiquitinate P53. P53 is monoubiquitinated when MDM2 is present in a low concentration 
and this modification rather seems to mediate nuclear export than decay (Li et al, 2003). On the 
other hand, high abundance of MDM2 leads to P53 polyubiquitination (Li et al, 2003). Due to 
this discrimination in MDM2 levels, it was discussed whether MDM2 might also need additional 
help in the elongation of ubiquitin chains on P53. p300 was speculated to be a possible 
candidate for this function although this is still under investigation (Grossman et al, 2003). 
Next to its ubiquitination function, MDM2 can directly bind an α-helix in the P53 transactivation 
domain through its P53-binding domain and thereby inhibit the interaction of P53 with the basal 
transcription machinery (Momand et al, 1992; Oliner et al, 1993). This hypothesis was 
supported in vitro by the inability of an MDM2 mutant, lacking parts of the P53 binding domain, 
to efficiently inhibit P53 transactivation function (Haines et al, 1994). Although the data looked 
promising, recent in vivo studies in genetically engineered mouse models so far failed to directly 
support the theory that MDM2 masks P53 transactivation (Francoz et al, 2006; Toledo et al, 




rich domain which had decreased transactivation activity. When introduced into the Mdm2-/- 
mouse the p53ΔP was not able to rescue embryonic lethality (see also paragraph 2.1.4). 
 
In contrast to MDM2, the regulatory pattern of P53 by MDM4 is less well defined. So far, it is 
known that MDM4 does not ubiquitinate P53 because it does not contain any intrinsic E3 ligase 
function. MDM4 rather builds up heterodimers with MDM2 via their RING domains and 
enhances MDM2 ubiquitination of P53 (Linares et al, 2003). Quite recent data also indicates 
that heterodimerization of MDM2 with MDM4 changes MDM2 function from mono-ubiquitination 
to poly-ubiquitination (Wang & Jiang, 2012). Like MDM2, MDM4 is also able to mask the P53 
transactivation domain and ablate the assembly of a functioning transcription machinery. In 
contrast to MDM2, this hypothesis also was supported by in vivo data, since overexpression of 
p53ΔP (see paragraph before) rescued the Mdm4-/- phenotype (Francoz et al, 2006; Toledo et al, 
2006). 
 
2.1.3 Pre- and posttranslational regulation of MDM2 
According to the human protein atlas (http://www.proteinatlas.org/) and the Universal Protein 
Resource database (www.uniprot.org/) the MDM2 protein is detected especially in the nuclear 
compartment of a cell. It is highly expressed in embryonic stem cells and only to low extent in 
developed tissues (data generated by Northern Blot; tissue array data on MDM2 protein 
expression controversial, due to the presence of many unspecific antibodies used) (Montes de 
Oca Luna et al, 1995). By regulating the tumor suppressor P53, a tight regulation of MDM2 
expression and activity is needed to ensure cell proliferation under normal conditions and p53 
release during cell stress situations.  
2.1.3.1 Transcriptional regulation of MDM2 
MDM2 expression is regulated through the two distinct promoters, P1 and P2. P1 mediates 
constant basal expression whereas P2 is highly regulated and responsible for dynamic 
expression changes (Barak et al, 1994). In fact, one main transcription factor activating MDM2 
expression through the P2 promoter is P53 itself (cf. Figure 2-2) (Wu et al, 1993). It is thereby 
ensured that P53 induced cell cycle arrest and apoptosis induction is reversed after P53 
activation. This so called autoregulatory feedback loop is a crucial tool to mediate cellular 




Furthermore, the P2 promoter is bound by several other transcription factors e.g. activated 
members of the ETS (E26 transformation-specific) family and SP1 (specificity protein 1) (Bond 
et al, 2004; Truong et al, 2005) which can rapidly induce MDM2 expression (Figure 2-3) (Wade 
et al, 2013).  
 
Figure 2-3 Transcriptional regulation of MDM2.  
Expression of the MDM2 gene is induced by multiple transcription factors through the two 
distinct promoters P1 and P2. Resulting transcripts are further controlled via miRNA mediated 
mRNA destabilization processes (Wade et al, 2013).  
 
2.1.3.2 Posttranscriptional and –translational regulation of MDM2 
Both MDM2 promoters give rise to the same transcripts which differ in their 5’ untranslated 
region (UTR). However, the P2 transcript is translated much more efficiently due to interaction 
of the 5’UTR with La antigen (Trotta et al, 2003). The P1 transcript does not only lack La binding 
properties but also contains two open reading frames slowing down the translational process 
(Zhao et al, 2014). In addition, many micro RNAs (miRNA) as well as other RNA binding 
proteins like RNPC1 can bind to the 3’ UTR of MDM2 (and to some extent also MDM4) 
transcripts and target it for destabilization and degradation (cf. Figure 2-3) (Xu et al, 2013). 
These miRNAs provide further regulation (e.g. also by P53) and their MDM2 regulation is quite 
frequently lost during tumor formation (Zhao et al, 2014).   
Upon translation, the MDM2 protein is characterized by a high turnover rate and many 
posttranslational modifications (cf. Figure 2-4) and protein interactions (cf. Figure 2-5). MDM2 is 
e.g. stabilized through phosphorylation of Ser166 and Ser186 by the kinase AKT for a more 
effective inhibition of P53 (highlighted in Figure 2-4). On the other hand, DNA-dependent protein 
kinase (DNA‑PK) dissociates MDM2 from P53 through Ser17 phosphorylation in the case of 
genotoxic stress (Mayo et al, 1997). Activation of the DNA damage cascade also induces the 




impairs the MDM2 mediated export of P53 from the nucleoplasm as well as diminishes E3 
ligase function (Maya et al, 2001). Dephosphorylation of Ser-395 by the protein phosphatase 1D 
(Wip1) stabilizes MDM2 and in return leads to P53 inhibition (Lu et al, 2007). 
 
Figure 2-4 Posttranslational modifications of MDM2.  
After translation, the MDM2 protein is modified by a variety of posttranslational modifications 
including phosphorylation, sumoylation, ubiquitination and acetylation. These modifications 
determine MDM2 protein activity, protein-protein interactions and stability (Fåhraeus & Olivares-
Illana, 2013; Wade et al, 2013) 
 
As already indicated in paragraph 2.1.1, the MDM2 protein is interacting with a large group of 
proteins and also RNA. The acidic domain is the major platform for protein interactions whereas 
the RING domain interacts both with proteins as well as RNA. Figure 2-5 shows a fraction of the 
so far identified interaction partners of MDM2. One important protein is the main physiological 
antagonist of MDM2 – p14/p19ARF. ARF sequesters MDM2 and localizes it to the nucleolus 
during the activation of oncogenes like c-Myc (Zindy et al, 1998). Furthermore, MDM2 also 
interacts with proteins under p53 independent conditions. Nbs1 and E2F1 are interesting 





Figure 2-5 The many interaction partners of MDM2.  
Apart from the well-studied interaction with P53, MDM2 interacts with a variety of proteins, 
mainly through its acidic domain (Fåhraeus & Olivares-Illana, 2013)  
 
2.1.4 Knock out studies of MDM genes and P53 – jumping to conclusions too soon? 
Due to their significance in cellular survival and oncogenesis, P53 and MDM2 were amongst the 
first genes to be analyzed in genetically engineered mouse models.  
Remarkably, homozygous P53 deletion did not affect embryonic development. P53-/- mice 
develop normally but generate a variety of neoplasms at a later developmental stage 
(Donehower et al, 1992). Analysis of the P53 family members p63 and p73, indicated though 
that the main developmental functions might be carried out by p63 and – to some extent – also 
p73 (Levrero et al, 2000).  
 
The absence of MDM2 as well as MDM4 is embryonically lethal due to a massive upregulation 
and activation of P53 (Jones et al, 1995; Montes de Oca Luna et al, 1995; Parant et al, 2001). 
These studies further led to two important notions:  
1) Although MDM2 and MDM4 share P53 regulatory functions, they control P53 in a non-
redundant manner. However, Steinmann and colleagues published that overexpression of 




2) Whereas MDM2 ko is lethal due to apoptosis in the pre-implantation phase, MDM4 ko 
lethality only occurs later during mid-gestation and is characterized by cell cycle arrest. This 
time dependency is hinting at possible independent roles of each factor as well as a temporal 
spatial distribution of their activity (Finch et al, 2002; Jones et al, 1995; Migliorini et al, 2002; 
Montes de Oca Luna et al, 1995; Parant et al, 2001). This was further supported by conditional 
MDM2/MDM4 ko studies in the heart; whereas loss of MDM2 was lethal due to embryonic heart 
failure, loss of MDM4 did not affect heart development at all (Grier et al, 2006). 
 
Most interestingly Montes de Oca Luna et al., as well as Jones and colleagues showed in their 
studies that the MDM ko phenotype was reversed with a concomitant p53 deletion. P53-/- 
Mdm2/- as well a p53-/- Mdm4-/- mice developed normally. In respect to late stage cancer 
generation these mice behaved comparably to the single P53 ko mouse. Oca Luna mentioned 
though subtle abnormalities in the reproduction of the double ko mice, since the mice had only 
few litters and also only few pubs within a litter (Montes de Oca Luna et al, 1995).   
The same phenotype was found for mice carrying a mutation in the RING domain (C462A) of 
MDM2 and MDM4. The C462A mutation in MDM2 abrogated E3 ligase function and interfered 
with MDM2/MDM4 heterodimer formation but not with the binding to P53. Along the same line, 
C462A mutation in MDM4 disintegrated MDM2 binding, but P53 interaction stayed intact. 
MDM2/MDM4C462A/C462A mice were embryonically lethal due to P53 upregulation and lethality 
was reversed by additional loss of P53. These findings revealed the following: 1) Insufficient E3 
ubiquitin ligase function of MDM2 is enough to drive embryonic lethality. The lethal activation of 
P53 cannot be rescued by the binding of the MDM proteins to P53. 2) The MDM2-MDM4 
heterodimerization through their RING domains is necessary for efficient MDM2 ubiquitination 
function which explains why neither homolog can compensate the other (Huang et al, 2011; 
Itahana et al, 2007; Pant et al, 2011).  
The P53/MDM2 ko studies provided a distinct insight into the relevance of the system in 
development and embryogenesis. However, the simple conclusions that were drawn – no 
developmental regulation by P53 and only P53 dependent functions for MDM2/4 in development 
– are facing now strong counter-arguments. It is still a fact that a murine organism can develop 
without P53 but already in 1995, two independent groups related an increase in embryonic 
lethality to the loss of P53. According to their data, this was caused by developmental defects 
especially during neural tube closure (Armstrong et al, 1995; Sah et al, 1995). Until now, these 




differentiated cells into iPS cells (Hong et al, 2009; Kawamura et al, 2009) and is involved in  
stem cell differentiation, self-renewal and plasticity (Aloni-Grinstein et al, 2014). It e.g. controls 
the differentiation of mesenchymal stem cells and cells of the B-cell lineage and regulates 
transcription of the stem cell factors Oct4 and Nanog as well as different factors of the 
homeodomain containing transcription factor family (Aloni-Grinstein et al, 1993; Molchadsky et 
al, 2008; Villasante et al, 2011). The insights into P53/MDM2 activity in stemness and 
differentiation are quite controversial and will need further elucidation during the upcoming 
years. 
2.1.5 MDM proteins in cancer 
As MDM2 mediates the regulation of P53 levels and activity, amplification of its corresponding 
genes as well as inhibition of any negative MDM2 regulation pattern was assumed to drive 
tumorigenesis. Indeed, roughly 10 % of all human cancers are characterized by an 
overexpression of MDM2, being most abundant in soft tissue tumors and osteosarcomas, but 
also in hematologic malignancies, gliomas, colorectal-, bladder- and breast cancer (Momand et 
al, 1998; Onel & Cordon-Cardo, 2004). 
Deregulation was identified to be mediated through gene amplification processes, release of 
p14/p19ARF regulation and induction of gene expression (cf. paragraph 2.1.3.1) (Li & Lozano, 
2013).  
Defining the carcinogenic role of MDM2 in in vitro cell-based studies revealed that MDM2 alone 
was not always sufficient to drive proper cell transformation; stable overexpression of MDM2 
was even correlated with cellular toxicity making it hard to draw any conclusions from these 
studies. Only in the presence of pre-existing genetic changes (e.g. in immortalized NIH3T3 
cells) supra-physiological expression manifested MDM2 oncogenic functions (Fakharzadeh et 
al, 1991). In in vivo studies in mice though, overexpression of a MDM2 transgene was 
responsible for increased polyploidy and genomic instability independent of the P53 status 
(Lundgren et al, 1997). These genomic aberrations were correlated to the appearance of 
induced sarcomas, lymphomas and carcinoma.  
The role of MDM4 in tumorigenesis is less well defined. MDM4 protein levels are elevated in 
several cancers, most prominently retinoblastoma and overexpression is mainly caused by gene 
amplification. In addition, Gilkes and colleagues postulated the upregulation of MDM4 through 





All of these findings support the relevance of the MDM proteins in tumorigenesis, but mainly in 
the context of repressing wt P53. However, there are several hints to P53 independent functions 
of MDM2. Jones and colleagues described already in 1998 the predisposition of a  P53 ko mice 
with a transgenic MDM2 towards increased occurrence of sarcomas and spontaneous tumor 
formation (Jones et al, 1998). Heterozygous loss of MDM2 in P53-/- mice changes the tumor 
spectrum towards sarcomas (McDonnell et al, 1999) and similarly, close observations revealed 
a faster tumor onset in mice lacking MDM4 and P53 in comparison to P53 alone (Matijasevic et 
al, 2008).  
 
2.1.5.1 P53-independent functions of the MDM proteins in cancer and beyond 
As Jones and colleagues already suggested, MDM2 influences oncogenesis and tumor cell 
survival not only through P53 but also via independent functions. This hypothesis was 
supported by the identification of human sarcomas and bladder cancers which overexpressed 
MDM2 even in the absence of wt P53 (Cordon-Cardo et al, 1994; Lu et al, 2002). Moreover, Eµ-
myc driven lymphomas overexpress MDM2 when generated in a P53 null or mutated 
background (Eischen et al, 1999) and tumors were identified that overexpressed MDM2 splice 
variants that are unable to bind P53 (Sigalas et al, 1996).  
 
One of the earliest explanations was brought up by two different groups who described the 
destabilization of the retinoblastoma (Rb) protein and subsequent activation of the cell cycle 
regulator E2F1 through MDM2. Rb negatively regulates E2F1, a transcription factor driving cell 
cycle and survival. Through Rb decay, E2F1 is released of its negative regulation and can itself 
be activated by MDM2, which increases proliferation and genomic instability (Martin et al, 1995; 
Uchida et al, 2005; Xiao et al, 1995; Zhang et al, 2005). Most interestingly, in a context-specific 
situation in which E2F1 induces apoptosis, MDM2 has been detected to rather mediate E2F1 
degradation than activation (Loughran & La Thangue, 2000). 
As outlined in Figure 2-6, MDM2 is also responsible for the degradation of the negative cell 
cycle regulators p21 and hnRNP (Jin et al, 2003; Moumen et al, 2005) as well as the 
antiapoptotic protein FOXO3a (Yang et al, 2008). Furthermore, MDM2 does not only control 
cellular self-renewal but also plasticity. The epithelial marker protein E-cadherin, which is 
important during normal and malignant epithelial to mesenchymal transition processes (EMT) 
can be directly targeted for degradation by MDM2 which facilitates cell migration and metastasis 




inflammation and wound healing through interaction with NFΚB and co-localization on its NFΚB -
target gene promoters (Mulay et al, 2012).   
 
 
Figure 2-6 P53-independent functions of the MDM2 protein.  
MDM2 is mainly known for its regulation of the tumor suppressor P53. Since its’ first description 
in 1998 P53 –independent functions of the MDM protein have been intensively studied and are 
summarized in the context of cancer relevance (Li & Lozano, 2013) 
 
2.1.6 The role of MDM2 in gene expression, epigenetics and development 
2.1.6.1 MDM2 in gene expression regulation and epigenetic control 
P53 is the major scientific focus of gene expression regulation by MDM2/4. As a matter of fact, 
there is a distinct regulation of P53 inducible genes by MDM2 and MDM4. Whereas the effects 
of MDM2 ko can be delayed by the additional loss of the pro-apoptotic gene Bax, MDM4 ko was 
partially rescued through loss of p21 (Chavez-Reyes et al, 2003). Indeed, further in vitro studies 
in MEF cells confirmed that MDM2 and MDM4 affect P53 activation through defined target gene 
selection (Barboza et al, 2008). MDM2 does not only influence gene expression through P53 
but also via independent mechanisms. Apart from the P53 independent regulation of E2F1 (cf. 
paragraph  2.1.5.1) other transcription pathways have been identified to depend on MDM2 
signaling, among them the NFΚB and TGFβ pathways (Biderman et al, 2012). Of note, most of 
the data concerning MDM2 as a regulator of transcription was generated in malignant cells and 




Concerning epigenetic relevance, it was published that MDM2 associates to chromatin in 
several different settings. MDM2 was immunoprecipitated from P53 target gene chromatin in the 
presence of P53. According to the authors, MDM2 bound P53 directly on the chromatin of the 
CDKN1a promoter and inhibited transcription through the abrogation of transcription machinery 
binding, as outlined in 2.1.2.2 (Arva et al, 2005). In addition, MDM2 can recruit the histone 
methylases SUV39H1 and EHMT1 to P53 target gene promoters and thereby convert them to 
repressive chromatin (Chen et al, 2010). Most interestingly, Minsky and colleagues developed a 
P53 deficient in vitro system, in which MDM2 was still able to repress gene expression from a 
luciferase reporter plasmid. This repressive function was dependent on the MDM2 RING finger 
domain and was mediated through ubiquitination of histone H2A and H2B (Minsky & Oren, 
2004).  
So far, a chromatin associated function of MDM4 has not been published.  
 
2.1.6.2 P53-independent functions of MDM2 in development 
For most scientists, the results obtained in the genetically modified mouse models outlined in 
2.1.4 were reason enough to doubt any possible p53-independent roles of the MDM proteins 
during stemness and differentiation. Several follow-up publications which used conditional MDM 
ko models in specific organs supported this assumption. Hence, a role in organ development 
and stem cell differentiation has been so far only been analyzed in a P53 proficient context, 
describing MDM2 and MDM4 as important factors for stem cell survival due to P53 shut-down 
(Abbas et al, 2010; Hilliard et al, 2014; Lengner et al, 2006).  
However, the same studies also implicated, that there is no major function of P53 during 
development which was proven wrong at least in vitro when several groups in parallel 
indentified a stem cell barrier function of P53 in the generation of induced pluripotent stem cells 
(iPSCs) (Hong et al, 2009; Kawamura et al, 2009). If the developmental role for p53 is more 
complex than a ko mouse model can explain, it will most probably also not be the final answer 
for the MDM protein family.  
 
During my master thesis project I observed a stemness maintenance function of MDM2 which 
works through the interaction with the well-known stemness- and epigenetic related Polycomb 






2.2 Chromatin modifications regulate gene expression 
2.2.1 DNA compaction – not just a matter of storage 
In a multicellular organism, each cell contains the same genetic information. To produce diverse 
cell differentiation, a highly complex system must regulate which genes are switched on and off, 
resulting in a specific gene expression code that determines cell fate. One mechanism, which 
was already introduced via p53, is the usage of distinct transcription factors that can either 
transactivate or repress gene expression. Another mechanism which can act more broadly 
covers the modification of the chromatin as such (Yan et al, 2010).  
In general, DNA is not just loosely contained within the cell nucleus but is highly compacted 
together with histone and non-histone proteins into a dynamic polymer called chromatin as 
highlighted in Figure 2-7 (GM., 2000; Yan et al, 2010). The DNA double helix is wrapped around 
an octamer of four core histones (H2A, H2B, H3 and H4) building up a nucleosome, which is 
secured by the addition of the linker histone H1 (Rothbart & Strahl, 2014). This nucleosome 
structure is further coiled and condensed, ensuring proper chromosome structure during 
mitosis.  
 
The chromatin structure is the basis of several regulation patterns as indicated in Figure 2-7. 
The DNA itself can be methylated at DNA stretches rich in CpG dinucleotides – so called CpG 
islands. This methylation is associated with repressed gene expression and is one of the major 
epigenetic changes during stem cell differentiation and malignant transformation (Reik et al, 
2001).  
Furthermore, non-coding RNAs regulate gene expression through various and not yet 
completely understood ways. e.g. inhibition of gene expression through direct binding but also 





Figure 2-7 The three fundamental mechanisms of epigenetic regulation.  
Epigenetic regulation of gene expression consists of three defined processes. (1) DNA is  
methylated at CpG rich regions, so called CpG islands, which represses gene expression (Reik 
et al, 2001). (2) Histone proteins are post-translationally modified at amino acid residues on 
their N- and C-terminal tails. These modifications alter DNA or effector protein binding and 
therefore modulate gene expression (Rothbart & Strahl, 2014). (3) Non-coding RNA structures 
can modify chromatin dynamics through direct binding or recruitment of other epigenetic effector 
proteins (Bernstein & Allis, 2005). Each of these mechanisms can act on its own but can also 
influence the others (Yan et al, 2010).   
 
2.2.2 The histone code 
Apart from regulation through DNA methylation and RNA-based mechanisms, histones are 
covalently modified, especially on their N- and C-terminal domains. This leads to alterations in 
the nucleosome compaction and/or the binding of specific DNA binding proteins. Since the first 
description in 2000, the histone code has been slowly revealed and was found to be defined by 
writers (proteins that modify histones), erasers (proteins that remove the modifications) and 
readers (proteins that bind to the modifications) (Strahl & Allis, 2000; Turner, 2000). Histones 
can be acetylated, methylated, phosphorylated, ubiquitinated, sumoylated, citrullinated and ADP 
ribosylated which is partly summarized in Figure 2-8. Many other modifications have been 
described but most lack any regulatory explanation yet. Apart from amino acid modifications, 





Figure 2-8 The histone code hypothesis - simplified.  
Amino acid residues of histone proteins are post-translationally acetylated, methylated, 
phosphorylated and ubiquitinated, which influences their interaction with the DNA and other 
DNA binding proteins. Histone-DNA interaction is a major source of gene expression regulation 
(Spivakov & Fisher, 2007). 
 
Histone acetylation and methylation are among the most widely studied modifications and were 
already described in 1964 by Allfrey and colleagues (Allfrey et al, 1964). Histones are acetylated 
by histone acetyl transferases (HATs) which will reduce the positive charge of the nucleosome 
and thus weaken the DNA histone interaction (Shogren-Knaak et al, 2006). The lack of 
compaction will facilitate transcription machinery binding and gene expression is favored. 
Furthermore, effector proteins containing a bromo-domain are able to bind to acetylated 
histones and further facilitate transcription (Dhalluin et al, 1999). 
The contributions of histone methylation are less well defined. Methylation can either repress or 
activate gene expression, depending on the residue which is methylated and also on the 
number of methyl groups added (Spivakov & Fisher, 2007). For example, histone 3 lysine 27 
trimethylation (H3K27me3) generally represses gene expression whereas H3K4me3 is 
associated with active expression (Santos-Rosa et al, 2002; Schwartz & Pirrotta, 2007). 
Monomethylated H3K4 was identified in gene enhancer regions whereas trimethylated H3K4 
was linked to promoter regions (Greer & Shi, 2012). 
This project mainly focused on the histone methyl transferase (HMT) Enhancer of Zeste 




epigenetic complex which is responsible for gene expression control in a variety of different 
physiological contexts.  
 
2.3 The Polycomb Group family proteins (PcG) 
The Polycomb group family is a sophisticated protein machinery which establishes histone 
modifications important in gene repression. This repression is important in cellular self-renewal 
and - plasticity, X-chromosome inactivation and malignant transformation (Breiling, 2015; Richly 
et al, 2011; Simon & Kingston, 2013). The group of PcG proteins was clustered together in 1985 
by Jürgens and colleagues since mutants of all of their genes lead to a similar fly phenotype - 
additional sex comb structures on male legs. This was roughly 40 years after the first 
description of the so called Polycomb mutant (Jürgens, 1985; Slifer, 1942).  
The similar phenotypes were caused by the ectopic upregulation of homeotic transcription factor 
expression in each PcG mutant. These transcription factors typically ensure specific cell identity 
along the embryonic axis and distortion of their expression transforms embryo segments and 
body structures (Lewis, 1978). It is now believed that the PcG and their highly conserved 
vertebrate homologs not only repress homeotic transcription factors (also known as Hox genes) 
but also many other genes, which maintain cell cycle and embryonic development (Boyer et al, 
2006; Lee et al, 2006; Schwartz et al, 2006)  
2.3.1 Polycomb repressive complex 2 (PRC2) 
The Polycomb Repressive Complex 2 (PRC2) is one of the two well-known repression 
machineries of the PcG family and consists of four different complex proteins. The PRC2 
methylates H3 on lysine 27 and 9 (mono-, di- and trimethylation) and histone 1 on lysine 26, 
however, its main catalytic target is H3K27 (Kuzmichev et al, 2004; Margueron et al, 2008). 
PRC2 catalytic activity is provided by EZH2, the Drosophila homolog of the Enhancer of Zeste 
E(z) gene (Czermin et al, 2002). EZH2 is a SET domain containing histone methyl transferase, 
which is only catalytically active when assembled with SUZ12 (Suppressor of Zeste 12) and 
EED (ESC in flies) (Cao & Zhang, 2004; Ketel et al, 2005; Pasini et al, 2004). This interaction 
was highly conserved from fly to human and homologs can be found even in plants but not in 
yeast (Ito & Sun, 2009; Whitcomb et al, 2007).  
 
Apart from the intrinsic factors, PRC2 can build complex specifying interactions with accessory 




Landeira et al, 2010; Nekrasov et al, 2007; Walker et al, 2010). Both, PCL proteins and JARID2, 
have been described to be involved in the recruitment of the PRC2 to specific and also broader 
target sites. As an example, PCL2 recruits the PRC2 especially to the X-chromosome whereas 
PCL3 stabilizes overall PRC2 mediated H3K27me3 (Hunkapiller et al, 2012; Walker et al, 2010). 
PCL proteins can also boost the enzymatic activity of EZH2, facilitating the conversion of 
H3K27me2 into H3K27me3 (Nekrasov et al, 2007). Chromatin occupancy of PRC2 proteins 
largely overlap with the second multiprotein complex of the PcG family – the PRC1 
(Schuettengruber & Cavalli, 2009) and both complexes are tightly linked according to numerous 
studies (Comet & Helin, 2014) 
 
 
Figure 2-9 Composition of the Polycomb Repressive Complex 2 (PRC2) in fly and human.  
The canonical subunits building up the fly and human PRC2 are shown. Lavender colored 
proteins are essential core subunits of the fly proteins and their respective homologs in human. 
Arrows indicate the conserved interaction of the PRC2 with JARID2 and PCL proteins (Simon & 
Kingston, 2013) 
 
2.3.2 Polycomb repressive complex 1 (PRC1) 
Three years before detection of the PRC2, the Polycomb repressive complex 1 (PRC1) was 
introduced (Shao et al, 1999). The original core components isolated from Drosophila were 
Polycomb (PC), Polyhomeotic (PH), Posterior sex combs (PSC), and Sex combs extra 
(SCE/dRING) (Shao et al, 1999). A few years later homologs of each gene were isolated from 
mammalian species, each had faced duplication events and evolutionary development (Levine 
et al, 2002). The PC protein evolved into five different CBX proteins which contain a chromo-
domain and can bind to H3K27me3 (Fischle et al, 2003). PH and PSC became three (PHC1-3) 
and six different homologs (PSC: Polycomb group RING fingers, PCGF1–6), respectively. Two 
different dRING proteins (RING1A and RING1B) make up the catalytic part of the complex and 




other proteins were described to interact with the PRC1 (cf. Figure 2-10). Only from the number 
of homologs present of all PRC1 complex members can one estimate how many different 
composition forms can be built up. According to Gao and colleagues, six biochemically distinct 
PRC1 complexes can be defined which do not only differ in their composition but also harbor 
complex specific functions (Gao et al, 2012). 
 
Figure 2-10 Composition of the Polycomb Repressive Complex 1 (PRC1) in fly and 
human.  
The canonical core subunits of the fly and human PRC1 are shown. PRC1 is built up of the 4 
proteins PC, PH, PSC and dRING in fly and diverse set of its homologs in human (Simon & 
Kingston, 2013). 
 
The PRC1 was long thought to be a downstream effector of the PRC2 mediating its function 
especially through ubiquitination of H2AK119. Thereby, a CBX (= chromo-domain) containing 
PRC1 complex can recognize amino acids methylated by the PRC2 leading to its chromatin 
recruitment. Subsequent ubiquitination of H2AK119ub1 blocks chromatin remodeling and halts 
RNA polymerase II mRNA elongation (Cao et al, 2005). Spreading of PRC1 protein complexes 
along the downstream regions further compacts the chromatin structure for repression 
maintenance (Francis et al, 2004). The idea behind the repressive functions of PRC1 
ubiquitination is generally accepted but the whole molecular mechanism of PRC1 functioning as 
well as its recruitment is not completely solved yet. In fact, Eskeland and colleagues 
demonstrated that chromatin compaction by PRC1 is independent of its ubiquitination function 
(Eskeland et al, 2010). This correlated nicely with a publication by Francis and colleagues who 
defined the compaction ability as histone tail independent (Francis et al, 2004). In addition, 
although all PRC1 complexes contain RING1A/B, only specific PRC1 setups seem to be 




2.3.3 Recruitment of the PcG proteins to their target gene chromatin 
Although sequencing analysis and motif predictions of chromatin immunoprecipitation 
approaches are increasing in computational strength, it is not defined clearly yet, how the PRC2 
is localized to its target sites in mammalian cells. In Drosophila this question was answered 
more straightforward. In 1993 and 1994 two distinct groups published the existence of cis-
regulatory Polycomb response elements (PREs) which are bound by specific DNA-binding 
proteins that can recruit PcG complexes (Chan et al, 1994; Simon et al, 1993). Being located 
upstream of the gene promoters the PREs are thought to interact through protein interactions 
with the promoter via loop formation (Kahn et al, 2006). The only known homologue of these 
DNA binding proteins in mammalian cells is PHO/YY1 and so far only two mammalian PRE-like 
elements were identified. This makes it hard to believe that the PRE mechanism is the main 
driver of PcG recruitment here (Sing et al, 2009; Woo et al, 2010).  
 
In mammalian cells the PRC2 is thought to be recruited through interactions with specific DNA 
binding proteins (cf. paragraph 2.3.1), CpG dinucleotides (CpG islands) (Ku et al, 2008) and 
non-coding RNA (Plath et al, 2003). According to Tanay and colleagues, the presence of CpG 
islands correlates with PcG binding in the absence of methylated CpGs and transcriptional 
activators. The PRC2 interaction partner PCL3 is able to direct the PRC2 towards unmethylated 
CpG islands and facilitate interaction with Tet1, an important factor in DNA demethylation (see 
also Figure 2-11 a) (Hunkapiller et al, 2012; Wu et al, 2011).   
Apart from the recruitment to CpG sites, non-coding RNAs were found to direct the PRC2 to its 
target sites. Two prominent examples are the long non-coding RNAs (lncRNAs) X-inactive 
specific transcript (XIST) (Plath et al, 2003) and HOTAIR (Gupta et al, 2010).  
Chromatin dynamics can further modify PcG recruitment. Activating histone marks, such as 
trimethylated H3K4 and H3K36 have been reported to prevent PRC2 binding and subsequent 
methylation of H3K27 (Schmitges et al, 2011; Voigt et al, 2012), whereas H3K27me3 and 
H2AK119ub1 stimulate PRC2 enzymatic activity (Hansen et al, 2008; Kalb et al, 2014). In 
addition, recognition of nucleosome density (Yuan et al, 2012) as well as specific PRC2 cofactor 
engagements (cf. paragraph 2.3.1) modify PRC2/chromatin interaction and gene repression. 
 
The general opinion about PRC1 recruitment is still mainly based on the recognition of 
methylated H3K27 via the PRC1 chromo-domain containing CBX proteins. This idea was 
analyzed through CBX chromatin immunoprecipitation experiments in PRC2 wt and mutant cells 




2003) (see also Figure 2-11 a). However, two publications in 2007 and 2010 demonstrated 
retention of PRC1 on the chromatin even in the absence of PRC2 in pluripotent as well as 
differentiated cells (Leeb et al, 2010; Pasini et al, 2007; Tavares et al, 2012) and they postulated 




Figure 2-11 Recruitment of PcG proteins by unmethylated CpG islands.  
PRC2 and PRC1 can be recruited through accessory binding partners to unmethylated CpG 
islands. This recruitment is speculated to facilitate their interaction with each other in a non-
hierarchical fashion (Comet & Helin, 2014).  
 
One striking and recent finding in this context was that only CBX protein containing PRC1 
complexes are dependent on methylated histone 3 for recruitment whereas RYBP containing 
PRC1 can mediate H2AK119ub1 independent of H3K27me3 (Tavares et al, 2012). RYBP and 
CBX presence exclude each other due to a mutually exclusive binding site on RING1A/B (Wang 
et al, 2010), giving rise to two distinct PRC1 targeting strategies and the termination of 
canonical (CBX-containing) and variant (RYBP-containing) PRC1.   
In 2014, Blackledge and colleagues further extended this finding and postulated PRC2 
recruitment and H3K27me3 placement through variant PRC1 occupancy at specific target sites 
(see also Figure 2-11 b). This recruitment was H2AK119ub1 dependent and loss of catalytic 
activity dramatically reduced H3K27me3 and PRC2 levels at these target sites in murine ESCs 
(Blackledge et al, 2014). Kalb and colleagues confirmed this dependency of the PRC2 on PRC1 
and postulated that JARID2–Aebp2–containing PRC2 complexes can bind H2AK119ub1 and 
methylate H3K27 on monoubiquitinated nucleosomes (Kalb et al, 2014).  
As already mentioned for the PRC2, CpG islands can also recruit the PRC1 when it is 
assembled to the protein KDM2B/FBXL10 (cf. Figure 2-11 b). The PRC1-KDM2B interaction not 
only directs the complex to CpG island but also facilitates H2AK119ub1 at these sites (Wu et al, 
2013). In accordance with the PRC2 binding pattern, the PRC1 is only recruited to non-
methylated CpG islands, since methylation inhibits KDM2B binding. In the context of variant 




variant as a requirement for PRC2 levels at specific CpG islands, which was necessary for 
embryonic development (Blackledge et al, 2014).   
 
2.3.4 PcG gene regulation in stem cells and cancer 
2.3.4.1 Stem cell plasticity regulated by the PcG 
Stem cells are characterized by continuous self-renewal and the ability to differentiate into 
specialized cell types (Morrison et al, 1997). Stem cell self-renewal and specification is a major 
target of epigenetic regulation and especially regulation via the PcG family (Spivakov & Fisher, 
2007). 
Before anything was known about the PcG regulatory mechanism, their corresponding fly 
mutants had revealed their importance in embryonic development and especially body 
segmentation (cf. paragraph 2.3). In mice, loss of the main three PRC2 proteins (EZH2, SUZ12 
and EED) as well as RING1B, the main catalytic subunit of the PRC1, leads to early embryonic 
lethality (Faust et al, 1995; O'Carroll et al, 2001; Pasini et al, 2004; Voncken et al, 2003). Mice 
deficient of the PRC1 members BMI1 and PHC1 are suffering from malformation in the anterior-
posterior patterning and severe anemia due to reduced self-renewal of hematopoietic stem cells 
(Lessard & Sauvageau, 2003; Ohta et al, 2002).  
 
The striking influence of PcG proteins on organism development was supported by genome 
wide analysis, mapping their gene regulatory function to key stem cell factors, cell cycle 
regulators, X-chromosome inactivation as well as stem cell plasticity and also tumor progression 
(Breiling, 2015; Simon & Kingston, 2013). Upon differentiation of pluripotent embryonic stem 
cells (ESCs) PcG proteins delocalize from specific lineage associated transcription factors and 
subsequently silence stem cell associated genes. In concordance total PcG protein levels 
decrease during the onset of differentiation (Lee et al, 2006; Simon & Kingston, 2013) and loss 
of the epigenetic regulation by the PcG accelerates differentiation capacity in many different 
directions (Chou et al, 2011).  
In 2012 Onder and colleagues verified the importance of PRC2 regulation also in the 
reprogramming of differentiated fibroblasts into iPS cells. According to their study, loss of EZH2 
weakens reprogramming efficiency (Onder et al, 2012). This finding correlated to the finding of 
Boyer et al., who proposed the regulation of Yamanaka factor target genes by PcG mediated 




generation of pluripotent stem cells is highly dependent on the 3 (4) different transcription 
factors – Oct3/4, Klf4 and Sox2 (sometimes also c-myc) (Takahashi & Yamanaka, 2006). 
 
2.3.4.2 PcG deregulation in cancer 
Already in 1983, it was published that cancer cells are characterized by an altered DNA 
methylation landscape (Feinberg & Vogelstein, 1983). Although no one really understood what 
these findings meant at that point it was clear that transformation had changed the epigenetic 
landscape (or vice versa) and that this must be correlated by the intensive shut down of specific 
gene clusters (Baylin et al, 1991). Next to the deregulation of DNA methylation processes 
histone modifications go awry during tumorigenesis (Fraga et al, 2005; Seligson et al, 2005). In 
parallel, many tumor types were identified that dependent on flawed PcG signaling, among them 
hormone-refractory metastatic prostate cancer, breast- and bladder cancer as well as 
melanoma (Hochedlinger et al, 2005; Lee et al, 2006). It is believed that the PcG proteins are 
able to repress gene loci important in cell arrest and apoptosis to support malignancy. One quite 
early identified and important locus for this is the CDKN2a locus which encodes the INK4A and 
ARF genes (Jacobs et al, 1999) INK4A is a regulator of the Rb pathway and ARF regulates the 
activity of MDM2 (cf. Figure 2-2) and both genes encode crucial tumor suppressive functions 
(Sherr, 2001).  
The underlying mechanisms how PcG signaling is malignantly changed are versatile and not yet 
completely understood. BMI1, SUZ12 and EZH2 have all been found to be aberrantly 
upregulated in different tumor cells, which did not only alter the epigenetic landscape of these 
tumors but was also highly correlated with their aggressiveness and resistance towards 
chemotherapy. (Iliopoulos et al, 2010; Malekzadeh Shafaroudi et al, 2008; Weikert et al, 2005). 
Upregulation of PcG proteins can be caused by e.g. gene amplification and translocation 
processes. Moreover, loss of miRNA-mediated PcG regulation pathways is a key mechanism 
for cellular transformation (Beà et al, 2001; Godlewski et al, 2008; Smith et al, 2003; Varambally 
et al, 2008). In addition, the upregulation of associated factors and deregulation of interacting 
lncRNAs like HOTAIR that are involved in PcG recruitment have been described to mediate 
PcG hypersilencing (Gupta et al, 2010; Tange et al, 2014). 
2.3.4.3 PcG proteins and their connection to cancer stem cells 
The interconnection of the PcG proteins in both, stem cell maintenance and malignant 




cancer stem cells (CSC) (Richly et al, 2011; Sparmann & van Lohuizen, 2006). According to the 
hypothesis of CSCs, the majority of tumors are characterized by very heterogeneous cell 
populations which can be separated into a small number of proliferating “stem cells” (CSCs) and 
a larger amount of more differentiated daughter cells (cf. Figure 2-12) (Kreso & Dick, 2014; 
Pardal et al, 2003). CSCs and normal stem cells share the capacity of continuous self-renewal 
and dedifferentiation and recent studies have shown that CSCs have a similar gene expression 
and epigenetic profile when compared to normal stem cells, even in the absence of the same 
driver mutation that initiated malignancy (Bartholdy et al, 2014; Eppert et al, 2011). In fact, 
several independent groups were able to isolate CSCs and proved that only the cancer stem 
cells proliferated extensively, were able to form new tumors in nude mice and mainly conferred 
towards chemoresistance (Al-Hajj et al, 2003; Bonnet & Dick, 1997; Singh et al, 2003). 
However, the whole concept is under intensive debate since there are tumors which are not built 
up by a clear CSC vs. non-CSC structure.  
 
Figure 2-12 Cancer stem cells and their possible dependence on PcG signaling  
According to the concept of CSCs, the majority of tumors are characterized by heterogeneous 
cell populations which can be separated into a small number of proliferating “stem cells” (CSCs) 
and a larger amount of more differentiated daughter cells. Gene expression regulation mediated 
by PcG proteins is speculated to be responsible for the generation and maintenance of the CSC 
population (Sparmann & van Lohuizen, 2006) 
 
The PcG proteins EZH2 and Bmi1 have been extensively discussed in the field of CSC 
research. As an example, elevated EZH2 and H3K27me3 levels were detected in breast and 
prostate cancer CSCs. Inhibitor or shRNA mediated decrease in EZH2 protein significantly 
reduced prostate CSC spheroid formation and frequency, and intracranial tumor formation from 




2.4 Previous work  
This PhD thesis deals with a functional network of the oncoprotein MDM2 and the PcG family. 
The project design was based on experimental data that I had obtained during my 6 months 
master thesis project. Before I started my thesis, initial work had indicated a functional 
interaction of MDM2 and members of the PRC2 via exogenous protein interaction and co-
localization assays. The major question to answer in my master thesis was whether we can 
identify any functional relevance of this interaction. Therefore, I depleted multiple cancer cell 
lines of MDM2 and EZH2 and analyzed the expression of single PRC2 target genes. 
Surprisingly, several PRC2 target genes were upregulated not only in the absence of EZH2 but 
also MDM2, even in the absence of p53. 
Since PcG proteins silence genes important for stem cell differentiation and cellular survival (cf. 
paragraphs 2.3.4.1 and 2.3.4.2) we further tested whether the regulation of PRC2 target genes 
via MDM2 was also connected to this function. Indeed, loss of MDM2 accelerated the 
differentiation of human mesenchymal stem cells (hMSCs) and impeded cancer cell survival, 
both in the absence of p53.  
2.5 Project Aim  
This project was conducted to further define the cellular consequences and molecular 
mechanism behind the gene regulatory function of MDM2 on PRC2 target genes.  
Since differentiation experiments of hMSCs had already pointed out a stem cell maintenance 
function of MDM2 we wanted to investigate its relevance also in pluripotent reprogramming.  
The generation of iPSCs had already highlighted an unexpected stemness barrier function for 
P53 (cf. paragraph 2.1.4). Based on the data we received from our MSC system we expected 
less efficient reprogramming of differentiated cells into iPS cells in the absence of MDM2.  
 
Since we already knew about a possible gene regulatory function of MDM2 on single PRC2 
target genes we wanted to approach the gene expression modulation in a global way. Via whole 
transcriptome sequencing or hybridization approaches we wanted to identify possible MDM2 
target genes in different cell types including primary murine embryonic fibroblasts (MEFs), 
cancer- and stem cells and analyze these for PcG correlated enrichment. We were thinking to 
identify specific pathways that are enriched by the MDM2 gene regulatory function and which 
could also serve as a link that connects MDM2s’ influence on stemness and malignancy. 
Because malignant transformation processes are supported by stem cell pathways the question 





PcG gene silencing is mediated by or at least correlated to changes in the epigenetic 
organization of their target genes (cf. paragraph 2.3). In the case of a joint gene regulatory 
function for MDM2 and PcG proteins we wanted to address several questions:  
1) Does MDM2 itself bind to the target gene promoters and could it also be recruited there 
through interactions with proteins of the PRC2? MDM2 has indeed been found to bind 
chromatin in a p53 dependent- and independent manner (cf. 2.1.6) and localization experiments 
had already indicated a relocalization of MDM2 with EZH2 in specific nuclear compartments. 
This encouraged us to determine the MDM2 occupancy on the identified target genes via 
chromatin immunoprecipitation (ChIP). 
2) Are the gene expression changes accompanied by changes in the respective H3K27me3 or 
H2AK119ub1 levels on the target gene promoters? In the case of repression release we were 
expecting a change of the epigenetic landscape associated with the gene promoter so that the 
transcription machinery can access the transcriptional start site and gene body. Interestingly, 
MDM2 had already been reported once to ubiquitinate H2A at lysine 119 (Minsky & Oren, 2004) 
leading to gene repression. Genome wide profiles of H3K27me3 and H2AK119ub1 would serve 
us for a more global analysis if we found a connection between MDM2 and histone modification 
changes. 
3) Is MDM2 somehow involved in the recruitment of the PcG proteins to their target gene 
promoters or does it influence its activity? As it was already introduced in paragraph 2.3.3 there 
are versatile mechanisms by that PcG proteins get recruited to their target genes. Interaction 
with accessory proteins that can direct target gene binding has been detected and MDM2 could 
be involved by binding to the PRC2 proteins. Furthermore, a possible influence on activity could 
be rendered by ubiquitination processes directed either at decay or at changes of enzymatic 
activity and complex formation.   
 
On the long run, analyzing the mechanisms of a p53-independent gene regulatory function of 
MDM2 which is not only mediating stemness maintenance but also cancer cell survival will be of 
utmost interest in the development of therapeutic cancer drugs. So far, many different 
compounds which are already tested in clinical trials are all aiming at the reactivation of P53 
mostly through inhibiting the interaction of MDM2 with P53 (Li & Lozano, 2013). In case of 
PRC2 target gene regulation by MDM2 (and also other p53-independent functions cf. paragraph 
2.1.6.2), this therapeutic approach might not be enough and it will be necessary to expand the 
drug design to interfere with the chromatin modifier function of MDM2 as well. 
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3 Material and Methods 
3.1 Material 
3.1.1 Technical devices 
Table 3-1 Technical devices 
Device Company 
Autoclave DX-200 Systec GmbH 
Blotting chamber Biozym, Hessisch Oldendorf, Germany 
Cell counting chamber Neubauer improved Brand, Wertheim, Germany 
Centrifuge 5415R Eppendorf, Hamburg, Germany 
Centrifuge 5810R Eppendorf, Hamburg, Germany 
Centrifuge Megafuge 1.0R Heraeus, Thermo Scientific, Waltham, MA, United States 
Chemiluminescence imager Chemocam HR 
16 3200 
Intas Science Imaging Instruments, Göttingen, 
Germany 
DNA gel chamber Biotch Service Blu 
DynaMag™-2 Life Technologies, Thermo Scientific, MA, United States 
Electrophoresis system for SDS-PAGE Amersham Biosciences, GE Healthcare 
Freezer -20°C Liebherr, Bulle, Switzerland 
Freezer -80°C Heraeus, Thermo Scientific, Waltham, MA, United States 
Heating Block Grant Instruments 
Ice machine B100 Ziegra 
Incubator for bacteria Memmert, Schwabach, Germany 
Incubator for cell culture Hera Cell 150 Heraeus, Thermo Scientific, Waltham, MA, United States 
Laminar flow cabinet Hera Safe Heraeus, Thermo Scientific, Waltham, MA, United States 
Liquid nitrogen tank LS 4800 Taylor-Wharton, Theodore, AL, United States 
betic stirrer MR Hei-Standard Heidolph, Schwabach, Germany 
Microscope Axiovert 40C Zeiss, Oberkochen, Germany 
Microwave Cinex, Lippstadt, Germany 
Mini Centrifuge MCF-2360 LMS, Tokyo, Japan 
PCR machine for qPCR CFX96, C1000 Bio-Rad Laboratories 
PCR machine Thermocycler T personal Biometra, Göttingen, Germany 
pH-meter WTW-720 WTW, Weilheim, Germany 
Pipets Multipipet Eppendorf, Hamburg, Germany 
Pipets Eppendorf Research Series 2100 
(0.1-2.5μL; 0.5-10µl; 2-20μL; 20-200μL; 100-
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1000μL) 
Power supply unit Powerpack P25T Biometra 
Qubit 2.0 Fluorometer Invitrogen 
Refrigerator 4°C Liebherr 
Roller RM5 V-30 CAT, Staufen, Germany 
Rotator PTR 300 Grant Instruments 
Scales Acculab ALC-6100.1 Sartorius, Göttingen, Germany 
Scales LE623S Sartorius, Göttingen, Germany 
Scanner CanoScan 8600F Canon 
Shaker PROMAX 2020 Heidolph 
Sonication device Bioruptor® Diagenode, Liège, Belgium 
Sonication device Bioruptor® Pico Diagenode, Liège, Belgium 
Spectrophotometer NanoDrop ND-1000 PeqLab, Erlangen, Germany 
Thermomixer comfort Eppendorf, Hamburg, Germany 
UV-transilluminator Intas UV system Gel Jet 
Imager Intas Science Imaging Instruments 
Vacuum pump IBS Integra Biosciences, Fernwald, Germany 
Vortex Genie 2 Scientific Industries, Bohemia, NY, United States 
Water bath TW 20 Julabo Labortechnik, Seelbach, Germany 
 
3.1.2 Consumables 
Table 3-2 Consumables 
Product Company 
96-well plates for qPCR 4titude, Wotton, United Kingdom 
Bacteria culture dishes Sarstedt, Nümbrecht, Germany 
Bacteria culture vials (14 cm) Becton Dickinson 
Bioruptor® Pico Microtubes with Caps (1.5 ml) Diagenode 
Cell culture dishes (10 cm, 15 cm) Greiner, Frickenhausen, Germany 
Cell culture plates (6-well, 12-well) Greiner, Frickenhausen, Germany 
Cell scraper (16 cm, 25 cm) Sarstedt, Nümbrecht, Germany 
Cryo tubes Cryoline Nunc, Thermo Scientific 
DNA LoBind tubes (1.5 mL) Eppendorf 
Filter tips (10 µL) Starlab, Hamburg, Germany 
Filter tips (20 µL, 200 µL, 1,000 µL) Sarstedt, Nümbrecht, Germany 
Parafilm Brand 
Pipet tips (10 µL, 20-200 µL, 1,000 µL) Greiner, Frickenhausen, Germany 
Protran nitrocellulose transfer membrane, 0.2 µM Whatman, Dassel, Germany 
Reaction tube (0.2 mL) Sarstedt, Nümbrecht, Germany 
Reaction tube (0.5 mL, 1.5 mL, 2.0 mL) Eppendorf, Hamburg, Germany 
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Falcon reaction tube (15 mL, 50 mL) Greiner, Frickenhausen, Germany 
Safe-lock reaction tube (1.5 mL) Eppendorf, Hamburg, Germany 
Sterile filter (0.2µM and 0.45µM) Millipore, Merck 
Syringe, 1mL, 5mL, 10mL, 50mL Henke-Sass, Wolf, Tuttlingen, Germany 
Syringe canules (different sizes) B.Braun, Melsungen, Germany 
Transparent sealing foil for 96-well plate 4titude, Wotton, United Kingdom 
Whatman paper Whatman, Dassel, Germany 
 
3.1.3 Chemicals and reagents 
Table 3-3 Chemicals and reagents 
Substance Company 
Acetic Acid Roth 
Acrylamide/bisacrylamide (A/BA) Roth 
Agar Sigma-Aldrich 
Agarose Roth 
Agencourt AMPure XP Beckman Coulter 
Albumin Fraction V (Bovine Serum Albumine, BSA) for 
molecular biology Roth 
Ammonium persulfate (APS) p.a. Roth 
Ammonium sulphate ((NH4)2SO4) >99.5%, p.a. Roth 
Ampicillin Roth 
Bromophenol blue Sigma-Aldrich 
Calcium chloride dihydrate (CaCl2 x 2H2O) >99%, p.a., ACS Roth 
Chloroform, Rotipuran Roth 
Complete Mini Protease Inhibitor EDTA free Roche, Basel, Schweiz 
Deoxynucleotide triphosphates (dNTPs) Primetech 
Deoxyribonucleotide triphosphates (dNTPs) in single tubes Primetech 
Dimethyl sulfoxide (DMSO) AppliChem 
Dithiotreitol (DTT) Roth 
DNA ladder GeneRuler Fermentas, Thermo Scientific 
DNA stain clear G (39804) Serva 
Ethanol 99.8% Roth 
Ethylene glycol tetraacetic acid (EGTA) Roth 
Formaldehyde, 37% solution Roth 
Glucose Roth 
Glycerol, >99%, p.a. Roth 
Glycerophosphate (ß-) dissodium salt hydrate Sigma-Aldrich 
Glycine, >99%, p.a. Roth 
Glycogen, molecular biology grade Roth 
HEPES Pufferan >99%, p.a. Roth 
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Hexadimethrine bromide (Polybrene) Sigma 
Hydrogen chloride (HCl) Roth 
Igepal (NP-40), Ca-630 Sigma-Aldrich 
Isopropanol Roth 
Lipofectamine RNAiMAX Invitrogen, Life Technologies 
Lipofectamine 2000 Invitrogen, Life Technologies 
Lithium chloride Roth 
Magnesium chloride hexahydrate (MgCl2 x 6H2O) Roth 
Magnesium sulfate (MgSO4) AppliChem 
Methanol >99% (MetOH) Roth 
Nonidet P-40 substitute (NP-40) Fluka 
Nuclease free water Ambion, Life Technologies 
Page Ruler™ Prestained Protein Ladder Fermentas, Thermo Scientific 
Pefabloc SC protease inhibitor Roth 
Pepstatin A AppliChem 
Phenol solution (pH 8,0) for ChIP Sigma-Aldrich 
Ponceau S Roth 
Potassium chloride (KCl) Applichem 
Potassium hydrogenphosphate (KH2PO4) Roth 
Powdered milk Roth 
Protein A/G Agarose Santa Cruz 
Puromycin Sigma-Aldrich 
Random Hexamer Primer (0.2µg/µL) Thermo Scientific fisher 
RNase inhibitor Fermentas, Thermo Scientific 
Rotiphorese Gel 30 Roth 
Sodium (di-) hydrogenphosphate dihydrate (Na2HPO4 x 
2H2O) >99%, p.a. Roth 
Sodium acetate (NaAc) Roth 
Sodium chloride (NaCl) Roth 
Sodium deoxycholate Applichem 
Sodium dodecyl sulphate (SDS) Biorad 
Sodium Ethylene diamine tetraacetatic acid (Na-EDTA) Roth 
Sodium hydrogen carbonate (NaHCO3), >99,5%, p.a., ACS, 
ISO Roth 
Sodium hydrogenphosphate monohydrate (NaHPO4 x H2O), 
p.a. Roth 
Sodium hydroxide (NaOH), pellets Sigma-Aldrich 
SYBR green Invitrogen, Life Technologies 
Tetramethylethylenediamine (TEMED) Merck 
Trehalose dehydrate Usb corporation, Cleveland 
Trisamine (Tris) Pufferan, >99% p.a. Roth 
Triton X-100, molecular biology grade Applichem 
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Trizol Invitrogen, Life Technologies 
Tryptone Roth 
Tween 20 Applichem 
 
3.1.4 Buffers and solutions 
6x Laemmli buffer 
  
Phosphate buffered saline 
(PBS), pH 7.4 Tris pH 6.8 0.35 M 
 Glycerin 30.00% 
 
NaCl 24.00 mM 
SDS 10.00% 
 
KCl 0.27 mM 
Dithiotreitol 9.30% 
 
Na2HPO4 x 7H2O 0.81 mM 
Bromophenol blue 0.02% 
 
KH2PO4 0.15 mM 
dissolved in H2O 
  
dissolved in H2O 
 
     Tris buffered saline + Tween 20 
(TBST), pH 7.6  
WB blocking solution 
 
milk powder 5% 
Tris 50 mM 
 
dissolved in TBST 
 NaCl 150 mM 
   Tween 20 0.10% 
 
RIPA lysis buffer, pH 7.5 
dissolved in H2O 
  
Triton X-100 1.00% 
   
Sodium 
deoxycholate 1.00% 
10x qPCR reaction buffer (RB) 
 
SDS 0.10% 
Tris (pH 8.8) 750 mM 
 
NaCl 150 mM 
(NH4)2SO4 200 mM 
 
EDTA 10 mM 
Tween 20 0.10% 
 
Tris-HCl, pH 7.5 20 mM 
dissolved in H2O 
  
dissolved in H2O 
 
     10x Western Salt buffer, pH 8.3 
 
Cell lysis buffer   
Tris 250 mM 
 
Urea 2 M 
Glycin 1,92 M 
 




 dissolved in H2O 
  
Pefabloc 10 μM 
   
Pepstatin A 1 μg/ml 
WB transfer buffer, pH 8.3 
 
Leupeptin/Aprotinin 1 μg/ml 
10x Western Salt buffer 10% 
   MetOH 20% 
 
SDS running buffer 
dissolved in H2O 
  
Tris 25.0 mM 
   
Glycin 86.1 mM 
   
SDS 3.5 mM 
  
dissolved in H2O 
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qPCR reaction mix, 25x  Ponceau S Solution 
10x qPCR RB 1x 
 
Ponceau S 0.50% 
SybrGreen 0,001620 
 
Acetic acid 1.00% 
MgCl2 3.0 mM 
 
dissolved in H2O  
Trehalose in 10 mM Tris 




Buffer A for chromatin harvest 
(for ChIP) dNTPs 0.2 mM 
 Triton X-100 0.25% 
 
NaCl 0.1 M 
Taq polymerase 20 U/mL 
 
EDTA, pH 8.0 1 mM 
dissolved in H2O 
  
EGTA, pH 8.0 0.5 mM 
   
HEPES pH 7.6 50 mM 
Buffer B for chromatin harvest      
(for ChIP)  
dissolved in H2O 
 
  
Triton X-100 0.25% 
 
Crosslinking buffer for 
chromatin harvest EDTA, pH 8.0 10 mM 
 EGTA, pH 8.0 0.5 mM 
 
PFA 1.1 % 
HEPES pH 7.6 20 mM 
 
Buffer A 7 % 
dissolved in H2O 
  
dissolve in PBS  
   
  
Buffer C for chromatin harvest          
(for ChIP)  
Washbuffer 1 for ChIP 
 
SDS 0.10% 
NaCl 0.15 M 
 
NaDOC 0.10% 
EDTA, pH 8.0 1 mM 
 
Triton-X-100 1% 
EGTA, pH 8.0 0.5 mM 
 
NaCl 0.15 M 
HEPES pH 7.6 50 mM 
 
EDTA, pH 8.0 1 mM 
dissolved in H2O 
  
EGTA, pH 8.0 0.5 mM 
   
HEPES pH 7.6 20 mM 
Washbuffer 3 for ChIP   
 
dissolved in H2O  









EDTA, pH 8.0 1 mM 
 
NaDOC 0.10% 
EGTA, pH 8.0 0.5 mM 
 
Triton-X-100 1% 
HEPES pH 7.6 20 mM 
 
NaCl 0.5 M 
dissolved in H2O 
  
EDTA, pH 8.0 1 mM 
   
EGTA, pH 8.0 0.5 mM 
Washbuffer 4 for ChIP 
  
HEPES pH 7.6 20 mM 
EDTA, pH 8.0 10 mM 
 
dissolved in H2O  
EGTA, pH 8.0 5 mM 
 
  
HEPES pH 7.6 200 mM 
 
  
dissolved in H2O 
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Elutionbuffer for ChIP 
  
Incubationbuffer stock for 
ChIP, 5x SDS 1%  
NaHCO3 0.1 M  SDS 0.75% 
dissolved in H2O   Triton-X-100 5% 
   NaCl 0.75 M 
CoIP buffer    EDTA, pH 8.0 5 mM 
Tris-HCl, pH 7.5 50 mM  dissolved in H2O 
 Sodium chloride 300 mM  
  NP-40 0.5 %  TAE buffer 
Sodium deoxycholate 0.1 %  Tris 40 mM 
Complete Mini, Protease 
Inhibitor Mix 
1 x  Acetic acid 20 mM 
  EDTA 2 mM 
dissolved in H2O   dissolved in H2O  
     
HBS Buffer    DNA gel loading buffer, 6x 
NaCl 68 mM  Sucrose 40% 
KCl 2,5 mM  Glycerin 10% 
Dextrose/Glucose 0,2 %  Bromophenol blue 0.25% 
Hepes 10,5 mM  dissolved in H2O  
Na2HPO4x7H2O 0,37 mM    
dissolved in H2O   
  pH between 6.8 and 7.0 with 1M NaOH 
  Re-pH a day or two later again  
   
3.1.5 Enzymes and buffers 
Table 3-4 Enzymes and buffers 
Reagent Company 
Buffer for M-MuLV RT, 10x New England Biolabs (NEB) 
Buffer for Taq (KCl+, -MgCl2), 10x Fermentas, Thermo Scientific 
M-MuLV Reverse transcriptase (RT) New England Biolabs (NEB) 
Maxima SYBR Green qPCR Master Mix Thermo Scientific 
Taq DNA polymerase (Taq) Fermentas, Thermo Scientific 
Taq DNA polymerase (Taq) for qPCR Primetech 
 
3.1.6 Kits 
Table 3-5 Kits 
Name Company 
Immobilon Western HRP Substrate Peroxide Solution Millipore, Merck 
Leukocyte Alkaline Phosphatase Kit (86R-1KT) Sigma 
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NEBNext® Ultra™ DNA Library Prep Kit for Illumina® New England Biolabs 
NEBNext® Multiplex Oligos for Illumina®                        
(Index Primers Set 1 and 2)  New England Biolabs 
MinElute PCR Purification Kit Qiagen 
Pierce BCA Protein assay kit Thermo Scientific fisher 
PureYield Plasmid Midiprep System Promega 
Qubit dsDNA HS Assay Kit Invitrogen 
SuperSignal West Femto Maximum Sensitivity Substrate Thermo Scientific fisher 
TruSeq RNA Sample Preparation Kit Illumina 
 
3.1.7 Plasmids 
Table 3-6 Plasmids 
Plasmid Origin 
pcDNA3 Invitrogen 
pcDNA3 Mdm2 301-491 cloned from pcDNA3 Mdm2 wt by site directed mutagenesis 
(QuikChange, Stratagene) 
pcDNA3 Mdm2 wt Addgene (#16233) 
pcDNA3 SUZ12 Flag S. Wu (Cao & Zhang, 2004) 
pCMV-dR.8.91 Plasmidfactory Bielefeld 
pCMV EZH2 HA K. Helin (Bracken et al, 2003) 
pCMV Mdm2 B. Vogelstein (Oliner et al, 1992) 
pCMV-myc3-HDM2 Addgene ( #20935) 
pCMV β-gal M. Dobbelstein (Dobbelstein et al, 1999) 
pMD2.G (VSV-G) Addgene (#12259) 
pTY-Control Y. Zhang (He et al, 2008)  
pTY-shRing1b Y. Zhang (He et al, 2008) 
M420 GFP from AG Dietrich, GSH Frankfurt  
 
3.1.8 Antibodies 
Table 3-7 Primary antibodies used for immunoblot, ChIP and Co-IP 
Antibody species Amount used Catalog # Source 
Anti-Flag Affinity Gel mouse 10 µl for 300 µl cell lysate A2220 Sigma 
EZH2 rabbit ChIP 2 µg C15410039  Diagenode 
EZH2 (AC22) mouse WB 1:1000; Co-IP 3 µg 3147 Cell Signaling 
GAL4(DBD) 
(RK5C1) 
mouse ChIP 2 µg sc-510 Santa Cruz 
H2AK119ub rabbit ChIP 2 µg C15410002 Diagenode 
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H3 rabbit ChIP 2 µg; WB 1:5000 ab1791 abcam 
H3K27me3 rabbit ChIP 2 µg; WB 1:5000 pAb-069-050 Diagenode 
IgG rabbit ChIP 2 µg; Co-IP 3 µg ab46540 Abcam 
Mdm2  mouse WB 1:500; ChIP 2 µg; 
Co-IP 3 µg 
IF2, OP46 Millipore 
RING1B (D22F2) rabbit WB 1:500; ChIP 2 µg 5694 Cell Signaling 
SUZ12 (D39F6) rabbit WB 1:500; Co-IP 3 µg 3737 Cell Signaling 
β-actin rabbit WB 1:10000 ab8227-50 Abcam 
β-actin (AC15) mouse WB 1:10000 ab6276-100 Abcam 
β-galactosidase mouse Co-IP 3 µg, WB 1:5000 Z378B Promega 
 
Table 3-8 Secondary antibodies used for immunoblot 
Antibody Company Cat. No. Dilution 
HRP-coupled AffiniPure F(ab')2 
fragment, anti mouse IgG (H+L) Jackson Immunoresearch 711-036-152 1:10,000 
HRP-coupled AffiniPure F(ab')2 
fragment, anti rabbit IgG (H+L) Jackson, Immunoresearch 715-036-150 1:10,000 
 
3.1.9 Inhibitors 
Table 3-9 Inhibitors 
Name Target/Function Company 
EPZ 6438 EZH2 inhibitor Epizyme 
MG132 Proteasome inhibitor Calbiochem 
 
3.1.10 Bacteria 
Table 3-10 Bacteria strains used for plasmid amplification 
Strain Description Source 
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Table 3-11 Bacteria growth medium 
2YT medium  2YT agar 
Tryptone 1.60%  YT agar 15% 
Yeast extract 1.00%  2YT medium 100% 
NaCl 0.50%    
     
3.1.11 Cell culture 
Table 3-12 Human and mouse cell lines 
Name Source 
HCT116 p53-/- p53-deficient human colon carcinoma cell line (Bunz et al, 1998) 
HEK 293T human embryonic kidney cells, harbouring SV40 antigen 
H1299 human non-small cell lung carcinoma cell line, homozygous partial deletion of P53 gene 
p53-/- MEF p53- and p53 Mdm2 deficient mouse embryonic fibroblasts; 
generated by Lozano lab, MD Anderson Cancer Center, Texas 
USA (Montes de Oca Luna et al, 1995) p53
-/- Mdm2-/- MEF 
p53-/- MEF 
p53-deficient mouse embryonic fibroblasts with additional Mdm2 
knock out or RING finger mutation knock in; generated by Zhang 
lab, UNC Medial School, North Carolina, USA (Clegg et al, 2012) 
p53-/- Mdm2-/- MEF 
p53-/- 
Mdm2C462A/C462A MEF 
SJSA human osteosarcoma cell line, overexpression of Mdm2 due to gene amplification 
 
Table 3-13 Cell culture media 
Reagent Company 
Antibiotic-Antimycotic (100X) Gibco, Life Technologies 
Dulbecco’s Modified Eagle Medium 
(DMEM), powder Gibco, Life Technologies 
Fetal Calf Serum (FCS) Gibco, Life Technologies 
L-Glutamine Gibco, Life Technologies 
Minimal essential medium (MEM) Gibco, Life Technologies 
Opti-MEM® I Reduced Serum Media Gibco, Life Technologies 
PBS (tablets) Gibco, Life Technologies 
Penicillin/Streptomycin Gibco, Life Technologies 
Trypsin/EDTA Gibco, Life Technologies 
McCoy's medium Gibco, Life Technologies 
 
 DMEM (dissolved in H2O) 
 DMEM, powder 10.0 g/L 
NaHCO3 3.7 g/L 
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HEPES 5.96 g/L 
dissolved in H2O 
   
DMEM with supplements 
 DMEM 
 FCS 10% 
L-Glutamine 200 µM 
Penicillin/Streptomycin 100 U/ml 
  McCoy's medium with 
supplements 
 McCoy's medium 
 FCS 10% 
L-Glutamine 200 µM 
Penicillin/Streptomycin 100 U/ml 
  
MEM with supplements  
MEM  
FCS 10% 
L-Glutamine 200 µM 
Antibiotic-Antimycotic (100x) 1x 
 
3.1.12 Oligonucleotides 
Table 3-14 Human siRNAs from Ambion/Life Technologies 
Target Catalogue No./ID Sequence 
EZH2 (a) 4390828 sense: 5'-GACUCUGAAUGCAGAAGCUtt-3' 
 
(customer select) antisense: 5'-AGCAACUGCAUUCAGAGUCtt-3' 
EZH2 (b) 4390828 sense: 5'-CGGUGGGACUCAGAAGGCAtt-3' 
 
(customer select) sense: 5'-UGCCUUCUGAGUCCCACCGtt-3' 
MDM2 (a) 4390829 sense: 5‘-GCCAUUGCUUUUGAAGUUAtt-3’ 
 
(customer select) antisense: 5’-UAACUUCAAAAGCAAUGGCtt-3' 
MDM2 (b) 4390824, s8630 sense: 5‘-AGUCUGUUGGUGCACAAAAtt-3’ 
 
(silencer select) antisense: 5‘-UUUUGUGCACCAACAGACUtt-3’ 
P53 4390824, s605 sense: 5‘-GUAAUCUACAGGGACGGAAtt-3’ 
 
(silencer select) antisense: 5‘-UUCCGUCCCAGUAGAUUACca-3’ 
RING1B (a) 4392420, s12068 sense: 5‘-CAAACGGACCAAAACAUCUtt-3’ 
 (silencer select) antisense: 5‘-AGAUGUUUUGGUCCGUUUGtt-3’ 
RING1B (b) 4392420, s12069 sense: 5‘-GGAGUGUUUACAUCGUUUUtt-3’ 
 (silencer select) antisense: 5‘-AAAACGAUGUAAACACUCCtt-3’ 
siRNA negative 
control 1 4390843 Undisclosed 
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Table 3-15 Primer sequences for gene expression studies in human cells 
hn36B4 forward 5’-GATTGGCTACCCAACTGTTG-3’ 
hn36B4 reverse 5’-CAGGGGCAGCAGCCACAAA-3’ 
hnALPL forward 5’-TGGGCCAAGGACGCTGGGAA-3’ 
hnALPL reverse 5’-AAGGCCTCAGGGGGCATCTCG-3’ 
hnBGLAP forward 5’-GCCCTCACACTCCTCGCCCT-3’ 
hnBGLAP reverse 5’-CGGGTAGGGGACTGGGGCTC-3’ 
hnBMP4 forward 5’-GAGTATCTAGCTTGTCTCCCCG-3’ 
hnBMP4 reverse 5’-ACAAACTTGCTGGAAAGGCTC-3’ 
hnCXCR4 forward 5’-CGCCTGTTGGCTGCCTTACT-3’ 
hnCXCR4 reverse 5’-ACAGAGGTGAGTGCGTGCTG-3’ 
hnDUSP4 forward 5’-ATGCTGGACGCCCTGGGCAT-3’ 
hnDUSP4 reverse 5’-CCCACGGCAGTCCTTCACGG-3’ 
hnEZH2 forward 5’-5’-AGCCGCCCACCTCGGAAATTT-3’ 
hnEZH2 reverse 5’-AGGAAGTGCGCCTGGGAGCT-3’ 
hnGDF6 forward 5’-ACTCCATCGCTGAGAAGCTG-3’ 
hnGDF6r reverse 5’-AGGAGTGTGCGAGAGATCG-3’ 
hnIGF2 forward 5’-CTCCTGGAGACGTACTGTGC-3’ 
hnIGF2 reverse 5’-ACGTTTGGCCTCCCTGAAC-3’ 
hnKLF2 forward 5’-TGCGGCAAGACCTACACCAAGAGT-3’ 
hnKLF2 reverse 5’-AGCCGCAGCCGTCCCAGTT-3’ 
hnMDM2 forward 5’-TCAGGATTCAGTTTCAGATCAG-3’ 
hnMDM2 reverse 5’-CATTTCCAATAGTCAGCTAAGG-3’ 
hnRNPK forward 5’-GACCGTTACGACGGCATGGTTGG-3’ 
hnRNPK reverse 5’-ATCCGGAGCCACCCTGTGGTT-3’ 
hnSNX31 forward 5’-ACAGTGAGGATAGTTGCTGGC-3’ 
hnSNX31 reverse 5’-AGTCTTTCTGCTGGCTTTGTTG-3’ 
hnTEX261 forward 5’-TGGACTCTATTACCTGGCAGAAC-3’ 
hnTEX261 reverse 5’-GCGCTCAAAGACGTAGAGG-3’ 
hnTIMP3 forward 5’-CTGTGCAACTTCGTGGAGAG-3’ 
hnTIMP3 reverse 5’-TCACAAAGCAAGGCAGGTAG-3’ 
hnWNT6 forward 5’-CAACTGCACAACAACGAGGC-3’ 
hnWNT6 reverse 5’-GCGAAATGGAGGCAGCTTCTG-3’ 
 
Table 3-16 Primer sequences for gene expression studies in murine cells 
mmHhip forward 5’-GCCTCACGACCACATTCTTC-3’ 
mmHhip reverse 5’-CAGAAACACCCTGGCTGTTC-3’ 
mmHoxb13 forward 5’-ATTCTCTGCTTCCCGTGGAC-3’ 
mmHoxb13 reverse 5’-CATACTCCCGCTCCAACTCC-3’ 
mmHoxc10 forward 5’-TCGGATAACGAAGCTAAAGAGGA-3’ 
mmHoxc10 reverse 5’-TCCAATTCCAGCGTCTGGTG-3’ 
mmHoxc13 forward 5’-AGTCTCCCTTCCCAGACGTG-3’ 
mmHoxc13 reverse 5’-GATGAATTTGCTGGCTGCGT-3’ 
mmHprt forward 5’-CGTCGTGATTAGCGATGATGAAC-3’ 
mmHprt forward 5’-CATCTCGAGCAAGTCTTTCAGTC-3’ 
mmNotch1 forward 5’- GTCAATGCCTCGCTTCTGTG-3’ 
mm Notch1 reverse 5’- ACAGAAGGTTACACAGGGACC-3’ 
mmJag1 forward 5’- CCTGTCATCGGGGGTAACAC-3’ 
mm Jag1 reverse 5’- CGAAGTGGGCAATCCCTGTG-3’ 
mmTxnip forward 5’- GAGTTCCAGTTCATGCCCCC-3’ 
mmTxnip reverse 5’- TTGCCACCCATCTTGAGGAG-3’ 
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Table 3-17 Primer sequences for targeted ChIP qRT-PCR in human cells 
CXCR4 for 5’-CAAATAAGCCCGGAGAGATG-3’ 
CXCR4 rev 5’-TTCTGATTCGTGCCAAAGC-3’ 
DUSP4 for 5’- GAGCCTCTTCTTCCCTGTCC-3’ 
DUSP4 rev 5’- GCGGTCCTCTCTCGTAAACAC-3’ 
FGF1 for 5‘-TTCTTTCCTAGTGCCCATCG-3’ 
FGF1 rev 5‘-TGTGTCAGCTCAGGGTTTTG-3’ 
GAPDH for 5’-TACTAG CGGTTTTACGGGCG-3’ 
GAPDH rev 5’-TCGAACAGGAGGAGCAGAGAGCGA-3’ 
KLF2 for 5’-TCAGGAGAGGAGGATGCGG-3’ 
KLF2 rev 5’-CTGCTTGCCTTTTACCACCC-3’ 
MYO for 5’- CTCATGATGCCCCTTCTTCT-3’ 
MYO rev 5’- GAAGGCGTCTGAGGACTTAAA -3’ 
TEX261 for 5‘-AAAGGAAGTTGCCCTGGGTC-3‘ 
TEX261 rev 5‘-GGGAATTAGGCCGGAGGATG-3‘ 
TGFBI for 5‘-GCTCTCTGGGTACAGCAAGG-3’ 
TGFBI rev 5‘-CCCCATTTGAACAGTGTGTG-3’ 
TLR3 for 5‘-CGAGAGTGCCGTCTATTTGC-3’ 




Table 3-18 Primer sequences for targeted ChIP qRT-PCR in murine cells 
Eomes forward 5`-AAATTCCACCGGCACCAAAC-3` 
Eomes reverse 5`-TAAACACCCTAAGCAGAGCCC-3` 
Evx1 forward 5`-TGGCAGCAGC CTTAAACCTT-3`  
Evx1 reverse 5`-AGCTGCAGTA GACCGTTGAC-3`  
Gapdh forward 5`-TCCTGGCTTCTGTCTTTGGC-3` 
Gapdh reverse 5`-GCATCCTGACCTATGGCGTA-3` 
Hhip forward 5`-TAATCCGGGAAGGCTTATGGG-3` 
Hhip reverse 5`-TCAAGGCAGAGATTGGGTACAG-3` 
Hoxb13 forward 5`-GGGTCGGAATCTAGTCTCCC-3` 
Hoxb13 reverse 5`-CACTGCTTTGGTGGCTCTG-3` 
Hoxc10 forward 5`-TTCAACTGCGGGGTGATGAG-3` 
Hoxc10 reverse 5`-AGAGGTAGGACGGGTAGGTG-3` 
Hoxc11 forward 5`-GTGCTCGGGGAGAGAGACTA-3` 
Hoxc11 reverse 5`-CGTTCTCTTCTCCTGCCTCC-3` 
Hoxc13 forward 5`-CGAGCTATGCTGAGGAATGC-3` 
Hoxc13 reverse 5`-GATTGCTTCACTCTGGACCC-3` 
Tuba1a forward 5`-AGGTAATCTCTCCCCCACCC-3` 
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3.1.13 Software and databases 
Table 3-19 Software 
Name Company 
AxioVision 3.0  Zeiss 
CFX Manager Software  
for qPCR cycler  
Bio-Rad 
Excel Microsoft, Redmond, WA, United States 
Graph Pad Prism GraphPad Software, Inc., CA, USA 
INTAS lab ID  Intas Science Imaging Instruments 
NanoDrop Software Peqlab 
R studio R studio, Boston, USA 
UV imager software Intas Science Imaging Instruments 
IGV 2.3 Broad Institute of MIT and Harvard, Boston, USA (Robinson et al, 




www.usegalaxy.org; www.cistrome.org/ap/root; open source, 
web-based platform for data intensive biomedical research; used 
for ChIP-Seq analysis (Blankenberg et al, 2010; Giardine et al, 
2005; Goecks et al, 2010; Liu et al, 2011; Ramírez et al, 2014) 
 




www.ensembl.org software system for automatic annotation on 
selected eukaryotic genomes; used for gene expression primer 
design 
UCSC genome browser www.genome.ucsc.edu information on ENCODE analysis, finding 
functional elements on the human and mouse genome; used for 
ChIP-Seq track analysis and ChIP targeted PCR primer design 
NCBI Pubmed www.ncbi.nlm.nih.gov/pubmed; literature search 
NIH Roadmap 
Epigenomics 
www.ncbi.nlm.nih.gov/epigenomics; genome viewer for genome-
wide maps of DNA and histone modifications from diverse 
epigenomic data sets; used for protein-chromatin binding prediction 
and targeted ChIP PCR primer design 
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3.2 Methods 
3.2.1 Cell Biology 
3.2.1.1 Transformation of chemically competent E.coli 
For heat shock transformation of chemically competent E.coli, 1 µl of DNA was incubated with 
50 µl of competent cells for 30 min on ice, 10 min at 37 °C and another 10 min on ice. 
Afterwards, 200 µl of LB was added and cells were mildly shaken at 37 °C for 30-60 min. The 
cells were then plated onto an 2YT Agarplate with the appropriate antibiotic (Ampicillin 100 
µg/mL, Kanamycin 50 µg/ml) and incubated overnight at 37 °C. After overnight incubation a 
single colony was picked using an autoclaved 10 µl pipet tip which was then given into 5 ml of 
2YT medium containing antibiotic. The 5 ml culture was kept at 37 °C shaking for 8-12h and 
was then transferred into 45 ml of 2YT medium overnight (37°C, shaking).  
3.2.1.2 Culture of adherent cells 
Cell culture work was conducted under sterile conditions and human as well as mouse cells 
were grown in cell culture dishes in a humidified atmosphere at 37 °C and 5 % CO2. The 
different cell lines used were cultured in specific media (Table 3-13 and Table 3-21) and were 
sub-cultured 2-3 times a week dependent on confluence. For this purpose, growth medium was 
removed the cells were washed with pre-warmed PBS and detached using a 3-5 min incubation 
with 0.1 % trypsin/EDTA. An appropriate portion of the detached cells were transferred to a new 
culture plate and taken up in new growth medium to stop the trypsinization process and for 
continuous culture.  
Table 3-21 Specific culture medium for cell culture 
Cell line Growth medium 
HCT116 p53-/- McCoy's with supplement 
hMSCs MEM with supplements 
H1299 DMEM with supplements 
MEF  DMEM with supplements 
SJSA DMEM with supplements 
PANC1 DMEM with supplements 
 
For experimental purposes the cells were seeded in appropriate amounts into specific culture 
dishes. For counting, the cells were taken up into fresh medium after trypsinization and were 
counted using a Neubauer counting chamber. 
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3.2.1.3 Freezing and thawing of cells 
For long term storage, cells were expanded in 15cm culture dishes and harvested using 
trypsin/EDTA as described above. After detaching, the cells were transferred into a falcon tube 
of appropriate size and counted. After determination of the cell number the cell suspension was 
centrifuged at RT and 1000 g for 5 min and settled cells were taken up in pre-cooled FCS 
supplemented with 10 % DMSO to a final concentration of 1x106 cells/ml. Cryo vials were filled 
with 1 ml of the cell suspension and frozen for 24 h at -80 °C before moving them into -196 °C 
liquid nitrogen. 
For thawing, the cryo vials were taken out of the liquid nitrogen and the cells were transferred as 
quickly as possible into pre-warmed growth medium into 15cm dishes and grown as described. 
As soon as the cells had settled, the medium was exchanged in order to get rid of residual 
DMSO. 
 
3.2.1.4 Transient siRNA knock down in human cells 
Transient knock down of gene expression was done with a reverse siRNA transfection 
procedure using final concentrations of 10 or 15 nM siRNA (Table 3-14). Therefore, the 
transfection reagents were prepared according to the following scheme:  
Table 3-22 siRNA transfection set up 
Cell line Culture plate 
Cell 
number Solution A Solution B 
final 
volume 
      250 µl DMEM(-), 
100 nM siRNA 




p53-/- 6 well 400,000 2.5 mL 
   250 µl Opti_MEM(-), 2.5 µl Lipofectamine 
RNAiMax, 60 nM siRNA 
 
hMSCs 12 well 100,000 1 mL 
   
250 µl DMEM(-), 
100 nM siRNA 
250 µl DMEM(-), 5 µl 
Lipofectamine 2000  MCF7 6 well 400,000 2.5 mL 
   250 µl DMEM(-), 
100 nM siRNA 
250 µl DMEM(-), 5 µl 
Lipofectamine 2000 
 
PANC1 6 well 180,000 2.5 mL 
   250 µl DMEM(-), 
100 nM siRNA 
250 µl DMEM(-), 5 µl 
Lipofectamine 2000 
 
SJSA 6 well 125,000 2.5 mL 
 
Solution A and B were vortexed and incubated for 5 min at RT before they were mixed and 
incubated at RT for another 20 min. For hMSC transfection only one solution was made 
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containing all transfection reagents at once. In the 20 min incubation time, target cells were 
detached from their culture plate via trypsinization and counted as described before (cf. 
paragraph 3.2.1.2). The transfection mixture was transferred into the culture plate and cells 
were added in the appropriate volume in growth medium without antibiotics. For proper 
distribution the culture plate was shaken gently. 24 h after transfection the transfection medium 
was removed and cells were grown further in normal growth medium with supplements.  
For better knock down efficiency, the cells were treated with a double transfection protocol. 48 h 
after the first transfection, cancer cells were reverse transfected again following the protocol as 
before. hMS cells were treated with a forward transfection 72 h after the first knock down (kd), 
giving the transfection reagent directly onto the attached cells.  
After 96h of knock down in total the cancer cells were harvested for RNA and protein isolation.  
   
3.2.1.5 Transient vector transfection of human cells 
For expression vector transfection a forward transfection procedure of the plasmid DNA (cf. 
Table 3-6) in H1299 cells was followed. 280,000 cells were seeded 24 h before transfection into 
the wells of a 6-well plate. The transfection solutions A and B (specific volumes described in 
Table 3-23) were handled as described in 3.2.1.4. 6 h after transfection the transfection medium 
was removed and the cells were grown in normal growth medium with supplements. 24 h after 
transfection the cells were harvested. 
Table 3-23 Plasmid transfection set up 
Cell line culture dish cell number solution A solution B final volume 
H1299 6 well plate 
 
200 µl DMEM(-), 
2.4 µg DNA 
200 µl DMEM(-), 8 µl 
Lipofectamine 
2.4 mL 
     
3.2.1.6 Differentiation of human mesenchymal stem cells into osteoblasts 
To analyze the effect of gene expression kd on stem cell differentiation, human mesenchymal 
stem cells (hMSCs) were transfected with siRNA as described in 3.2.1.4. Differentiation of 
MSCs was started 24 h after the first transfection via culturing the cells in osteoblast 
differentiation medium (cf. Table 3-24), which was described by Karpiuk and colleagues 
(Karpiuk et al, 2012). Differentiation media was exchanged every 24 h for 5-7 days and cells 
were then harvested for RNA and protein isolation as well as alkaline phosphatase staining. 
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Alkaline phosphatase staining was done using the Leukocyte Alkaline Phosphatase Kit by 
Sigma (cf. Table 3-5). 
Table 3-24 Osteoblast differentiation medium by Karpiuk and colleagues 
Osteoblast Differentiation Media 
MEM with supplements (Table 3-13) 
β-Glycerophosphate disodium salt hydrate 10 mM   
Ascorbate 0.2 mM 
Vitamin D 10 nM 
 
3.2.1.7 Induction of pluripotent stem cells from murine embryonic fibroblasts 
This procedure was carried out by Alice Nemajerova from the Department of Pathology of the 
Stony Brook School of Medicine according to a method described previously (Nemajerova et al, 
2012). Briefly, human Klf4, Oct4 and Sox2 in the retroviral vector Rebna were transfected into 
packaging Phoenix E cells using Lipofectamine. 24 hours later, transfected Phoenix E cells 
were selected with 2 ug/ml puromycin for 2-3 days. Viral supernatants were collected and 
filtered through a 0.45-μm cellulose acetate filter. MEFs were plated at a density of 2 × 105 cells 
per 6-cm plate and incubated with the viral supernatant overnight. After four successive 
infections, cells were switched to knockout serum replacement (KSR) medium consisting of 
DMEM/F12 containing 10% KSR (Invitrogen), 1 × nonessential amino acids, 1 × Glutamine, 1 × 
Pen/Strep, 0.1 μM β-mercaptoethanol and 1000 U/ml leukemia inhibitory factor (Millipore). The 
transduction efficiency of MEFs was determined by extrapolation from parallel infections with 
GFP-expressing control viruses. Efficiency of iPSC production was determined based on their 
undifferentiated morphology. Also, all hand-picked iPSC colonies (11-21 dpi) were transferable 
and could be further propagated on feeder cells (irradiated mouse embryo fibroblasts, 
GlobalStem). 
3.2.1.8 Clonogenic assay of MCF7 cells  
MCF7 cells were transfected with siRNAs as described above (3.2.1.4). 48 hrs post-
transfection, cells were trypsinized, counted and seeded in 6-well plates (40,000 cells/well). 
After 7 days of growth, cells were washed with PBS and fixed with methanol at 4°C for 30 min. 
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3.2.1.9 Generation of stable Ring1b kd MEFs using shRNA 
To generate stable knock down cells, lentiviral constructs expressing pTY-Puro-shRing1b were 
generated in HEK293T cells (pTY constructs were kindly provided by Prof. Yi Zhang (He et al, 
2008)). Briefly, HEK cells were seeded in 10 cm cell culture dishes and transfected with 2.5 µg 
shRNA construct, 1.6 µg pCMV-dR.8.91 and 1 µg pMD2.G (VSV-G) packaging plasmid (Naldini 
et al, 1996; Stewart et al, 2003) using calcium phosphate transfection (Graham & Van der Eb, 
1973). For control purposes lentiviruses expressing GFP were generated in addition. Plasmids 
and buffers were set up in the following ratios per 10 cm dish: 
2x HBS buffer (see also 3.1.4) 500 µl 
Sterile H2O 440 µl – plasmid volume 
2 M CaCl2 60 µl (added last, followed by vigorous shaking) 
 
24 h after transfection the medium was changed. MEF cells were seeded accordingly (one well 
of a 6-well plate was transduced with virus produced from a 10 cm dish Plat-E cells) and 
transduced twice with generated virus (48 and 72h after transfection). For transduction, virus 
supernatant was filtered through a 0.45 µm sterile filter and supplemented with final 
concentrations of 8 µg/ml polybrene.  
72h after the first transduction, MEF cells were splitted as appropriate and stable kd cells were 
selected using final concentrations of 1.5 µg/ml puromycin in growth medium. After selection, 
puromycin was removed and cells were used for qRT-PCR and cell growth analysis. 
 
3.2.1.10 Proliferation assay (Celigo) 
Cells were transfected with siRNA as described above (3.2.1.4), and cell proliferation was 
measured using automated light microscopy with quantitative image analysis (Celigo, 
Nexcelom, software version 2.0). 24 h after the second transfection, cells were harvested via 
trypsinization and counted. From each transfection sample, three replicates of 20.000 cells 
(HCT116 cells; 10,000 cells taken for experiments with SJSA and PANC1 cells) were seeded 
into 12-well plates, and cell confluence was measured every 24 h for 4-6 days. 
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3.2.1.11 Protein harvest of cultured human and mouse cells 
For protein isolation, cells were handled on ice to avoid proteolytic degradation. For all cancer 
cells as well as the hMSCs one well of a 6-well plate was sufficient for the protein amounts 
desired. MEF cells were harvested from one 10cm dish.  
6-well plates were kept on ice and the cells were scraped from the plate directly in the growth 
medium using a cell scraper. Cell containing medium was then transferred into a 2 mL 
Eppendorf tube which was centrifuged at 3000 g and 4 °C for 5 min. The supernatant was 
removed without disturbing the cell pellet and cells were washed with ice-cold PBS. After 
removal of PBS, the cells were taken up in Cell Lysis Buffer (cf. paragraph 3.1.4) and boiled at 
95 °C for 5min before sonication for 10 min at high power using 30 s on/off cycles. 150-200 µl of 
cell lysis buffer was used depending on cell confluence. 
MEF cell proteins were harvested directly in the 10 cm culture dish. For this the growth medium 
was removed and cells were washed in the dish with ice-cool PBS. After removal of PBS the 
cells were scraped from the plate directly in cell lysis buffer. The lysate was transferred into an 
Eppendorf tube and treated by sonication as described before. 250 µl of cell lysis buffer was 
used per dish. 
In order to determine the protein concentration, a Bicinchoninic Acid (BCA) test was performed 
(cf. Table 3-5) as indicated by the manufacturer’s instructions. Protein samples with adjusted 
concentration were then incubated with 6x Laemmli buffer (cf. paragraph 3.1.4) for 5 min at 
95 °C in the ratio 2:3.  
 
3.2.2 Molecular Biology 
3.2.2.1 Isolation of plasmid DNA 
Plasmid DNA was isolated from a 50 ml culture of transformed E.coli using the PureYield 
Plasmid Midiprep System according to the manufacturer’s instructions (Table 3-5). Elution was 
done using 500 µl of nuclease free H2O and plasmid concentration was determined using the 
NanoDrop ND-1000. 
3.2.2.2 Gene Expression Analysis 
To evaluate mRNA expression in target cells, RNA was isolated from cells, reverse transcribed 
into cDNA and analyzed via quantitative real-time PCR (qRT-PCR) or whole transcript 
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hybridisation or -sequencing. For all cells that were handled, one well of a 6-well plate was 
enough to harvest sufficient amounts of RNA. 
3.2.2.2.1 RNA isolation 
Cells were washed with PBS directly in the plate and lysed for 5 min in 1 mL TRIzol® RNA 
Isolation Reagent and isolation procedure was continued according to the manufacturer’s 
instructions. The lysate was transferred into an Eppendorf tube and mixed 1:5 with chloroform 
via shaking for 15 s and incubation at RT for 3 min. Afterwards the mixture was centrifuged at 
12.000 g for 20 min at 4 °C and the colorless upper phase was mixed in a new tube with 500 µl 
isopropanol and incubated for 10 min at RT. The tube was centrifuged at 12.000 g and 4 °C for 
at least 30 min, the supernatant was discarded and the resulting RNA pellet was washed twice 
with 500 µl of 75 % EtOH. The supernatant was discarded and the pellet was dried at 37°C for 
15 min and resuspended in 10-30 µl (depending on pellet size) RNase-free water via incubation 
at 55 °C for 3 min. 
For purification purposes, isolated RNA was mixed via vortexing with 1-2 µl GlycoBlue, 1:10 v/v 
3 M NaAc (pH 5.2) and 2.5 time volume µl of EtOH abs. and centrifuged for another 15 min at 
12.000g. The resulting (blue) pellet was washed with 70 % EtOH, dried and resuspended in 
10-30 µl RNase-free water. RNA concentration and purity was measured with the 
spectrophotometer NanoDrop ND-1000, using absorbance values at 230, 260 and 280 nm. 
Absorbance at 260 nm was used for concentration analysis whereas contamination with protein 
and/or aromatic solvents was determined with the 230 and 280 nm absorbance ratios. The 
following ratios were used as purity standards:    
A260/A280 > 1.8  
A260/A230 > 2.0 
3.2.2.2.2 cDNA synthesis 
Reverse transcription of the harvested RNA into a complementary DNA (cDNA) library was 
done using a reverse transcriptase (RT) derived from moloney murine leukemia virus (M-MuLV, 
see also Table 3-4) (Spiegelman et al, 1971). After determination of RNA concentration, 1 µg of 
total RNA was mixed with 2 µl of combined primers (50 µM Oligo dT23VN Primer and 15 µM 
random nonamer primer), 4 µl of 2.5 mM dNTP mixture and RNase-free water to a final volume 
of 16 µl and was incubated at 70 °C for 5 min. After this, the reagents were spun down and put 
on ice. To each reaction 4 µl of the following master mix was given for a final volume of 20 µl. 
For control purposes all samples were prepare with and without the addition of reverse 
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transcriptase (-RT control) to avoid signal contamination with DNA that could have been co-
purified together with the isolated RNA.  
Table 3-25 cDNA synthesis master mix 
Component (for 1 reaction) Volume [μl] 
10x Reaction Buffer for M-MuLV Reverse Transcriptase 2 
RNase Inhibitor (10 U) 0.25 
M-MuLV Reverse Transcriptase (25 U) 0.125 
H2O 1.625 
 
The reverse transcription reaction was carried out for 1 h at 42 °C with subsequent enzyme 
inactivation at 95 °C for 5 min and storage at 4 °C. Before usage, the resulting cDNA was 
diluted 1:50 and 5 µl of cDNA was used for qRT-PCR analysis 
3.2.2.2.3 Quantitative real time polymerase chain reaction (qRT-PCR) 
qRT-PCR was conducted via real time analysis of PCR amplification with SYBR green 
fluorescent dye incorporation for quantitative analysis (PCR originally described by Mullis and 
colleagues (Saiki et al, 1985) and further developed for quantification by Higuchi et al. (Higuchi 
et al, 1993). The reaction set up was pipetted as follows for a total reaction volume of 25 µl. For 
enzyme and buffer information see also Table 3-4 and 3.1.4. Each PCR reaction was conducted 
in triplets via the following program shown in Table 3-27. 
Table 3-26 qRT-PCR reaction set up 
Component Stock [μl] for 1 reaction 
qPCR reaction mix 
 
14 
forward primer 100 pmol/μl 0.1 








Table 3-27 qRT-PCR protocol for gene expression studies 
Step Temperature Time 
1 95 2 min 
2 95 15 s 
3 60 30 s 
4 fluorescence read  
back to step 2, 39 times more 
5 melting curve, 55-95 °C 
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Analysis was done using the ΔΔCt method according to Livak and colleagues (Livak & 
Schmittgen, 2001). Gene expression was normalized to the housekeeping gene 36B4, an acidic 
ribosomal phosphoprotein P0 (RPLP0) for all cancer cell lines and HPRT1 for all MEF cells. 
MSC gene expression was normalized to the heterogeneous nuclear ribonucleoprotein K 
(hnRNPK). Primer sequences that were used for qRT-PCR analysis are listed in Table 3-15 and 
Table 3-16. 
 
3.2.2.2.4 Global gene expression analysis using microarray 
Microarray analysis was performed to generate global expression data from HCT116 and hMS 
cells that had undergone Mdm2 knock down. For each approach, RNA of a minimum of two 
replicates per sample was isolated (3.2.2.2.1) and given to the transcriptome analysis laboratory 
(TAL) Göttingen. Via Bioanalyzer measurements RNA quality and concentration was 
determined and 200 ng of total RNA were reverse transcribed into cDNA. Cy3-CTP labelled 
antisense RNA was subsequently generated from the cDNA using dNTPs (including Cy3-CTP) 
and T7 RNA polymerase and was hybridized to a microarray slide in the presence of 
complementary oligonucleotides. For the visualization of complementary bound probes the 
microarray slides were excited with a laser beam of defined wavelength and fluorescent 
emission of the Cy3 signal intensity was measured. In the case of intensive gene transcription 
strong fluorescence emission was expected, and vice versa. According to this principle control- 
and target kd samples were compared and analyzed which was done by Claudia Pommerenke 
(former bioinformatician at TAL). Biological replicates were combined and the threshold of 
differentially regulated mRNA expression was set to 1 given as log2 induction values.   
3.2.2.2.5 Global gene expression analysis using RNA-Sequencing 
For RNA-sequencing the quality of total RNA was determined with the Bioanalyzer 2100 from 
Agilent. All samples analyzed exhibited a RIN>8. Library preparation was conducted by using 
the TruSeq RNA LT SamplePrep Kit (Illumina) starting from 1000 ng of total RNA. Barcodes for 
sample preparation were used according to the indications given by the protocol. Accurate 
library quantitation of cDNA libraries was performed with the QuantiFluor™dsDNA System 
(Promega). The size range of final cDNA libraries was determined applying the DNA 1000 chip 
on the Bioanalyzer 2100 from Agilent (290-310 bp). cDNA libraries were amplified and 
sequenced via cBot and HiSeq 2000 from Illumina (SR, 1×50 bp, 6 Gb/sample ca. 30 million 
reads per sample). Sequence images were transformed with Illumina software BaseCaller to bcl 
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files, which were demultiplexed to fastq files with CASAVA (version 1.8.2). Quality check was 
done via FastQC (version 0.10.1, Babraham Bioinformatics). Fastq files were mapped to the 
mm9 reference transcriptome (UCSC) using Bowtie 2 (version 2.1.0) (Langmead & Salzberg, 
2012). Read counts for each sample and each gene were aggregated using a custom Ruby 
script. DESeq (version 1.14.0) was used for measuring differential expression (Anders & Huber, 
2010) and heatmaps were calculated via the heatmap.2 function of the R package gplots. RNA 
library preparation and sequencing was done by the Transcriptome and Genome Analysis 
Laboratory (TAL, University Medical Centre, Göttingen) as also published before (Pirouz et al. 
2015). 
 
3.2.2.3 Preparation of a ChIP-sequencing (ChIP-Seq) library 
ChIP-Seq libraries were prepared according to the instructions given in NEBNext Ultra™ DNA 
Library Prep Kit for Illumina. Before preparation, the concentration of precipitated DNA was 
measured using the Qubit Fluorometer and the Qubit dsDNA HS Assay Kit. 10 ng of input DNA 
and 2.5 ng of histone ChIP DNA were taken up in a total volume of 55.5 µl in nuclease free 
water, using DNA LoBind tubes, and were sonicated in the Biorupter Pico (20 cycles, 30 s on, 
30 s off). This additional sonication step ensured fragment DNA fragment size around 300 bp. 
Fragment end preparation and adapter ligation was done as described in the manual. For 
adaptor ligation the adaptors were diluted 1:15 for input ChIP DNA and 1:20 for histone ChIP 
DNA. Afterwards a cleanup of adaptor-ligated DNA without size selection was performed using 
77.85 µl (0.9x) Agencourt AMPure XP magnetic beads per sample and the DynaMag™-2 
magnetic rack for magnetic separation. PCR amplification and subsequent cleanup of PCR 
amplification was done according to the manufacturer’s advice. Different index primers were 
taken for each sample and the PCR cycling protocol was conducted using 13 cycles for 10 ng 
and 17 cycles for 2.5 ng of starting ChIP DNA material. The concentration of the prepared 
library samples were measured using the Qubit Flourometer and were analyzed for size 
distribution on an Agilent high sensitivity chip (done by TAL, University Medical Center, 
Göttingen). Library preparations were expected to have an average fragment size of 280-320 bp 
and no contamination with adaptor dimers as shown in Figure 3-1. In the case of adaptor dimer 
presence the last AMPure XP bead cleanup was repeated and the samples were analyzed 
again. Library sequencing was done as described in 3.2.2.4. 
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Figure 3-1 ChIP-Seq library size distribution analysis on an Agilent high sensitivity chip 
A ChIP-Seq library was prepared from p53-/- MEFs input ChIP DNA and was analyzed for size 
distribution and adaptor dimer contamination on an Agilent high sensitivity chip.   
3.2.2.4 Sequencing of ChIP-Seq libraries and subsequent analysis 
Sequencing of prepared ChIP DNA libraries was performed by the TAL using the Illumina HiSeq 
2500. Libraries were amplified and sequenced by using cBot and HiSeq 2000 from Illumina (SR, 
1×50 bp, ca. 25 million reads per sample). Sequence images were transformed with Illumina 
software BaseCaller to bcl files, which were demultiplexed to fastq files with CASAVA (version 
1.8.2). Quality check was done via FastQC (version 0.10.1, Babraham Bioinformatics). 
Resulting reads were mapped to the mouse genome (UCSC mm9) using Bowtie 2 (Galaxy Tool 
Version 0.4) (Langmead et al, 2009) and peak calling was performed using MACS (Galaxy Tool 
Version 1.0.1) (Zhang et al, 2008). Coverage was determined by normalizing the total number of 
mapped reads per hundred million and the data was visualized using the Integrative Genome 
Viewer (Thorvaldsdottir et al, 2013). Differential methylation and ubiquitination patterns were 
determined using DiffBind analysis in R (Stark & Brown, 2011). Gene body coordinates and 
TSSs were obtained from UCSC Table Browser (Karolchik et al, 2004). Aggregation plots 
around defined regions were calculated using the “computeMatrix” and “heatmapper” function in 
Galaxy/deeptools (Ramírez et al, 2014). Galaxy/deeptools functions were also used for the 
generation of fused RNA-Seq and ChIP-Seq data. 
3.2.3 Protein biochemistry 
3.2.3.1 SDS-PAGE 
In 1967, Shapiro and colleagues developed a method called SDS-PAGE (Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis) which they used for protein separation depending on 
electrophoretic mobility and molecular weight (Shapiro et al, 1967). Therefore, they denatured 
p53-/- MEF Input DNA 
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their protein samples in a buffer devised by Laemmli and colleagues (Laemmli, 1970), which 
was characterized by the anionic detergent sodium dodecyl sulfate (SDS). Thereby they 
ensured a constant negative charge of the protein and a tendency to move to the anode in an 
electric field. The proteins are run in a two-phase gel which consists of an upper stacking gel 
and a lower separation gel and are separated according to the principle that lower weight 
proteins migrate faster through the gel than those with larger weight.  
Within the stacking gel, which is characterized by an acrylamide/bisacrylamide (A/BA) 
concentration of 5 %, a pH of 6.8 and relatively large gel pores, the denatured proteins are 
stacked between the leading chloride ions and the trailing Glycine ions. Protein separation is 
then conducted in the lower gel part with A/BA concentration of 12 % and a pH of 8.8. 
Depending on the separation grade higher or lower percentage separation gels can be used.   
Gels for protein separation were casted as described in Table 3-28 between two glass plates. 
First the stacking gel was applied and overlaid with 2-Propanol to avoid air bubble formation at 
the top. After polymerization, 2-Propanol was removed and stacking gel was applied. For 
protein application into the gel, 10- or 15-slot combs were inserted into the not yet polymerized 
stacking gel. 
Table 3-28 Stacking and separating gel composition for SDS-PAGE 
Compound Stacking gel Running gel 
Acrylamide-bisacrylamide 5% 12% 
Tris-HCl, pH 6.8 (0.5 M) 125 mM - 
Tris-HCl, pH 8.8 (1.5 M) - 380 mM 
SDS (10%) 0.1% 0.1% 
APS (10%) 0.1% 0.06% 
TEMED 0.2% 0.06% 
  
Cell lysates were prepared as described in 3.2.1.7. Before gel application the proteins were 
boiled for another 5 min at 95 °C. Gel combs were removed and the gels were placed into the 
electrophoresis system containing 1 x SDS running buffer. 20-45 µl of protein samples were 
applied into each slot together with at least one lane containing 5 µl of protein marker and gels 
were run at constant current of 20 mA per gel. 
3.2.3.2 Immunoblotting 
Proteins that are separated by SDS-PAGE can be specifically analyzed using immunoblotting 
(also known as Western Blotting, WB), which enables visualization of protein levels as well as 
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post-translational modification and interaction. The blotting procedure hereby follows the original 
protocol developed by Renart et al. as well as Towbin and colleagues (Renart et al, 1979; 
Towbin et al, 1979). The separated proteins were transferred onto a 0.2 μm pore size 
nitrocellulose membrane via the wet-blot application (Bittner et al, 1980) using WB transfer 
buffer for 1.5 h at 100 V. To estimate transfer efficiency, the membrane was stained with 
Ponceau S and then washed with TBST. For blocking purposes, the membrane was 
subsequently incubated for at least 45 min in WB blocking solution and was then labelled with 
the appropriate primary antibody (see also Table 3-7) diluted in blocking solution at 4 °C 
overnight. After primary antibody binding the nitrocellulose was washed 3x 10 min in blocking 
solution before incubation with donkey anti-mouse or anti-rabbit secondary antibody (see Table 
3-8). Used secondary antibodies were coupled to horseradish peroxidase (HRP) and applied 
1:10000 diluted in blocking solution for 1 h at RT. Before antibody binding detection, the 
membrane was washed again three times for 10 min in blocking solution. 
Antibody binding was detected using either Super Signal West Femto Maximum Sensitivity 
Substrate for expected weak signals, or Immobilon Western Chemiluminescent HRP Substrate 
for expected strong signals. HRP coupled to the secondary antibody oxidizes the luminol 
contained in the substrate solution, emitting light that can be detected on a light sensitive film or 
by a chemiluminescent sensitive camera. 
3.2.3.3 Complex Immunoprecipitation (Co-IP) 
Co-IP was performed to detect interaction between Mdm2 and PRC2 complex members. In this 
project Co-IP was done either with endogenous protein levels or after exogenous 
overexpression. For exogenous Co-IP, cells were transfected and harvested from a 6-well plate 
(cf. paragraph 3.2.1.5). Endogenous Co-IP was performed in SJSA cells and cells from one 15 
cm dish were harvested for one antibody precipitation. Before harvesting, cells were treated with 
the protease inhibitor MG-132 for 6-8 h (20 µM final concentration, only for endogenous Co-IP). 
Reagents volumes used in the protocol are depicted in Table 3-29. Co-IP samples were always 
handled on ice or at 4 °C. 
Table 3-29 Co-IP set up 





SJSA Endogenous 15 cm dish 1 mL 1 mL 50 µl + 50 µl 
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Before cells were harvested for Co-IP, protein G sepharose (PGS) was equilibrated. Therefore, 
the 50/50 slurry beads per sample were washed 3 times with Co-IP buffer (cf. paragraph 3.1.4) 
with intermediate centrifugation at 3000 rpm for 2 min. Afterwards the beads were taken up in 
equal volumes of fresh Co-IP buffer. 
Growth medium was removed from the cells and the cells were washed with pre-cooled PBS. 
Co-IP buffer was added to the washed cells and cells were scraped from the plate and 
transferred into a tube. The cell lysate was homogenized via pushing it through a 26G syringe 
(5x) and sonicated using a Bioruptor® at medium power for 10min (30 s on, 30 s off) for DNA 
disruption. For the removal of cellular debris the lysate was then centrifuged at maximum speed 
for 10 min and the supernatant was transferred into a new tube. For control purposes a 
supernatant sample and the cell pellet were taken up in 6x Laemmli to test protein solubility. 
In order to get rid of unspecific bead reactions, the protein lysates were pre-cleared with 50 µl of 
prepared PGS beads via incubation for one hour on a rotator. The beads were centrifuged down 
and pre-cleared cell lysates were transferred into a new tube. 20-50 µl of each lysate were 
boiled with equal amounts of 6 x Laemmli buffer and taken as input control. 
For immune-reaction, each cell lysate was now substituted with 2 µg of antibody binding the 
protein of interest on a rotating device overnight. For background control, one sample of each 
lysate was also incubated with a non-specific IgG antibody. For immunoprecipitation, PGS 
beads were prepared as described before and 50 µl were added to each sample tube and 
incubated further on a rotating device for 2 h.  
After antibody-PGS coupling, all samples were washed 5 times with 800 µ of Co-IP buffer via 
inverting the tubes 5-10 times and subsequent centrifugation at 3000 rpm for 2 min. The last 
spin-down was performed at 6000 rpm and all supernatant was carefully discarded before 
taking up the beads in 50 µl of 6x Laemmli buffer with subsequent incubation at 95 °C for 5 min. 
The samples were stored at -20 °C or directly used for SDS-PAGE and immunoblot analysis. 
 
3.2.3.4 Chromatin harvest for chromatin immunoprecipitation (ChIP) 
Chromatin immunoprecipitation was used as a method to detect protein-DNA interaction in the 
cell and was done according to Denissov and colleagues (Denissov et al, 2007). For chromatin 
harvest, two 15 cm cell culture dishes with 80-90 % confluent MEF or SJSA cells were taken to 
get roughly 800 µl of chromatin (depending on confluence). The cells were washed with room 
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temperature PBS and protein and DNA were crosslinked directly in the dish with crosslinking 
buffer for 20 min at RT. The crosslinking procedure was quenched for 5 min using final 
concentration of 125 mM glycine. Afterwards the cells were washed twice with ice cold PBS and 
lysed in the plate with 2 mL of pre-cooled Buffer B for 10 min at 4 °C. After incubation, the cells 
were scraped from the plate into a 2 mL Eppendorf tube on ice and centrifuged at 4 °C for 5 min 
at 1600 rpm. After centrifugation the cells were washed in 2 mL ice-cold Buffer C, centrifuged at 
the same speed for 10 min and the nucleus was lysed in 800 µl  of 1x Incubation buffer 
supplemented with 0.375 % SDS and 1 x protease inhibitors (Roche). The DNA was fragmented 
using the Bioruptor sonicator (Diagenode) for 25 cycles of 30 seconds on and 30 seconds off at 
highest power with intermediate ice-water changes. Afterwards remaining cellular debris were 
centrifuged down at maximum speed and the chromatin was either directly used for 
immunoprecipitation or was frozen at -80 °C.   
For MDM2 ChIP, the cells were fixed in 1.1 % PFA for 30 min. Fixation was stopped as before 
and the cells were lysed in a lysis buffer containing 0.1 % SDS. Sonication was done using the 
Pico sonicator (Diagenode) in Biorupter microtubes for 10 cycles. 
 
3.2.3.5 Chromatin Immunoprecipitation 
For the immunoprecipitation procedure, the chromatin was incubated together with protein A/G 
coupled beads as well as the antibody targeting the protein of interest (cf. Table 3-7); samples 
were always kept at 4°C or on ice. 50 µl of the 1:5 bead solution were taken per precipitation, 
centrifuged at 4 °C and 4000 rpm for 2 min and washed twice with 100 µl per reaction of wash 
buffer (1x Incubation buffer supplemented with 0.2 % BSA). Afterwards the beads were taken 
up in wash buffer in half of the initial volume. 30 µl of the washed beads were pipetted into a 1.5 
ml Eppendorf tube with 1x incubation buffer substituted with 0.1 % BSA and 1 x protease 
inhibitors (Roche) to a final volume of 178 µl. To this, 120 µl of chromatin and 2 µg of antibody 
(see Table 3-7) were added and precipitation was conducted over night on a rotator in the cold 
room. 12 µl of chromatin input was kept also at 4 °C. 
After incubation, the beads were washed two times with 400 µl washbuffer 1, once with 
washbuffer 2 and 3 and twice with wash buffer 4 using intermediate centrifugation at 4 °C and 
4000 rpm for 2 min. Afterwards the input samples were included and antibody-bead interaction 
was reversed by a 20 min RT incubation with 200 µl of incubation buffer on a rotating device. 
The beads were centrifuged down for 1 min at maximum speed and the supernatant was 
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transferred to a new Eppendorf tube. DNA and protein were de-crosslinked via incubation with 
final concentrations of 200 mM NaCl for 4-5 h at 65 °C shaking. 
The DNA was then isolated following the instructions of the MinElute PCR Purification Kit 
(Qiagen). After purification the input DNA was diluted 1:10 and PCR was conducted with 5 µl of 
ChIP product. For this Maxima SYBR Green qPCR Master Mix (2X) and primers given in  
Table 3-18 were taken. The PCR protocol was programmed as described in the master mix 
manual.  
 
3.2.4 Statistical evaluation of scientific data 
If not stated otherwise, statistical testing was performed using Graph Pad Prism 6. An unpaired t 
test was calculated and multiple comparisons were corrected using the Sidak Bonferroni 
method with an assumed significance for p-values ≤ 5%. Asterisks represent significance in the 
following way:  
*** = p ≤ 0.001 
** = p ≤ 0.01 
* = p ≤ 0.05  






In order to avoid confusion there has not been any notation separation between mouse and 
human annotation before. However, in the following paragraphs it will be discriminated 
between cell systems derived from mouse (Mdm2, p53, Ezh2 etc.) and human (MDM2, P53, 
EZH2 etc.). 
4.1 Accession Numbers 
The NCBI Gene Expression Omnibus accession number for RNA-Seq-, microarray- and 
ChIP-Seq data reported in this thesis is GSE73602. 
 
4.2 Mdm2 enables stemness and cell proliferation through PRC2 
target gene regulation 
4.2.1 Mdm2 attenuates iPS cell generation from MEFs 
In corroboration of the results obtained previously we wanted to identify whether a possible 
stem cell maintenance function of Mdm2 can be further validated in the system of induced 
pluripotent stem cells (iPSCs). MEFs from p53-/- and p53-/- Mdm2-/- mice were obtained from 
Guillermina (Gigi) Lozano at the MD Anderson cancer center and reprogrammed into iPSCs 
following the widely accepted protocol of Yamanaka and colleagues (Takahashi & 
Yamanaka, 2006) (cf. 3.2.1.7). Reprogramming protocols included transduction of OSK 
(Oct3/4, Sox2 and Klf4), OS (Oct3/4 and Sox2) and OK (Oct3/4 and Klf4). All three 
reprogramming protocols led to the successful generation of iPS cell colonies from p53-/- 
cells, with the 2-factor protocols resulting in a 10-fold decrease of colony numbers compared 
to the 3-factor protocol (cf. Figure 4-1 A-C). Loss of Mdm2 significantly decreased the 
generation of iPSC colonies up to 80 % compared to p53-/- cells (Figure 4-1 A-C). This 
reduction was continuously observed regardless of the reprogramming protocol. For 
comparison, we also investigated the potential difference of iPSC generation from wt MEFs. 
As published before, wt MEFs were reprogrammed less efficiently than p53-/- MEFs (Hong et 
al, 2009), but the efficiency was still higher than the one observed in p53-/- Mdm2-/- cells 






Figure 4-1 Mdm2 is required for iPS cell generation from murine embryonic fibroblasts 
(MEFs).  
(A) p53-/- and p53-/- Mdm2-/- MEFs were reprogrammed into induced pluripotent stem (iPS) 
cells using the 3-factor protocol described in paragraph 3.2.1.7 (Oct4, Sox2, and Klf4; OSK). 
The number of obtained iPS colonies per MEFs was determined (mean ± SEM, n=3). (B, C) 
Same MEF cell preparations were reprogrammed into iPS cells using a 2-factor protocol (OS: 
Oct4, Sox2; OK: Oct4, Klf4) and obtained iPS colonies per MEFs were counted (mean ± 
SEM, n=2). (D) For comparison, wt MEFs were reprogrammed as described.  
All reprogramming experiments were conducted by Alice Nemajerova, Department of 
Pathology, School of Medicine, Stony Brook University, USA. Figure data and legend also 
published in Wienken et al, under review. 
 
4.2.1.1 Mdm2 regulates gene expression in MEF cells 
Reprogramming of differentiated cells into iPSCs is associated with a major change of the 
expression profile (Tanaka et al, 2015). Hence we hypothesized that the differences in iPSC 
reprogramming in Figure 4-1 were caused by a differential gene expression pattern of p53-/- 





points of reprogramming and global gene expression was analyzed via microarray 
hybridization. Essentially, unsupervised clustering separated the gene expression profile from 
p53-/- and p53-/- Mdm2-/- MEFs regardless of reprogramming. Several genes were identified 
that were continuously differentially regulated between the two cell types (Figure 4-2 A-B). 
Interestingly, we found factors important in stemness, development and differentiation (e.g. 
Hoxc11, Hoxc13, Hoxb13 and Notch1) (Artavanis-Tsakonas et al, 1999; Shah & Sukumar, 
2010). 
4.2.1.2 The RING domain in Mdm2 is important for gene regulation 
A gene regulatory function of Mdm2 in MEFs is displayed in Figure 4-2. Global gene 
expression was further validated in the p53-/- Mdm2-/- MEFs by sequencing RNA from MEFs 
generated in the laboratory of Yanping Zhang, University of North Carolina. Zhang also 
provided us with p53-/- Mdm2C462A/C462A knock in (KI) MEFs (further always referred to as p53-/- 
Mdm2CA/CA) (Itahana et al, 2007). These MEFs expressed a RING finger mutant of Mdm2 
which is unable to elicit E3 ligase function but still binds to p53. We used these cells to 
determine possible dependency of the gene regulatory function of Mdm2 on ubiquitin ligase 
function.  
RNA-Seq analysis revealed that many genes were deregulated after total loss of Mdm2 as 
well as after loss of ubiquitin ligase function when compared to p53-/- MEFs (Figure 4-3 A). 
RNA-Seq data were validated via qRT-PCR analysis which corroborated the upregulation of 
several Hox genes (Hoxb13, Hoxc10 and Hoxc13) as well as Hhip (Figure 4-3 B) and 
downregulation of the genes Notch1, Tgfb2 and Txnip (Figure 4-3 C). These genes were of 
particular interest for us, as they had been associated before with stemness and 
development before. Hox genes encode a family of homeotic transcription factors that are 
conserved from fly to human. They ensure specific cell identity along the embryonic axis (cf. 
paragraph 2.3) (Dolle et al, 1993; Lewis, 1978; Zacchetti et al, 2007) and are thus major 
drivers of embryonic development (Shah & Sukumar, 2010). On the other hand, Notch1 and 
Tgfb2 are usually supporting the self-renewal of pluripotent cells and have been identified to 
support stem cell maintenance (Duncan et al, 2005; Stier et al, 2002). Repression and 
activation of differentiation factors and stem cell factors, respectively, explained why p53-/- 






Figure 4-2 p53-/- and p53-/- Mdm2-/- MEFs are characterized by a differential gene 
expression pattern which is not influenced by cellular reprogramming. 
p53-/- and p53-/- Mdm2-/- MEFs were reprogrammed into iPSCs using the 3-factor protocol for 
two and seven days (cf. Figure 4-1; Oct4, Sox2, and Klf4). mRNA expression was quantified 
using microarray analysis and cell clustering according to gene expression was determined. 
(A) Cluster dendrogram was generated using a hierarchical approach with the average 
linkage-method. Distances were measured as 1 - Pearson's Correlation Coefficient. (B) From 
the normalized gene expression data, continuously differentially regulated genes were 
identified and are displayed in a heatmap (SKO = p53-/-, DKO = p53-/- Mdm2-/- MEFs). Figure 











Figure 4-3 Mdm2 regulates gene expression in MEFs through its RING domain. 
(A) Gene expression of p53-/-, p53-/- Mdm2-/- and p53-/- Mdm2CA/CA (Mdm2CA/CA = 
Mdm2C462A/C462A) MEFs was analyzed via next generation RNA-sequencing. Differentially 
expressed genes were identified using the DESeq analysis in R (cf. paragraph 3.2.2.2.5) and 
are shown as a heat map. (B-C) Differentially upregulated (B) and downregulated (C) genes 
were re-evaluated by qRT-PCR (mean ± SEM, n=4 for upregulated-, n=3 for downregulated 
genes). For RNA-Seq data see also Table S2 in Wienken et al, under review. Figure data and 
legend also published in Wienken et al, under review. 
 
4.2.1.3 Stem cell and development associated genes in MEFs are regulated by Mdm2 
Mdm2 repressed a group of genes in MEFs and we investigated their functional annotation 
via GO term analysis. According to C5 GSEA and DAVID Mdm2 repressed genes involved in 
development and differentiation (Figure 4-4 A, C). Genes belonging to this annotation were, 
among others, the Hox genes (cf. Figure 4-3). This enrichment correlated with the decreased 
ability of p53-/- Mdm2-/- MEFs to de-differentiate into iPSCs (cf. Figure 4-1). According to C5 
GSEA, genes activated by Mdm2 were also partially involved in development, but this finding 
was not supported by corresponding data from DAVID (Figure 4-4 B,D).  
In order to identify a common regulatory pathway of the deregulated genes, C2 GSEA was 
performed (Figure 4-5). Several upregulated gene sets in p53-/- Mdm2-/- MEFs were 
characterized by PRC2- and H3K27me3 epigenetic regulation (Figure 4-5 A). Downregulated 
genes on the contrary were enriched for the H3K27me3 opposite mark – H3K4me3 (Figure 
4-5 B, cf. 2.2.2) (Santos-Rosa et al, 2002) and also to some extent PRC2 regulation. 
H3K27me3 is the hallmark of PRC2 gene repression which is highly important during early 
differentiation processes of stem cells as well as reprogramming into iPSCs (cf. paragraph 
2.3.4). One well known gene family that is regulated by PRC2 is the Hox gene family (cf. 
paragraph 2.3), from which Hoxb13, Hoxc10 and Hoxc13 had already been confirmed to be 
Mdm2 target genes (cf. Figure 4-3). In line with our iPSC reprogramming data, gene sets 
were upregulated in p53-/- Mdm2-/- MEFs that are normally downregulated in stem cells (e.g. 
BOQUEST_STEM_CELL_DN or LIM_MAMMARY_STEM _CELL_DN) (Figure 4-5 A). Vice 
versa, stem cell specific gene sets were identified to be downregulated in p53-/- Mdm2-/- 
MEFs (e.g. WONG_EMBRYONIC_STEM_ CELL_CORE or BOQUEST_STEM_CELL_ UP 






Figure 4-4 Mdm2 regulated genes are involved in stemness and differentiation. 
(A-B) Gene set enrichment analysis (GSEA) from C5 GO gene sets (provided by the 





reads from Figure 4-3 (Mootha et al, 2003; Subramanian et al, 2005). Enriched gene sets 
were filtered for the cues “development”, “differentiation”, “stem_cell” and “remodeling” and 
are displayed for genes upregulated in p53-/- Mdm2-/- MEFs (A) and genes downregulated in 
p53-/- Mdm2-/- MEFs (B). q-values indicate false discovery rate (FDR); the threshold of 
significant enrichment (q ≤ 0.25) was implied according to the GSEA standards 
(http://www.broadinstitute.org/gsea/doc/ GSEAUserGuideFrame .html) for this and all 
following GSEA and DAVID analyses (for the total analysis see Table S3 in Wienken et al, 
under review). (C-D) For comparison, differentially expressed genes that had already been 
identified by DESeq were also subjected to GO term analysis by DAVID 
(https://david.ncifcrf.gov/) and are shown according to their significance by p-value and FDR 
according to Benjamini Hochberg (Huang et al, 2008) (for the total analysis see Table S3 in 







Figure 4-5 Mdm2 preferentially regulates stemness related genes controlled by the 
Polycomb Repressive Complex. 
(A-B) Gene set enrichment analysis (GSEA) from C2 curated gene sets (provided by the 
Molecular Signatures Database (MSigDB) v5.0) was run from normalized RNA-Seq reads (cf. 
Figure 4-3). Enriched gene sets were filtered for the cues “H3K27me3”, “H3K4me3”, “Ezh2”, 
“Suz12”, “development”, “differentiation” and “stem_cell” and are displayed for genes 
upregulated in p53-/- Mdm2-/- MEFs (A) and genes downregulated in p53-/- Mdm2-/- MEFs (B). 
Selected enrichment plots are provided as examples. (for the total analysis see Table S4 in 
Wienken et al, under review). Figure data and legend also published in Wienken et al, under 
review. 
 
4.2.1.4 Genes regulated by Mdm2 are direct targets of PRC2 regulation 
In order to proof whether Mdm2 regulated genes were direct targets of PcG regulation, p53-/- 
and p53-/- Mdm2-/- MEFs were treated with the selective Ezh2 inhibitor EPZ6438 (Knutson et 
al, 2013). EZH2 is the catalytic subunit of the PRC2 which drives H3K27me3 (O'Carroll et al, 
2001). According to our data, Mdm2 especially regulated genes which were characterized by 
regulation through H3K27me3 (Figure 4-5). If the putative Mdm2 target genes from Figure 4-
3 B are directly repressed by the PRC2, treatment with EPZ 6438 will activate gene 
expression through loss of H3K27me3. If the gene repression is furthermore dependent on 
Mdm2, a higher gene induction upon inhibitor treatment will be expected in the p53-/- MEFs in 
comparison to the p53-/- Mdm2-/- cells.  
EPZ6438 treatment lowered overall H3K27me3 levels in both cell lines without affecting Ezh2 
levels (Figure 4-6 A). Additionally, it released the gene repression of the target genes 
Hoxc10, -c13, -b13 and Hhip in the p53-/- and in the p53-/- Mdm2-/- MEFs. Remarkably, this 
induction was much higher in the p53-/- MEFs than in the p53-/- Mdm2-/- MEFs, which 
emphasized that Mdm2 regulates PRC2 target genes epistatically (Figure 4-6 B). For further 
analysis, H3K27me3 levels at the gene promoters were evaluated via ChIP (cf. 3.2.3.4 and 
3.2.3.5). Upon EPZ6438 treatment, H3K27me3 promoter levels were reduced to 40 % in the 
p53-/- cells. This reduction was less pronounced in p53-/- Mdm2-/- MEFs; overall the difference 






Figure 4-6 Ezh2 inhibitor treatment reveals epistatic regulation of Mdm2/PRC2 target 
genes by Mdm2. 
(A) Ezh2 was inhibited via 48 h incubation with 5 µM EPZ6438 in p53-/- and p53-/- Mdm2-/- 
MEFs. Downregulation of H3K27me3 after Ezh2 inhibition was visualized via immunoblot 
analysis. (B) Gene expression was quantified using qRT-PCR analysis and (C-D) H3K27me3 
promoter levels were analyzed via targeted ChIP. ChIP results are shown as fold decrease 
upon EPZ6438 treatment normalized to corresponding mock control (C). Figure data and 










4.2.2 Osteoblast differentiation is repressed by Mdm2 
Mdm2-mediated gene regulation executed stem cell maintenance function since its depletion 
abolished de-differentiation of fibroblasts into iPSCs (Figure 4-1 and Figure 4-3). 
Consequently, we asked the question whether loss of Mdm2 could vice versa drive stem cells 
into accelerated differentiation. As a suitable model, human mesenchymal stem cells 
(hMSCs) were differentiated into osteoblasts as described before (cf. 3.2.1.6 and Karpiuk et 
al, 2012). Since hMSCs were P53 wt cells, they were depleted of MDM2 and P53 and both in 
combination to focus on P53-independent functions of MDM2. Furthermore, EZH2 gene 
expression was repressed.  
According to our data in Figure 4-5 and Figure 4-6, Mdm2 regulated PRC2 target genes. 
Moreover, loss of PRC2 members had already been published to accelerate stem cell 
differentiation including the differentiation into osteoblasts (Dudakovic et al, 2014; Ezhkova et 
al, 2009; Pasini et al, 2007). EZH2 kd was included to compare the effects of both EZH2 and 
MDM2 kd in parallel and to overlap their gene regulatory profiles. If MDM2 executes PRC2 
target gene regulation also in hMSC cells, we will expect a de-repression of specific target 
genes and most probably also an alteration of differentiation.  
Knock down was done via double siRNA transfection and monitored via immunoblot after 96h 
of kd and after 7 days of differentiation using RNA expression data (differentiation started 48h 
after the first kd). According to Figure 4-7, protein expression was successfully abolished 
after 96 h of kd (Figure 4-7 A). As expected, kd of MDM2 alone induced P53 regarding 
protein levels and activity since its depletion elevated protein levels of the P53 target p21. 
Gene expression of MDM2 and TP53 was at low levels after the additional differentiation time 
of 7 days according to Figure 4-7 B. EZH2 gene expression had already recovered from kd 
but was still diminished by 20 %. 
MDM2 indeed repressed the differentiation of hMSC-Tert cells into osteoblasts. Its depletion 
increased alkaline phosphatase activity and expression (ALPL) as well as BGLAP 
(osteocalcin) expression, both established markers of osteoblast differentiation (Weinreb et 
al, 1990). This differentiation barrier function of MDM2 was independent of P53 but 






Figure 4-7 MDM2, P53 and EZH2 kd in hMSCs monitored by immunoblotting and gene 
expression analysis. 
(A-B) MDM2, P53 and EZH2 were knocked down in hMSCs using siRNA transfection for 96 
h (cf. paragraph 3.2.1.4 and 3.2.1.6). Knock down efficiency was verified 96 h after 
transfection via immunoblotting (A, n=2, already published in my master thesis) and after 
additional 7 days of differentiation using microarray data (B, n=2, microarray data shown in 






As already indicated in Figure 4-8 C, loss of MDM2 altered the gene expression of two 
differentiation marker genes in differentiating osteoblast which is why global gene expression 
was monitored via microarray analysis from these samples. EZH2 kd samples were also 
included to compare gene regulatory profiles from both, MDM2 and EZH2 kd samples. 
Loss of MDM2 (single kd and co-kd with P53) and loss of EZH2 cooperatively deregulated a 
vast number of genes. Figure 4-8 D shows a heatmap of the 50 most significantly up- and 
downregulated genes in the EZH2-, MDM2- and MDM2 & P53 kd samples in comparison to 
control- and single P53 kd. In total, loss of MDM2 together with P53 led to the deregulation of 
747 genes and around 50 % of these were coregulated by EZH2 (Figure 4-8 E). Interestingly, 
around 90 % of the coregulated genes were regulated in the same direction, either up 
(yellow) or down (blue) in comparison to control. For microarray validation, qRT-PCR analysis 
was performed from the known PRC2 target genes TIMP3 and GDF6 (Sher et al, 2012; Shin 
& Kim, 2012) and from the additional osteoblast differentiation marker genes BMP4 and IGF2 
(Twine et al, 2014) (Figure 4-8 F). 
 
4.2.2.1 The differentiation barrier function of MDM2 is P53 independent 
Due to the fact that P53 kd significantly decreased osteoblast differentiation (cf. Figure 4-8 A-
C) microarray data were used to confirm that the differentiation barrier function of MDM2 was 
indeed p53 independent. First evidence was given by the unsupervised clustering of the 
expression data from MDM2 kd and MDM2&P53 kd samples  together with EZH2 kd samples 
and apart from siCtrl and siP53 in Figure 4-8 D. Principal component analysis (PCA) from the 
whole array data mirrored this finding (Figure 4-9 A). Furthermore, differential gene 
expression from P53 kd samples did only overlap to some extent with MDM2-, MDM2 & P53- 
and EZH2 kd samples (Figure 4-9 B). 
 
In addition, P53 responsive genes were identified via comparison of MDM2 kd samples 
(assuming P53 induction; cf. Figure 4-7 A, p21 induction) and MDM2&P53 kd samples 
(assuming P53 repression, cf. Figure 4-7 A). These genes included the known P53 target 
genes INPP5D and CLCA2 (Figure 4-9 C) (Lion et al, 2013; Tanikawa et al, 2012) and only 
overlapped to a minor extent with previously identified MDM2/PRC2 target genes (Figure 4-9 






Figure 4-8 MDM2 hinders the differentiation of human mesenchymal stem cells 
(hMSCs) into osteoblasts and contributes to the regulation of PRC2 target genes. 
(A) MDM2, P53 and EZH2 depleted hMSCs were differentiated into osteoblasts (cf. Figure 
4-7). At day 7, alkaline phosphatase (AP) activity was detected via AP staining (cf. 3.2.1.6). 





quantitative image analysis (Celigo cytometer, mean ± SEM, n=3). (C-D) RNA from the 
differentiated osteoblasts was quantified by qRT-PCR of the differentiation genes ALPL and 
BGLAP (C, n=3; A-C already published in master thesis) and array hybridization (D, n=2; the 
50 most significantly deregulated genes are shown). (E) Venn diagrams present overlapping 
gene sets that respond to EZH2 and MDM2 & P53 depletion. Grey color indicates overall 
deregulated genes whereas blue and yellow coloring corresponds to downregulated- and 
upregulated genes, respectively, in comparison to control. (F) Differentially expressed 
osteoblast differentiation marker genes (BMP4 and IGF2) as well as known PRC2 target 
genes (TIMP3 and GDF6) identified in (C) were validated via qRT-PCR analysis (mean ± 
SEM, n=3). For microarray data see also Table S5 in Wienken et al, under review. Figure 
data and legend also published in Wienken et al, under review. 
 
4.2.2.2 MDM2 target genes in hMSCs are characterized by stemness functions and PRC2 
regulation 
According to C5 GSEA, genes upregulated upon loss of MDM2 (& P53) in osteoblasts were 
enriched for development-, differentiation- and bone morphogenesis annotations whereas no 
significant annotation was withdrawn from identified downregulated genes (Figure 4-10 A-B). 
DAVID analysis was conducted for the genes co-regulated by MDM2 and EZH2 (cf. Figure 
4-8 E). Cooperatively upregulated genes were comparably annotated as seen before in A 
(Figure 4-10 C). DAVID also identified annotations for some significantly downregulated gene 
sets which were involved in the immune response (Figure 4-10 D). Overall, the functional 
annotation of MDM2 repressed genes in MEFs and hMSCs overlapped (cf. Figure 4-4). 
 
C2 GSEA analysis of the Mdm2 target genes in MEFs had revealed a connection to PRC2 
gene regulation (cf. Figure 4-5) and EPZ6438 treatment had confirmed direct regulation of 
these target genes by Ezh2 (cf. Figure 4-6). Thus we tested a possible enrichment of 
H3K27me3 and PRC2 gene sets in the MDM2&P53 kd samples of differentiated osteoblasts. 
Indeed, similar epigenetic gene sets were enriched in the osteoblast samples after loss of 
MDM2 together with P53 (Table 4-1 A and B). Furthermore, this enrichment was much more 
pronounced in genes upregulated after loss of MDM2 than compared to downregulated ones. 
This overlap in gene set regulation supported our theory that MDM2 is a potential PRC2 gene 
repression partner not only in primary MEF cells but also in human mesenchymal stem cells. 
MDM2 hereby maintained stemness not only through favoring iPSC generation but also 











(A) Principal component analysis (PCA) of microarray data (cf. Figure 4-8 D). PCA was 
performed using the princomp-function in the R software. To estimate the average group 
values for each gene and assess differential gene expression, a simple linear model was 
fitted to the data, and group-value averages and standard deviations for each gene were 
obtained. (B) Venn diagrams present overlapping gene sets that respond to P53 depletion 
and also to the depletion of MDM2&P53, EZH2 or MDM2 alone. Note that this overlap does 
not discriminate between positive or negative regulation of genes. (C) P53-responsive genes 
were identified comparing microarray data from MDM2 and MDM2&P53 depleted samples. 
Well-known P53 target genes like INPP5D and CLCA2 are marked with an asterisk (Lion et 
al, 2013; Tanikawa et al, 2012). (D) Overlap of P53 responsive genes identified in C with 
PRC2/MDM2 target genes is shown in a Venn diagram. (E) Expression of TP53, MDM2 and 
EZH2 during osteoblastic differentiation of mesenchymal stem cells was analyzed via qRT-
PCR at different time points post differentiation induction. cDNA from hMSCs was kindly 
provided by Simon Baumgart, University Medical Center Göttingen. Figure data and legend 






Figure 4-10 Functional annotation of genes regulated by MDM2 and coregulated by 
MDM2 and EZH2.  
(A-B) C5 GSEA was performed based on normalized microarray data comparing siCtrl to 
MDM2&P53 knock down (kd) samples (cf. Figure 4-8). Enriched gene sets were filtered as 
described before (cf. Figure 4-4 A-B) for genes upregulated (A) and downregulated in 
P53&MDM2 kd samples (B). (C-D) For comparison, DAVID annotation analysis was 
conducted from genes that were coregulated by MDM2 as well as EZH2 (comparing 
siMDM2&P53 and siEZH2, each vs siCtrl) (cf. Figure 4-8 E). For the whole data set please 
refer to Table S4 in Wienken et al, under review. Figure data and legend also published in 
Wienken et al, under review. 
 
 
Table 4-1 MDM2 regulated genes in hMSCs are characterized by PRC2 and H3K27me3. 
(A-B) C2 GSEA was performed on normalized microarray data comparing siCtrl to 
MDM2&P53kd samples (cf. Figure 4-8). Enriched gene sets were filtered as described before 
(cf. Figure 4-5) and are displayed for genes upregulated in P53&MDM2 kd samples (A) and 
genes downregulated in P53&MDM2 kd samples (B). For the whole data set please refer to 
Table S4 in Wienken et al, under review. Figure data and legend also published in Wienken 






4.2.3 MDM2 ensures cancer cell proliferation independent of P53 
So far, murine primary cells as well as human adult stem cells were identified as systems in 
which MDM2 represses PRC2 target genes and enables stemness. Differentiated cells 
gather stem cell like features as they de-differentiate and self-renew in an unlimited manner 
to transform into a tumor cell (Reya et al, 2001). This requires a radical shift in the epigenetic- 
and gene expression profile of the cell (cf. paragraph 2.3.4).  
As MDM2 had already been identified as an important oncogene and we now defined an 
important role for MDM2 in stemness maintenance, different cancer cell lines were screened 
for related P53-independent gene regulatory functions. In the previous systems, MDM2 
cooperatively regulated gene expression with the PRC2. Loss of PRC2 proteins is fatal to 
cancer cell survival in several systems as outlined in 2.3.4.2. If MDM2 was indeed able to 
regulate PRC2 target genes also in cancer cells, we will expect P53-independent diminished 
cell survival after MDM2 depletion. 
 
In a panel analysis of different cancer cell lines (cf. Table 4-2) MDM2 gene expression was 
knocked down via siRNA (Figure 4-11 A, C, E and G) and cell survival was evaluated via 
automated microscopy (Figure 4-11 B, F, H) and colony formation assays (Figure 4-11 D). 
Cells bearing wt P53 were additionally depleted from P53 to focus on the P53-independent 
functions of MDM2. As outlined in paragraph 2.3.4.2, cancer cells depend on the presence of 
PRC2 and specifically EZH2. EZH2 was therefore depleted as a control for our study. Cell 
survival of all different cancer cell lines was diminished upon loss of MDM2 – even in the 
absence of P53 – as it was for EZH2 (Figure 4-11 B,D,F,H ). This phenotype supported our 
idea that MDM2 might have gene regulatory functions on PRC2 target genes also in cancer 
cells. It was tested via global expression analysis of MDM2 and EZH2 kd samples from the 
HCT116 p53-/- cell system.  
 
Table 4-2 Cancer cell lines used for panel analysis shown in Figure 4-11 
Cell line Origin P53 status 
HCT116 p53-/- Colon cancer - 
MCF7 Breast cancer wt 
SJSA Osteosarcoma wt 













MDM2 represses PRC2 target genes in different cancer cells 
HCT116 p53-/- cells were chosen for microarray analysis, because they provided us with a 
clean P53 ko system (Bunz et al, 1998). MDM2 and EZH2 were depleted, each using two 
different siRNAs, and gene expression was compared to control kd (siCtrl) and P53 kd (cf. 
Figure 4-11 A; since the cells were P53-/-, siP53 was used as a control siRNA). As it was 
already observed before, loss of MDM2 deregulated a group of genes which was also 
regulated by EZH2 (Figure 4-12 A). In total, 150 genes were differentially up- or 
downregulated upon MDM2 kd whereas EZH2 depletion deregulated nearly 1500 target 
genes. Most interestingly, 70 % of the MDM2 target genes were coregulated by EZH2 and 
none of these were regulated by EZH2 and MDM2 in a differential pattern (they were either 
downregulated (blue) or upregulated (yellow), Figure 4-12 B). qRT-PCR analysis of the PRC2 
target genes CXCR4, DUSP4, KLF2 and TEX261 was used for array validation (Figure 4-12 
C-D; TEX261 was selected as target due to H3K27me3 and EZH2 ChIP-Seq tracks on the 
UCSC genome browser; other genes were selected from literature (Lin et al, 2011; Nie et al, 
2015; Vanharanta et al, 2013)). In parallel to HCT116 cells (Figure 4-12 C), MDM2 repression 
of these PRC2 target genes was also observed in MCF7 cells (Figure 4-12 D).  
 
C2 GSEA which had previously indicated the relation of MDM2 and PRC2 target gene 
regulation (cf. Figure 4-5 and Table 4-1) revealed a similar gene regulation annotation. 
Genes upregulated by the loss of MDM2 were often associated with H3K27me3 (Figure 4-13 
A) whereas downregulated genes are stem cell associated (Figure 4-13 B). Functional 
annotation via C5 GSEA on MDM2 regulated genes did not give us any significant 
enrichment of gene sets (Figure 4-13 C-D). According to DAVID analysis MDM2/EZH2 target 
genes were involved in transcription (Figure 4-13 E-F). 
Figure 4-11 MDM2 mediates cell survival in several different cancer cell lines 
independent of P53. 
(A, C, E, G) The cancer cell lines HCT116 p53-/-(A), MCF7 (C), SJSA (E) and PANC1 (G) 
were depleted of MDM2 and EZH2 using double siRNA transfection for 96 h. Knock down 
efficiency was verified by immunoblotting or qRT-PCR (TP53 co-knockdown was done in cells 
bearing wt TP53). (B, F, H) Cell proliferation of HCT116 p53-/-, SJSA and PANC1 cells was 
determined using automated light microscopy with quantitative image analysis (Celigo 
cytometer), mean ± SEM, n=3), and (D) the amount of MCF7 cells displaying clonogenic 
survival, regardless of TP53 co-kd(mean ± SEM, n=3). Note, that the results for HCT116 p53-
/- cells were already partly published in my master thesis; MCF7 data were kindly provided by 






Figure 4-12 MDM2 represses PRC2 target genes in HCT116 p53-/- and MCF7 cells. 
(A) Differential gene expression was determined via microarray analysis of HCT116 p53-/- 
cells which were depleted of MDM2 and EZH2 (cf. Figure 4-11). The 50 most significantly 
deregulated genes are depicted in a heatmap (B) Overlap of gene sets regulated by both 
MDM2 and EZH2 are shown as Venn diagrams; note the absence of genes with opposite 
regulation. Grey color indicates overall deregulated genes whereas blue and yellow coloring 
corresponds to downregulated- and upregulated genes, respectively, in comparison to 
control. (C, D) Verification of identified target genes was conducted via qRT-PCR analysis in 
HCT116 p53-/- (C) and MCF7 (D) cells (mean ± SEM, n=3). MCF7 data was kindly provided 
by Dr. Xin Zhang. For microarray data see also Table S6 in Wienken et al, under review. 






Figure 4-13 C2 GSEA and GO term analysis of MDM2 and MDM2/EZH2 regulated genes. 
(A-B) C2 GSEA on normalized microarray data, comparing siCtrl to siMDM2 samples. 
Enriched gene sets were filtered as described before (Figure 4-5) and are displayed for 
genes upregulated in MDM2 kd samples (A) and genes downregulated in MDM2 kd samples 
(B, for the total analysis see Table S3 in Wienken et al, under review) (C-D) C5 GSEA 





before (cf. Figure 4-4) and are displayed for genes upregulated in MDM2 kd samples (C) and 
genes downregulated in &MDM2 kd samples (D). No significant classification was detected in 
these cases. (E-F) For comparison, annotation was analyzed via DAVID from genes that 
were coregulated by MDM2 and EZH2 (in comparison to siCtrl) (cf. Figure 4-12 B). For the 
total analysis see Table S3 in Wienken et al, under review. Figure data and legend also 
published in Wienken et al, under review. 
 
4.3 MDM2 is recruited to target gene promoters by the PRC2 
4.3.1 MDM2 directly interacts with the PRC2 members EZH2 and SUZ12  
We detected a gene repressive function of MDM2 on PRC2 target genes in three distinct cell 
systems – mouse embryonic fibroblasts, human mesenchymal stem cells and at least two 
different human cancer cell lines. Due to this regulatory relationship we wanted to know 
whether MDM2 directly interacted with members of the PRC2. Therefore, endogenous MDM2 
protein levels were boosted using the proteasome inhibitor MG132 over 6 hours in SJSA cells 
and MDM2 and the PRC2 members EZH2 and SUZ12 were immunoprecipitated. 
Endogenous levels of MDM2 were detected by immunoblotting in the precipitates of EZH2 
and SUZ12 indicating an interaction of the two proteins. Vice versa, the precipitation of 
MDM2 pulled down EZH2 and SUZ12 (Figure 4-14 A). The interaction of EZH2 with its 
protein partner SUZ12 was also detected as a positive control.  
When being transiently overexpressed in the cell line U2OS, MDM2 again bound to both, 
EZH2 and SUZ12, which indicated a direct interaction pattern (Figure 4-14 B and C). It was 
furthermore also possible to perform these interaction studies in MEF cells. For MEFs we 
immunoprecipitated endogenous Ezh2 from transiently overexpressed murine Mdm2 in p53-/- 
Mdm2-/-, MEFs indicating a conversation of the MDM2-PRC2 interaction from mouse to 
human (please refer to Wienken et al, under review) 
Further exogenous Co-IP experiments with deletion mutants of MDM2 identified a 300 amino 
acid (aa) stretch in the N-terminal domain as critical for EZH2 and SUZ12 binding (Figure 
4-14 D). The first 300 aa of MDM2 comprise the P53-binding- as well as the acidic domain. At 
least for EZH2 the P53 binding domain did not play any role in this interaction since P53-
binding domain deletion mutants still interacted with EZH2. Deletion mutants covering the 
acidic domain also persisted EZH2 and SUZ12 binding, which leaves a 130 aa stretch 






Figure 4-14 MDM2 interacts with the PRC2 components EZH2 and SUZ12. 
(A) Endogenous MDM2, EZH2 and SUZ12 were co-immunoprecipitated from MG132-
pretreated SJSA cells. Cell lysates (Input) and the immunoprecipitated (IP) material obtained 
with the indicated antibodies were analyzed by immunoblotting (IB). (B-C) Wild type MDM2 
was overexpressed by transfection, together with HA-tagged EZH2 (B) or Flag-tagged SUZ12 
(C) in H1299 cells, followed by IP and IB as in (A). Note that different appearance of the IgH 
band was caused by the species specificity of the IP and IB antibody (D) Graphical 
representation of exogenous Co-IP experiments with MDM2 deletion mutants. Indicated 
MDM2 mutants were transiently overexpressed in H1299 cells together with wt EZH2 or 
SUZ12 and interaction was monitored as in (B) and (C). For raw data, please refer to 
Wienken et al, under review. Co-IP data was generated in collaboration with A. Dickmanns 





4.3.2 MDM2 is recruited to the TSS of MDM2/PRC2 target genes by EZH2 
Both MDM2 and the PRC2 have been described to localize in the cell nucleus and bind to 
chromatin (cf. paragraph 2.1.6 and 2.3.1). Hence, we asked whether MDM2 can directly 
localize to PRC2 target gene chromatin and performed ChIP analysis (cf. 3.2.3.3 and 
3.2.3.4). For this approach SJSA cells were chosen as the most suitable cell system because 
it provided us with high levels of endogenous MDM2.  
Targeted ChIP analysis on promoter regions of previously identified MDM2 target genes (cf. 
Figure 4-12 C and D) revealed a specific enrichment of MDM2 in comparison to IgG negative 
control and the negative control gene MYO (Figure 4-15 A, siCtrl samples). Most 
interestingly, the binding of MDM2 to these genes was significantly decreased to background 
levels upon depletion of EZH2. Thus, Mdm2 was recruited to its target genes by EZH2 
(Figure 4-15 A-B). In concordance, MDM2 chromatin binding was not detected on the 
promoters of genes that are regulated by EZH2 but not MDM2 (Figure 4-15 C; genes 
identified from microarray data in Figure 4-12).  
In order to further validate the recruitment of MDM2 to gene promoters by EZH2, a cell line 
was used which carried an integrated luciferase gene with a Gal4-binding domain element 
(Hansen et al, 2008). Upon overexpression of Gal4-fused EZH2 and Myc-tagged MDM2 
(Figure 4-15 D), Myc-MDM2 was recruited to the heterologous promoter site (Figure 4-15 E, 
experiment done by Dr. Xin Zhang). This experiment further confirmed that EZH2 recruits 






Figure 4-15 MDM2 is recruited to target genes by EZH2. 
(A) Chromatin Immunoprecipitation (ChIP) of MDM2 in EZH2 depleted SJSA cells on 
MDM2/PRC2 target genes (cf. Figure 4-12, enrichment over IgG background; mean ± SEM; 
n=3). (B) Knock down efficiency of EZH2 was monitored via immunoblotting. (C) MDM2 
enrichment was analyzed via targeted ChIP on the gene promoters of FGF1, TLR3 and 
TGFB1. These genes responded to EZH2 depletion solely (not in cooperation with MDM2) 
according to microarray data from HCT116 p53-/- cells (cf. Figure 4-12). Enrichment on KLF2 





Statistical analysis was performed via 1way Anova using Dunnett's multiple comparisons test 
(D-E) HEK293 cells carrying an integrated Upstream Activation Sequence (UAS) that binds 
Gal4 either contained a tetracycline-inducible expression cassette for EZH2 fused to the Gal4 
DNA binding domain, or a control gene (Hansen et al, 2008). Upon tetracycline addition and 
transient overexpression of MDM2, protein levels were checked via immunoblot analysis (D) 
ChIP was performed with antibodies to EZH2 and Myc, followed by amplification of the UAS 
(E). Figure data and legend also published in Wienken et al, under review. 
 
With the results gathered, we identified a new role for MDM2 in direct gene regulation 
through the interaction with PRC2 members on the target gene promoters. As of now, these 
findings did not explain the underlying molecular mechanism of this new function of MDM2. 
Gene repression through the PcG family follows a widely accepted model in which the 
distribution of H3K27me3 is followed by H2AK119 monoubiquitination through PRC1 (Cao et 
al, 2005). Via the usage of targeted ChIP and ChIP-sequencing (ChIP-Seq) experiments in 
Mdm2 ko MEFs, we investigated whether Mdm2 is involved in this epigenetic interplay.  
 
4.4 Mdm2 supports H3K27me3 on target gene promoters without 
affecting Ezh2 levels 
4.4.1 H3K27me3 on previously identified target gene promoters depends on Mdm2 
According to Figure 4-3 specific target genes were de-repressed in total Mdm2 ko MEFs as 
well as C462A ki (CA/CA) MEFs which are deficient of Mdm2 RING finger domain function. 
These genes were proven to be direct targets of EZH2 repression (cf. Figure 4-6) and we 
evaluated whether loss of Mdm2 leads to any H3K27me3 promoter level changes. All three 
Mdm2 target genes, Hoxb13, Hoxc13 and Hhip, were deprived of H3K27me3 promoter levels 
in p53-/- Mdm2-/-- as well as in p53-/- Mdm2CA/CA MEFs (Figure 4-16 A and A2). This loss of 
H3K27me3 was not visible at the control genes Evx1 (positive control) and GAPDH (negative 
control) (Figure 4-16 A2). Loss of H3K27me3 was also not accompanied by a significant 
change of EZH2 occupancy on these target gene promoters (Figure 4-16 B and B2).  
In order to rule out that the effects of Mdm2/PRC2 target gene co-regulation and the loss of 
H3K27me3 levels on target gene promoters were due to changes in total EZH2 protein 
levels, immunoblot analysis was performed. According to Figure 4-16 C there are only minor 
changes between EZH2 and H3K27me3 protein levels comparing p53-/- MEFs with p53-/- 





and Ezh2 also ruled out that loss of Mdm2 de-stabilized PRC2 complex formation (Wienken 
et al, under review). To get a broader view of the H3K27me3 epigenetic signature in the p53-/- 
Mdm2-/- MEFs, DNA from immunoprecipitates was sequenced and analyzed in an 
experimental procedure called ChIP-Seq (cf. 3.2.2.3). 
Figure 4-16 Loss of Mdm2 destabilizes histone H3K27 trimethylation (H3K27me3) at 
Mdm2/PRC2 target gene TSSs without affecting global EZH2 protein levels. 
 (A-B) p53-/-, p53-/- Mdm2-/- and p53-/- Mdm2CA/CA MEFs were used for targeted H3K27me3 (A) 





were identified via qRT-PCR analysis and are shown as % of Input relative to p53-/- cells (A 
and B) together with the corresponding % of Inp values with suitable control genes in A2 and 
B2. Corresponding % of Input data is also given to prove enrichment of ChIP signal above 
IgG background. (C) Total protein levels of EZH2 and H3K27me3 in p53-/-, p53-/- Mdm2-/- and 
p53-/- Mdm2CA/CA MEFs were evaluated using immunoblot analysis. (H3K27me3 targeted 
ChIP: mean ± SEM, n=6; EZH2 targeted ChIP: mean ± SEM, n=4.). Figure data and legend 
also published in Wienken et al, under review. 
 
 
4.4.2 Loss of Mdm2 leads to H3K27me3 removal on target gene TSSs 
Sequencing of H3K27me3 ChIP material was conducted by the Transcriptome Analysis 
Laboratory (TAL) in Göttingen using single end 51 bp sequencing. Mapped fastq files were 
investigated for peak enrichment using MACS2 in Galaxy and aggregation around the TSS of 
known genes was done on the Galaxy / deepTools server using UCSC TSS region maps (cf. 
3.2.2.4) (Blankenberg et al, 2010; Giardine et al, 2005; Goecks et al, 2010; Karolchik et al, 
2004; Ramírez et al, 2014). There was no remarkable change in the general distribution of 
H3K27me3 around the TSS of known genes comparing p53-/- and p53-/- Mdm2-/- MEFs 
(Figure 4-17 A). A more sophisticated proof of differential methylation was done using the 
Biocite DiffBind analysis in R (Stark & Brown, 2011). The differentially methylated regions 
that were detected via DiffBind localized around transcriptional start sites (Figure 4-17 B). On 
average, the H3K27me3 signal decreased upon loss of Mdm2 (Figure 4-17 C, all regions). 
Only a subset of regions were found to add up H3K27me3 (double ko (dko) >single ko (sko)), 
whereas most regions were significantly deprived of H3K27me3 in the absence of Mdm2 
(sko>dko). Aggregating the identified differentially methylated regions around the TSS of their 
corresponding genes mirrored the same behavior (Figure 4-17 D). 
 
4.4.3 Mdm2 target gene expression is repressed by H3K27me3 
Since H3K27me3 is a repressive mark for gene expression, the H3K27me3 status from p53-/- 
and p53-/- Mdm2-/- MEFs was correlated with the previously detected differential gene 
expression pattern (cf. Figure 4-3). According to literature and the results obtained, we 
expected a loss of H3K27me3 on upregulated genes. Indeed, genes that were induced upon 
loss of Mdm2 were deprived of H3K27me3 whereas genes that were downregulated 










Figure 4-17 Mdm2 is required for histone H3 trimethylation at K27 (H3K27me3) on 
various transcription start sites (TSSs). 
(A) H3K27me3 ChIP DNA from p53-/- and p53-/- Mdm2-/- MEFs (cf. Figure 4-16 A) was 
subjected to next generation sequencing and aggregated around the TSS regions of known 
genes. (B) Differentially methylated sites were identified and localized according to their 
distance to the nearest TSS (Bioconductor packages DiffBind (Stark & Brown, 2011) and 
ChIPpeakAnno (Zhu et al, 2010)). (C) Log2 normalized reads of differentially methylated 
regions show methylation change of all identified regions as well as discrimination of the 
regions increased (dko>sko) or decreased (sko>dko) in p53-/- Mdm2-/- MEFs (sko: p53-/-; dko: 
p53-/- Mdm2-/-; boxplot widths corresponds to number of identified regions). (D) H3K27me3 
signal is shown in an aggregation plot around differentially methylated transcriptional start 
sites that were identified in (C). (E) In comparison with the gene expression levels (RNA-Seq; 
cf. Figure 4-3) relative H3K27me3 enriched genomic sites for either upregulated (UP), 
downregulated (DOWN) or non-regulated (non-reg.) genes were evaluated (comparing p53-/- 
Mdm2-/- to p53-/- MEFs) and are presented as boxplots. (H3K27me3 ChIP-Seq n=4). For 
ChIP-Seq and DiffBind data see also Table S2 and S7, respectively, in Wienken et al, under 
review. Figure data and legend also published in Wienken et al, under review. 
 
4.5 Mdm2 enhances H2AK119ub1 without affecting RING1B levels 
The influences of Mdm2 on H3K27me3 stabilization were meaningful in respect to the 
repression of target genes in MEF cells. However, these findings did not reveal anything 
about the direct functions of Mdm2 in this context. From the CA/CA (C462A ki) MEF data we 
knew that Mdm2 gene regulatory function was dependent on its ubiquitin ligase activity (cf. 
Figure 4-3). Therefore, ubiquitination of PRC2 proteins was assessed after overexpression 
and knock down of Mdm2 but no conclusive results were withdrawn.  
Next to PRC2 protein ubiquitination, the histones themselves are a possible target for 
ubiquitination (cf. 2.2.2). In fact, Minsky and colleagues published that Mdm2 
monoubiquitinates histone H2A in vitro (Minsky & Oren, 2004). H2AK119 monoubiquitination 
is usually carried out by the PRC2 complex partner PRC1 and its core enzyme Ring1b (cf. 
2.3.2) (Voncken et al, 2003). Thus, we asked whether Mdm2 also stabilizes or enhances 
H2AK119ub1 in our cell systems and whether it thereby affected the PRC1.  
 
4.5.1 Mdm2 maintains H2AK119ub1 at target genes without affecting Ring1B 
According to results from targeted ChIP, a total Mdm2 loss or loss of E3 ubiquitin ligase 
function significantly reduced the levels of H2AK119ub1 genes on target gene promoters 





control genes Evx1 and Tuba1a (Figure 4-18 A2). However, these control genes did not 
change their general expression levels in the ko or ki MEFs according to RNA-Seq data from 
Figure 4-3. The decrease of H2AK119ub1 was not a result of Ring1b loss but was rather 
accompanied by an increase of Ring1b signal (Figure 4-18 B and B2). Similar results were 
obtained from HCT116 p53-/- cells depleted of MDM2. Previously identified target genes (cf. 
Figure 4-12) were decreased in their H2AK119ub1 promoter levels but did not show any 
change of RING1B levels (Figure 4-18 C-D)  
As before, we also investigated for changes in H2AK119ub1 and Ring1b protein levels, both 
in MEFs and HCT116 p53-/- cells. Immunoblots in Figure 4-18 F and G displayed only minor 
changes of these proteins in MEFs (F) and no change in HCT116 p53-/- cells (G). Again, 
these results led us to analysis of the global H2AK119ub1 dependence on Mdm2 and 
sequenced targeted ChIP DNA as described before (cf. paragraph 3.2.2.4).  
4.5.2 H2AK119ub1 levels are enhanced by Mdm2 on the TSS of known genes  
After peak calling, global aggregates around the TSS of all known genes were generated 
from H2AK119ub1 ChIP-Seq signals. According to Figure 4-19 A, Mdm2 stabilizes 
H2AK119ub1 on gene promoters, since the general signal is decreased in its absence. In 
concordance, DiffBind analysis revealed on average a reduced H2AK119ub1 signal along all 
differentially ubiquitinated sites (Figure 4-19 B). As it was detected for H3K27me3, most of 
these differentially ubiquitinated regions localized around the TSS of known genes (Figure 
4-19 C).  
4.5.3 Mdm2 target gene activation is accompanied by loss of H2AK119ub1.  
According to the ChIP-Seq data presented in Figure 4-19 A and B, we speculated that gene 
de-repression observed in Figure 4-3 would be accompanied by a loss of H2AK119ub1. 
Indeed, upregulated (UP) target genes were significant deprived of H2AK119ub1. Moreover, 
not only these genes were reduced in H2AK119ub1 but also all upregulated and all non-
regulated genes (Figure 4-19 D). This was consistent with the aggregation plot in Figure 4-19 







Figure 4-18 Loss of Mdm2 de-stabilizes H2AK119 monoubiquitination (H2AK119ub1) at 
Mdm2/PRC2 target gene TSSs without affecting global levels of RING1B. 
(A-B) p53-/-, p53-/- Mdm2-/- and p53-/- Mdm2CA/CA MEFs were used for targeted H2AK119ub1 





Figure 4-3) were identified via qRT-PCR analysis and are shown as fold change of % of Input 
relative to p53-/- cells (A and B). In addition corresponding % of Inp values over IgG 
background with suitable control genes in A2 and B2 are given. (C-D) HCT116 p53-/- cells 
were depleted of MDM2 for 96 h using double siRNA transfection. H2AK119ub1 (C) and 
RING1B (D) levels around the TSS of Mdm2/PRC2 target genes (cf. Figure 4-12) were 
identified via qRT-PCR analysis and are shown as % of Input. (E-F) Total levels of RING1B 
and H2AK119ub1 protein in p53-/-, p53-/- Mdm2-/- and p53-/- Mdm2CA/CA MEFs (E) as well as 
HCT116 p53-/- cells (F) were evaluated by Immunoblot analysis. (H2AK119ub1 ChIP n=4; 
RING1B ChIP: mean ± SEM, n=3 for p53-/- and p53-/- Mdm2-/- MEFs, n=2 for p53-/- Mdm2CA/CA 
MEFs; ChIP data from HCT116 p53-/- cells: n=3).Figure data and legend also published in 
Wienken et al, under review. 
 
4.6 Interdependence and functional classification of Mdm2 
enhanced epigenetic modifications 
4.6.1 Differentially methylated and ubiquitinated regions overlap 
Absence of Mdm2 significantly decreased H3K27me3 on 1441 regions and ubiquitination on 
2134 regions according to ChIP-Seq DiffBind analysis (cf. Figure 4-17 C, Figure 4-19 B). 
Many different publications have illustrated a dependence of these two modifications on each 
other (see paragraph 2.3.3) which is why we analyzed an overlap of the detected differentially 
methylated and ubiquitinated regions. 
For the calculation, differentially methylated and ubiquitinated TSS regions were isolated and 
overlapping calculation was done using the Bioconductor ChIPpeakAnno package (Zhu et al, 
2010) as well as the intersection function of the Galaxy / deepTools server mentioned before. 
Iin order to achieve a conclusive result that was true even for different algorhythmic 
parameters I used the two approaches. Both methods presented withed the same trend and 
data shown here were derived from the ChIPpeakAnno package calculation. According to 
Figure 4-20 A, most of the differentially ubiquitinated TSS regions (green) overlapped with the 
differentially methylated ones (blue). When distinguishing between increased or decreased 
signals in the p53-/- Mdm2-/- double ko (dko) compared to the p53-/- single ko (sko) MEFs, the 
methylation and ubiquitination was either simultaneously decreased or enriched. 
Genes of the Hox cluster were initially found to be repressed by Mdm2 (cf. Figure 4-3 B). Via 
the IGV genome browser tool (Robinson et al, 2011), H2AK119ub1 and H3K27me3 ChIP 
signals were visualized along the Hoxc locus (Figure 4-20 B-C). Overall TSS signals from 
p53-/- Mdm2-/- MEFs were decreased along the whole locus when compared to p53-/- MEFs. 






Figure 4-19 Mdm2 is required for the global histone H2A monoubiquitination at K119 
(H2AK119ub1) at transcription start sites (TSSs) of known genes. 
(A) H2AK119ub1 ChIP DNA from p53-/- and p53-/- Mdm2-/- MEFs was subjected to next 
generation sequencing, and aggregated around TSS regions of known genes. (B) 
Differentially ubiquitinated sites were identified and log2 normalized reads show the 
methylation changes of all identified regions as well as discrimination of the regions 
increased (dko>sko) or decreased (sko>dko) in p53-/- Mdm2-/- MEFs (sko: p53-/-; dko: p53-/- 
Mdm2-/-; boxplot widths corresponds to number of identified regions, Bioconductor package 





according to their distance to the nearest gene TSS (Bioconductor package ChIPpeakAnno 
(Zhu et al, 2010)). (E) In comparison with the gene expression levels (RNA-Seq, Figure 4-3), 
relative H2AK119ub1 levels for either upregulated (UP), downregulated (DOWN) or non-
regulated (non-reg.) genes were evaluated (comparing p53-/- Mdm2-/- to p53-/- MEFs) and are 
presented as boxplots. (H2AK119ub1 ChIP-Seq: n=4). For ChIP-Seq and DiffBind data see 
also Table S2 and S7, respectively, in Wienken et al, under review. Figure data and legend 
also published in Wienken et al, under review. 
 
Figure 4-20 Loss of Mdm2 remodels the Polycomb-mediated epigenetic landscape, 
leading to the simultaneous loss of H2AK119ub1 and H3K27me3 on PRC2 target gene 
promoters. 
(A) Overlap of differentially methylated and ubiquitinated regions from H3K27me3 and 
H2AK119ub1 ChIP-Seq analysis (cf. Figure 4-17 and Figure 4-19); it was distinguished 
between sites which are decreased (dko<sko) or increased (dko>sko) for H3K27me3 and 
H2AK119ub1 in p53-/- Mdm2-/- in comparison to p53-/- MEFs. (B-C) Genomic binding profiles 
for H3K27me3 and H2AK119ub1 were generated along the Hoxc locus using the IGV 
genome browser. As an example, the TSS of HoxC10 is zoomed in (C). Figure data and 





4.6.2 Overlapping regions are involved in development and morphogenesis 
Differential gene expression in MEF and MSCs was enriched for developmental and 
morphogenesis relevant gene ontology (cf. Figure 4-4 and Figure 4-10). GREAT analysis 
offers a tool for the function prediction of cis-regulatory regions via internal gene annotation 
and was used to identify common biological processes of the differentially methylated and 
ubiquitinated regions (http://bejerano.stanford.edu/great/public/html/) (McLean et al, 2010). 
Remarkably, the biological processes that were enriched for both epigenetic modifications 
were again mainly involved in development and differentiation which further supported the 
relation between RNA-Seq and ChIP-Seq data from MEF cells (cf. Figure 4-21). 
 
Figure 4-21 Functional annotation of differentially methylated and ubiquitinated 





Cis-regulatory regions were predicted from all differentially methylated (cf. Figure 4-17 C) and 
ubiquitinated (cf. Figure 4-19 B) regions using GREAT and overlapping biological processes 
for both chromatin modifications are shown. For the total analysis see Table S7 in Wienken et 
al, under review. Figure data and legend also published in Wienken et al, under review. 
 
 
4.7 Mdm2 cooperates with Ring1b in gene repression and cell 
survival 
According to paragraph 4.5, Mdm2 stabilizes H2AK119ub1 levels. The major ubiquitin ligase 
for H2AK119 is Ring1b, the enzymatic component of the PRC1. In order to identify, whether 
there is a difference between Mdm2 and Ring1b regulated genes or whether the two factors 
might even support each other, Ring1b was knocked down via shRNA in p53-/- and p53-/- 
Mdm2-/- MEFs and target gene expression was assessed. According to the immunoblot in 
Figure 4-22 A, shRNA kd efficiently deprived the cells of Ring1b and also efficiently depleted 
total H2AK119ub1 (Figure 4-22 A). The Hox genes Hoxb13, Hoxc10 and Hoxc13 were 
induced upon loss of Ring1b in both cell lines but to a much higher extent in the p53-/- Mdm2-/- 
cells (Figure 4-22 B). This supported the idea that Ring1b and Mdm2 cooperatively regulate 
some of their target genes and may therefore also substitute each other. Remarkably, cells 
that were deprived of both, Mdm2 and Ring1b ceased their proliferation which was quantified 
by seeding equal amounts of cells and performing Hoechst staining after 48 h of cell growth 
(Figure 4-22 C-D).  
A similar phenotype was detected in HCT116 p53-/- cells after loss of MDM2 and RING1B in 
combination. Upon 96 h of knock down (Figure 4-23 A), many cells underwent cell cycle 
arrest or apoptosis (Figure 4-23 B and quantified in C). Fortunately, it was still possible to 
yield enough cells for ChIP experiments. Upon loss of both, MDM2 and RING1B, previously 
identified target genes were significantly further deprived of H2AK119ub1 when compared to 
loss of either MDM2 or RING1B (Figure 4-23 D, cf. Figure 4-12). According to previous 
experiments, MDM2 is recruited by EZH2 to target gene promoters (cf. Figure 4-15). Loss of 
RING1B also decreased MDM2 promoter levels on target genes but not as significantly as 







Figure 4-22 Mdm2 and Ring1b cooperatively regulate target gene expression and cell 
survival in MEFs. 
(A) p53-/- and p53-/- Mdm2-/- MEFs were transduced with a shRNA targeting Ring1b. Knock 
down efficiency was assed via immunoblot. (B) Mdm2 target gene expression was assessed 
using qRT-PCR analysis (cf. Figure 4-3, mean ± SEM, n=3) (C-D) The cells from A were 
plated in equal amounts and grown for 48 h. Subsequent Hoechst staining and fluorescence 
microscopy with quantitative image analysis was used to quantify cell growth (Celigo 
cytometer, cf. 3.2.1.10, mean ± SEM, n=5). Figure data and legend also published in 








Figure 4-23 MDM2 and RING1B cooperatively ensure cell survival of HCT116 p53-/- cells 





(A) HCT116 p53-/- cells were depleted of Mdm2 and RING1B for 96h. (B-C) For the second 
knock down equal amounts of cells were plated together with siRNA. After the total kd time of 
96 h, cells were imaged using brightfield microscopy (B) and confluence was measured via 
ImageJ (C; mean ± SEM, n=4). (D) Cells treated with the same kd procedure were used for 
targeted H2AK119ub1 ChIP, amplifying promoter regions of Mdm2/PRC2 target genes 
described before (cf. Figure 4-12 C, mean ± SEM, n=3). (E-F) SJSA cells were depleted of 
Ring1b and MDM2 recruitment to target gene promoters was analyzed via ChIP (mean ± 
SEM, n=3; detected differences are not significant). Figure data and legend also published to 
some extent in Wienken et al, under review. 
 
 
4.8 Mdm4 coregulates Mdm2/PRC2 target genes  
4.8.1 The expression of multiple genes is dependent on both, Mdm2 enzymatic 
function and Mdm4 
Mdm2 is not the only Mdm protein encoded in murine and human cells. Its homologue Mdm4 
can act in a redundant but also non-redundant manner (Barboza et al, 2008; Grier et al, 
2006; Steinman et al, 2005) and we assessed, whether Mmd4 can overtake at least some of 
the Mdm2 gene regulatory functions described in the last paragraphs. So far we knew that 
Mdm2 represses PRC2 target genes in different cell systems through stabilization of 
H3K27me3 and H2AK119ub1. Mdm4 is therefore not able to substitute these functions in an 
Mdm2 loss of function setting. Mdm4 does not contain intrinsic E3 ubiquitin ligase function 
but can increase Mdm2-mediated ubiquitination through dimerization (Linares et al, 2003). 
We therefore hypothesized that loss of Mdm4 in MEF cells de-represses Mdm2/PRC2 target 
genes through destabilization of the Mdm2-Mdm4 heterodimer and subsequent loss of 
H2AK119ub1 and H3K27me3. 
RNA from p53-/- Mdm4-/- MEF cells was included in the RNA-Seq analysis from Figure 4-3 
and indeed genes regulated by Mdm4, Mdm2 and the RING mutant Mdm2C462A overlapped 






Figure 4-24 Triple Venn diagram of genes regulated in Mdm2-/--, Mdm2CA/CA- and Mdm4-/- 
MEFs. 
Differentially regulated genes were identified via DESeq analysis from sequenced RNA of 
p53-/- Mdm2-/--, p53-/- Mdm2CA/CA and p53-/- Mdm4-/- MEFs in comparison to p53-/- MEFs (cf. 
Figure 4-3). Overlap of differential gene expression is presented in a triple Venn diagram.  
 
4.8.2 Mdm4 target gene regulation in MEFs is accompanied by loss of H3K27me3 
All genes that were significantly deregulated by both, Mdm2 and Mdm4 are visualized in a 
heatmap in Figure 4-25 A. According to the RNA-Seq data, several previously identified 
Mdm2 target genes (e.g. Hoxb13, Hhip and Eomes, cf. Figure 4-3 A) were also regulated by 
Mdm4. It was not possible to verify these results via qRT-PCR since this analysis resulted in 
only mild induction of some of the Hox genes (Figure 4-25 B). This discrepancy can be 
caused by biases during RNA library preparation and also due to very low sequencing reads 
of the corresponding genes, which was at least true for several of the Hox genes.  
Nevertheless, we were interested in the H3K7me3 promoter levels because they were 
diminished before in Mdm2 ko MEFs (cf. Figure 4-16 and Figure 4-17) and indeed detected a 
comparable decrease (Figure 4-25 C). This decrease was not detectable on the negative Ctrl 
gene Gapdh (Figure 4-25 D). As for p53-/- Mdm2-/- MEFs, EZH2 levels on the promoter of 
those target genes remained constant. To this end, no significant conclusions were drawn 











Figure 4-25 Mdm4 regulates Mdm2 target genes in MEFs to some extent via 
stabilization of H3K27me3. 
(A) p53-/-, p53-/- Mdm2-/- and p53-/- Mdm4-/- MEFs were analyzed via next generation RNA-
sequencing and differentially expressed genes are shown in a heat map. (B) Mdm2 target 
gene expression (cf. Figure 4-3 B) was evaluated in p53-/- Mdm4-/- MEFs by qRT-PCR (mean 
± SEM, n=3). (C-E) p53-/- and p53-/- Mdm4-/- MEFs were used for targeted H3K27me3 (C-D) 
and EZH2 ChIP (E). ChIP levels around the TSS of Mdm2/PRC2 target genes were identified 
via qRT-PCR analysis and are shown as % of Input relative to p53-/- cells (C, E) together with 
the corresponding % Inp values for Hoxc10 and with a suitable negative control genes (D). 
 
4.8.3 Mdm4 target genes in MEFs are also involved in stemness and development 
and are characterized by PRC2 regulation 
In concordance to the functional annotation of Mdm2 target genes in MEFs, target genes 
repressed by Mdm4 were also involved in development and differentiation. No clear 
accumulation of these gene sets was visible in the activated genes (Figure 4-26 A and B). 
DAVID analysis of the identified differentially genes confirmed this data, with many 
maturation-related gene sets in the group of repressed genes and a few in the activated 
genes (Figure 4-26 C-D).  
Since C2 GSEA analysis of the Mdm2 target genes in MEFs, hMSCs and HCT116 cells 
indicated a connection to PRC2 gene regulation (cf. Figure 4-5, Table 4-1 and Figure 4-13), a 
possible enrichment was also tested for the p53-/- Mdm4-/- MEFs. According to Table 4-3, 
genes upregulated upon loss of Mdm4 were targets of PRC2 regulation and were also 
characterized by the repressive mark, H3K27me3. Fairly reassuring was the appearance of 
the gene set “MARTORIATI_MDM4_TARGETS_FETAL_LIVER_UP”. Apparently, the genes 
that were upregulated in our Mdm4-/- MEF system correlated to this gene set which had been 
identified before to increase its expression upon loss of Mdm4 (Martoriati et al, 2005). 
Gene sets downregulated by the loss of Mdm4 were again involved in stemness and also 
characterized by H3K4me3. This overlap in gene set regulation supported us in the 



































Figure 4-26 GO term analysis of genes regulated by Mdm4 in p53-/- Mdm4-/- MEFs.  
(A-B) C5 GSEA was performed based on using normalized RNA-Seq reads comparing 
p53-/- to p53-/- Mdm4-/- MEFs. Enriched gene sets were filtered as described before (cf. 






(B). (C-D) For comparison, we conducted DAVID annotation analysis from genes that had 
been identified by DESeq to be differentially regulated in p53-/- Mdm4-/- MEFs in comparison 
to p53-/- MEFs. 
 
 
Table 4-3 Mdm4 preferentially regulates stemness related genes controlled by the 
Polycomb Repressive Complex 2. 
(A-B) C2 GSEA based on normalized RNA-Seq reads comparing p53-/- to p53-/- Mdm4-/- 
MEFs. Enriched gene sets were filtered as described before (cf. Figure 4-5) and are 
displayed for genes upregulated in p53-/- Mdm4-/- MEFs (A) and genes downregulated in p53-/- 








In this project, we analyzed novel functions of the oncoprotein MDM2 in the epigenetic 
regulation of gene expression (outlined in Figure 5-11). Here, MDM2 stabilized a gene 
repressive profile correlated to stemness maintenance and cell survival. This led to abrogated 
iPSC generation and accelerated hMSC differentiation into osteoblasts upon loss of MDM2. The 
genes that MDM2 regulated in primary-, stem- and cancer cells were direct targets of the PcG 
family. Remarkably, MDM2 directly interacted with the PcG complex members EZH2 and 
SUZ12, and was recruited to the promoters of MDM2/PRC2 target genes by EZH2. Presence of 
MDM2 enhanced the repressive histone modifications H3K27me3 and H2AK119ub1, leading to 
an induction of gene expression in the absence of it. Concomitant loss of MDM2 and RING1B 
which is the most well-known H2AK119 ubiquitin ligase abrogated cellular survival of MEF and 
cancer cells due to further exaggerated gene induction. Preliminary data on a similar gene 
regulatory function for the MDM2 homolog MDM4 indicated overlapping functions in respect to 
gene repression of a stemness associated gene profile. Furthermore, loss of MDM4 was also 
associated with a destabilization of H3K27me3.  
 
Figure 5-1 Mdm2 regulates gene expression in cooperation with the PcG family 
Mdm2 associates with proteins of the PcG family on the chromatin and thereby enhances 
H3K27 trimethylation and H2AK119 monoubiquitination. Mdm2 facilitates repression of genes 






5.1 Three cell systems – one conserved mechanism 
MDM2 represses PcG target gene expression in primary-, stem- and cancer cells and we 
investigated its PRC2 interaction and epigenetic function in cancer as well as MEF (primary) 
cells. Unfortunately, we did not identify shared regulation of many specific genes. However, 
MDM2 regulated PRC2 target genes in all different systems according to C2 GSEA (cf. Figure 
4-5, Table 4-1 and Figure 4-13). The lack of a specific shared gene profile is not completely 
astonishing. Until now it has been hard to identify a common motif for PRC2 target genes in 
different cell types, as also outlined in 2.3.3. According to current literature, the PRC2 regulatory 
profile is strongly dependent on the cellular context which includes presence and absence of 
DNA methylating agents, accessory proteins and specific chromatin modifications (Simon & 
Kingston, 2013). Since the recruitment of MDM2 was directly dependent on PRC2 (cf. Figure 
4-12 C-D), it was unlikely to detect a common profile of MDM2 chromatin occupancy for the 
different systems. 
Furthermore, the three different cell systems were selected not only to get broad information on 
the gene regulatory function of MDM2, but also due to technical reasons. MDM2 is a high 
turnover protein and only present in low amounts in most cell lines. Thus, for endogenous 
immunoprecipitation assays that are dependent on high protein levels, we used SJSA cells 
which are characterized by high MDM2 protein levels due to gene amplifications. 
Both, Co-IP and ChIP can be done with overexpressed protein, something that we also did in 
transient short-term experiments for the mapping approaches mentioned earlier (Figure 4-14 B-
D; transient overexpression for only 24 h). An obvious experiment would be to overexpress 
Mdm2 in the p53-/- MEFs and evaluate its chromatin occupancy on the target genes that we 
described (Figure 4-3). Unfortunately, several groups have tried to set up MDM2-
overexpressing cell systems, which failed due to high cell toxicity and overexpression artefacts 
(cf. paragraph 2.1.5) (Brown et al, 1998; Frum & Deb, 2003). Therefore, we also relied on the 
SJSA cells for an MDM2 ChIP (Figure 4-15 A). Fortunately, these results were further supported 
on a heterologous promoter system in HEK cells (Figure 4-15 E).  
 
5.2 MDM2 as a putative H2AK119 ubiquitin ligase 
According to our data in Figure 4-18 and Figure 4-19, MDM2 enhances H2AK119ub1 on target 





enzymatic function and together with data from Figure 4-23 D we hypothesize that MDM2 can 
directly ubiquitinate H2AK119 for gene repression (cf. Figure 4-3 A). However, we did not 
conclusively prove this. Two publications support our hypothesis that MDM2 is not only able to 
bind to the promoter DNA of PcG target genes (cf. Figure 4-15) but also to ubiquitinate 
H2AK119 (Challen et al, 2012; Minsky & Oren, 2004). Especially the data published by Minsky 
and colleagues showed that MDM2 can bind to the DNA and repress gene expression through a 
RING dependent H2A ubiquitination, in a p53 independent manner. Using purified histones 
which were incubated with bacterially expressed GST-MDM2 and HA-tagged ubiquitin they 
validated that MDM2 ubiquitinates H2A and H2B and that this function is RING domain 
dependent. The additional value of our data is the connection of this epigenetic regulation with 
direct cellular functions, namely stem cell maintenance and cancer cell survival.  
According to the results in Figure 4-22, Hox gene repression in MEFs relied on both, Ring1b 
and Mdm2. Since the loss of both, drove cells into arrest and apoptosis (Figure 4-22 C, D and 
Figure A, B), increased Ring1b promoter levels observed in p53-/- Mdm2-/- MEFs (Figure 4-18 B) 
could be a rescue effect to prevent a complete loss of H2AK119ub1 or chromatin compaction. A 
substituting function of Mdm2/Ring1b could also explain the lack of a developmental phenotype 
in p53-/- Mdm2-/- mice, since Ring1b might compensate for the lack of Mdm2 driven H2AK119 
ubiquitination. However, it will be hard to further study this in vivo because studies with Ring1b 
ko systems have already identified a strong lethal phenotype (Román‐Trufero et al, 2009; van 
der Stoop et al, 2008; Voncken et al, 2003). Still, possible attempts are discussed in paragraph 
5.10. 
5.2.1 PcG protein ubiquitination as a possible function for MDM2? 
Despite the strong evidence that Mdm2 is directly involved in H2AK119 ubiquitination (Figure 
4-23 D), it is still possible that these functions are mediated indirectly. Such an indirect 
mechanism could include the ubiquitination of PcG- or accessory proteins by MDM2, driving 
their proteasomal decay or activation. In MDM2 loss of function and overexpression studies, we 
did not obtain any data so far which would support this hypothesis. However, several PcG 
proteins get posttranslationally ubiquitinated, most of them for proteasomal decay (Dimri et al, 
2010; Zoabi et al, 2011), but also for increasing their enzymatic activity (Ben-Saadon et al, 
2006).  
As an example, the H2K119 ubiquitination activity of RING1B is dependent on atypical mixed 





polyubiquitin chains and it would be interesting to detect whether Ring1b activity is impaired in 
p53-/- Mdm2-/- and p53-/- Mdm2CA/CA MEFs. Decreased activity could be compensated by 
increased Ring1b promoter recruitment, as we detected it in Figure 4-18 B. It is still a bit 
controversial though, why the increased promoter levels were not able to substitute the loss of 
H2AK119ub1 and the induction of target gene expression (cf. Figure 4-18 A and Figure 4-3 B). 
Still, this increased recruitment could rescue the gene repression above a specific threshold 
(since we see further loss of H2AK119ub1 in MDM2/RING1B double kd samples, Figure 4-23 
D) that still ensures cell survival (as we detected it in Figure 4-22 B-C and Figure 4-23 A-B).  
 
5.3 MDM2 as a PcG complex member 
Corresponding to current literature, it is not completely known how PcG proteins recognize their 
target genes in the first place, under which circumstances H2AK119ub1 and H3K27me3 depend 
on each other and how PcG regulation discriminates between different stem cell potencies, 
lineage commitments and the pathways that determine malignancy. How could the interaction of 
the PcG proteins with MDM2 contribute to this discussion? 
5.3.1 Canonical- and variant PcG activity defined by MDM2 
Due to its many complex members, the PRC1 is defined by canonical and variant complex 
setups (cf. paragraph 2.3.3). Canonical PRC1 complexes contain CBX proteins and their activity 
strongly depends on upstream H3K27me3, whereas variant (RYBP-containing) complexes 
ubiquitinate their target genes independent of H3K27me3 (Tavares et al, 2012; Wang et al, 
2010). 
Along the same line Ku and colleagues identified that the PRC2 can also occupy chromatin 
independent of the PRC1 (Ku et al, 2008). Through the interaction with MDM2, the PRC2 could 
build up a variant complex that has intrinsic ubiquitination function which could ensure gene 
repression maintenance even in the absence of PRC1. In fact, MDM2 would not be the first E3 
ubiquitin ligase which is providing this function to the PRC2. TRIM37 and Cullin 4-Ring E3 
ligase B (CRL4B) were also detected to interact with the PRC2 and facilitate gene repression 
through the monoubiquitination of H2AK119 (Bhatnagar et al, 2014; Hu et al, 2012). Because 
H2AK119ub1 is such an explicit measure to ensure stemness integrity and proper differentiation 
(Boyer et al, 2006), the occupancy of different ubiquitin ligases can also ensure situation 






5.3.2 MDM2 epigenetic contribution in the classic PcG hierarchy 
In line with the classic PcG hierarchy, PRC2 methylates H3K27 and thereby recruits PRC1 
through the chromodomain protein CBX (Cao et al, 2005). Because the overall decrease of 
H3K27me3 levels was less prominent upon loss of MDM2 than the decrease of H2AK119ub1 
(cf. Figure 4-17 and Figure 4-19) and because EZH2 directly recruited MDM2 to its target genes 
(cf. Figure 4-15 E) MDM2 mediated ubiquitination of H2AK119 seems to be downstream of 
H3K27 trimethylation. As a matter of fact, Minsky and colleagues noted a low H2AK119ub1 
efficiency of MDM2 in their in vitro setting (cf. paragraph 2.1.6.1) and postulated that this might 
be caused by the absence of further covalent modifications which prime H2A as E3 substrate 
(Minsky & Oren, 2004). Our data could explain the rather low efficiency of H2AK119 
ubiquitination by MDM2 through missing PRC2 proteins to bind to (EZH2 recruits MDM2 to its 
target gene promoters, cf. Figure 4-15) and absence of H3K27me3. H3K27me3 has previously 
been identified as an enhancer of intrinsic PRC2 function (Hansen et al, 2008) and PRC2-bound 
MDM2 could be recruited more efficiently to sites of H3K27me3 and exert accelerated ubiquitin 
ligase function. Since we detected a cooperative gene regulation of MDM2 and RING1B (cf. 
Figure 4-22 B), the PRC1 could further maintain gene repression through additional H2AK119 
ubiquitination and also through direct chromatin compaction (Eskeland et al, 2010). 
5.3.3 MDM2 epigenetic contribution in the non-classic PcG hierarchy 
According to our data, the MDM2 epigenetic function directly depended on the presence of 
PRC2 on the chromatin (cf. Figure 4-15 E). Furthermore, gene repression by MDM2 was partly 
enhanced by RING1B (Figure 4-22 B). In a possible scenario of the non-classical PcG hierarchy 
(first H2AK119ub1, then H3K27me3), the PRC1 could provide baseline ubiquitination and 
chromatin compaction levels which are recognized by the PRC2, as recently described by Kalb 
and Blackledge (Blackledge et al, 2014; Kalb et al, 2014). PRC2 could subsequently recruit 
MDM2 to extend, renew and/or maintain the ubiquitination mark. Because the gene regulatory 
function of the PRC1 is not solely dependent on its ubiquitin ligase function (Eskeland et al, 
2010), ubiquitination could be carried out by other ligase like MDM2. 
 
The reverse hierarchy described by Kalb and colleagues was actually based on JARID2 
recognition of existing H2AK119ub1, whereas Blackledge hypothesized that the presence of 
variant PRC1 is responsible for PRC2 recruitment. Interestingly, the variant PRC1 protein RYBP 





al, 2009). Interaction between RYBP and MDM2 could support the PRC2-MDM2-PRC1 network 
in the non-classic hierarchy. However, this needs to be clarified through Co-IP experiments.  
So far the scientific community does not really agree on how the hierarchical relationship 
between PRC1 and 2 are set up (or whether there is one) (Comet & Helin, 2014). Further 
analysis of the PcG-MDM2 functional interaction is needed to evaluate a clear functional 
hierarchy. 
 
5.4 PRC2/MDM2 interactions through non-coding RNAs 
Only 1-2 % of the human genome comprises of protein-coding exons; this finding raised a huge 
interest in the other 98-99 %, which include repetitive sequences, telomeres, introns and the 
DNA sequences that give rise to non-coding RNAs (Venter et al, 2001). The long non-coding 
RNAs XIST and HOTAIR interact with the PRC2 and recruit it to specific target genes (XIST 
recruits to the X-chromosome and HOTAIR towards the Hox locus (Gupta et al, 2010; Plath et 
al, 2003)). The PRC2 has further been described to bind to nascent RNAs originating from 
target genes promoters and thereby halt the transcription machinery in a dynamic fashion 
(Kaneko et al, 2013).  
Along the same line, MDM2 binds to RNA and thereby regulates TP53 expression (Challen et 
al, 2012; Elenbaas et al, 1996). Since both, Mdm2 and the PRC2 bind RNA, it would be 
interesting to know whether their interaction is enhanced or diminished by the presence of RNA. 
Even though MDM2 has not been detected to bind one of the lncRNAs XIST or HOTAIR, its 
RNA binding ability could indicate a possible connection. Besides, HOTAIR is encoded on the 5’ 
HoxC locus, which we identified to be a target of MDM2/PRC2 regulation. It would be interesting 
to know whether MDM2 also regulates HOTAIR expression and thereby influences its mediated 






5.5 A role for MDM2 in the development of fat and bone 
Lineage differentiation is controlled by specified pathways. Osteoblastic and adipogenic 
differentiation follow a reciprocal way (cf. Figure 5-2) which is highly influenced by epigenetic 
PcG regulation (outlined for e.g. EZH2 by Chou et al, 2011). As already mentioned in paragraph 
2.1.5, MDM2 overexpression is most commonly found in soft tissue- and osteosarcomas. Since 
stem cell differentiation and cellular de-differentiation 
during malignant transformation share molecular 
pathways (Reya et al, 2001; Sell, 1993), it is important to 
study MDM2 during e.g. adipogenesis and osteogenesis.  
 
Figure 5-2 Reciprocal development of adipocytes and 
osteoblasts.  
hMSCs differentiated into adipocytes and osteoblasts 
(among others). These differentiation pathways are 
controlled by opposing signaling pathways (Takada et al, 
2009) 
 
According to our data, loss of MDM2 accelerated osteogenic differentiation from hMSCs (cf. 
Figure 4-8). On the other hand, Hallenborg and colleagues found that overexpression of MDM2 
facilitates adipogenic differentiation through activation of the CREB pathway (cf. Figure 5-2) 
(Hallenborg et al, 2012). Combining this data concludes that absence of MDM2 not only de-
represses early differentiation genes that drive the osteogenic lineage (e.g. AP and BGLAP) (cf. 
Figure 4-8 C and F) but also decreases CCAAT/enhancer-binding protein δ (C/EBPδ) 
expression induction through CREB. This will further shift differentiation along the osteogenic 
line (cf. Figure 5-2). In the presence of MDM2 this phenotype is reversed, giving rise to cells of 
the adipogenic lineage and suppressing the osteogenic differentiation. Indeed, when we started 
these differentiation studies, we also included adipogenic differentiation and did not detect any 
accelerated adipogenic differentiation after loss of MDM2.  
Remarkably, the same behavior was detected for EZH2 by Hemming and colleagues and 
Dudakovic et al.. According to their data, EZH2 overexpression drove MSC differentiation into 
the adipogenic lineage whereas loss of EZH2 favored osteoblast differentiation (Dudakovic et al, 





Sasaki and colleagues found that the depletion of EZH2 and BMI1 was not enough prevent the 
survival of osteosarcoma both in vitro and in vivo (Sasaki et al, 2010). It would be interesting to 
determine the MDM2 protein levels in the sarcomas that do not respond to EZH2 depletion and 
whether increased MDM2 levels are responsible for stabilized H3K27me3 and H2AK119ub1. 
Combining EZH2 inhibition and MDM2 decay (components driving MDM2 self-ubiquitination are 
under investigation) could be a possible treatment option for those tumor entities. 
 
5.6 Benefits of an MDM2/PcG joint venture 
Why would a cell benefit from the connection of a cell cycle regulator and an epigenetic protein 
complex involved in stem cell maintenance? And how can it circumvent loss of function for one 
but not the other factor?  
 
5.6.1 MDM2 – link between epigenetics and DNA damage? 
The ability to retain a perfect copy of DNA whenever a cell replicates is the major prerequisite a 
germ cell (and any other dividing cell) must provide. Loss of this proofreading ability will lead to 
mutation and drive cells into malignant transformation processes (Berg et al, 2002). As a matter 
of fact, any cell is facing a multitude of stressors every day, including UV radiation, reactive 
oxygen species, toxins etc. and several systems are making sure that the damage will be 
recognized and repaired. In case of intensive damage which cannot be repaired, cell death is 
induced to remove the altered cell from the progeny pool (Jackson & Bartek, 2009). The P53 
system is a key player involved in DNA damage recognition and repair as outlined in paragraph 
2.1.2.1. Under normal circumstances, DNA damage leads to increased inhibition and 
degradation of MDM2, releasing P53 from its control. P53 subsequently induces cell cycle arrest 
and, in case of intensive damage, apoptosis (Oren, 2003; Vogelstein et al, 2000; Vousden, 
2000). It furthermore also activates MDM2 expression to ensure autoregulatory feedback. 
 
In line with our data, the shutdown of MDM2 during a cell stress event would not only impede 
malignant transformation through P53 activation but also through its connection with the PcG 
gene regulatory network. Upon DNA damage, PcG mediated gene repression would be lifted 
due to downregulation of MDM2 (as observed in Figure 4-3 A and B, Figure 4-8 C-F and Figure 
4-12), enhancing differentiation pathways (cf. Figure 4-8 A-C) and inducing cell cycle arrest (cf. 





of differentiation controls proliferation capacity (Sela et al, 2012). We assume that this inter-
connection is a further safety measure to keep a perfect germ cell and stem cell pool and proper 
disposal of cells exhibiting DNA damage. In concordance, many malignancies benefit from high 
levels of MDM2 or PcG proteins and therapeutic inhibition of these proteins are of great 
therapeutic value (cf. paragraphs 2.1.5 and 2.3.4.2).  
 
5.6.2 How can MDM2 be dispensable for proper organism development? 
One of the most puzzling question of this project is why the epigenetic and stemness related 
function of MDM2 does not seem to play any role in the development of a murine organism. 
Embryonic lethality caused by MDM2 ko can be reversed by an additional loss of p53, both in a 
complete and conditional ko systems (cf. paragraph 2.1.4). Interestingly, a similar question was 
asked after the p53 ko mouse was generated: How can a factor like p53 be so negligible for 
development, when it is so indispensable for cell cycle regulation and survival?  
At least for p53, this statement has been relativized in the last couple of years especially in 
murine systems. Two independent groups around Armstrong and Sah reported increased 
embryonic lethality of the p53-/- mouse. Especially the female mice died due to improper closure 
of the neural tube and exencephaly, and in general fertility was decreased (Armstrong et al, 
1995; Sah et al, 1995). Furthermore, generation of iPS cells from p53-/- MEFs was greatly 
increased indicating a p53 stem cell barrier function (cf. Figure 4-1 B). This barrier function 
could also be a reason for the improper nervous system development (Hong et al, 2009; 
Kawamura et al, 2009). 
With our data, we are now able to directly connect gene regulatory and epigenetic functions of 
Mdm2 with stemness maintenance and cell survival. However, these functions disagree with the 
fact that the p53-/- Mdm2-/- mouse develops normally. One possible explanation could be based 
on cellular stress. The whole p53-Mdm2 axis is designed to act during cellular stress which 
might circumvent its function during development in an unstressed organism, as it is typically 
the case for laboratory animals.  
As mentioned before, Jones and colleagues detected embryonic lethality especially in female 
p53-/- mice. Female development requires a more intensive amount of epigenetic regulation due 
to X-chromosome inactivation which could provide a potential cell stress situation. As explained 





why you can expect lower MDM2 protein levels in tissues deficient of p53. In fact, we also 
detected these differences in our MEF cells when compared to wt MEF preparations. Such a 
decrease in Mdm2 expression could impair PcG target gene repression which is one of the most 
important factors in X-chromosome silencing (Plath et al, 2003). The additional stress of X-
chromosome inactivation can be a reason of induced female lethality. This could be further 
tested via checking imprinting efficiency of the X-chromosome in p53 ko mice (see also 5.10). 
5.6.2.1 Cell stress in analyzed systems 
Indeed, all systems that we analyzed are characterized by cell stress. Artificial overexpression 
of transcription factors (Oct3/4, Klf4 and Sox2) are per se stress factors and many generated 
iPSCs are undergoing cell death instead of pursuing reprogramming, due to DNA damage 
(Marión et al, 2009). Therefore, loss of p53 increases reprogramming but also decrease iPS cell 
quality as it was stated by Hong and colleagues (Hong et al, 2009). Next to iPS cell generation, 
MSC differentiation into osteoblasts harbors many stress points. siRNA mediated knock down 
as well as chemically induced osteoblast differentiation might facilitate MDM2 stemness 
function.  
In fact, we are not the first ones who postulate that p53 independent functions of MDM2 could 
be hidden under non-stress condition. According to Marine and Lozano, the p53-independent 
MDM2 functions become relevant under conditions of cellular stress including tumors (Marine & 
Lozano, 2010).  
 
5.7 MDM2 and PcG – linking cancer and stem cells? 
As already outlined in 2.3.4.3, a quite interesting hypothesis has been raised in the last years 
concerning the concept of cancer stem cells (CSCs). PRC2 proteins and MDM2 are major 
players in cancer and stemness, and at least the PcG proteins EZH2 and Bmi1 have been 
extensively discussed in the field of CSC research. As mentioned, elevated EZH2 and 
H3K27me3 levels were detected in CSCs of breast and prostate cancer (Crea et al, 2011; Suvà 
et al, 2009; van Vlerken et al, 2013).  
According to our data, the MDM2/PRC2 network could combine stemness and malignancy 
related pathways. MDM2, which is often overexpressed in tumor cells, could facilitate the 
conversion of differentiated normal cells into cancer stem cells via the induction of a stem cell 





H2AK119ub1 of target genes involved in differentiation and cell cycle arrest, which explains how 
high levels of MDM2 can support malignant transformation even in the absence of wt p53 
(Cordon-Cardo et al, 1994).  
The finding that MDM2 splice variants, which do not contain the P53 binding domain, still confer 
malignancy is also valid according to our data (Sigalas et al, 1996). The p53 binding domain is 
not needed for MDM2 interaction with the PRC2 as explained before, and these variants would 
still be able to repress PcG target genes supporting malignancy. 
It would be important know whether CSC maintenance is supported by high levels of MDM2 and 
how the epigenetic signatures of H3K27me3 and H2AK119ub1 are changed in case of MDM2 
loss or inhibition. 
 
5.8 Therapeutic relevance of the MDM2/PRC2 joint venture 
The P53-MDM2 system is under intensive therapeutic research. MDM2 binds P53 through the 
P53-binding domain and the majority of the small chemical compounds that are currently 
evaluated in animal and patient based trials, target exactly this interaction. Among those are the 
Nutlins, and the benzodiazepinediones. For these compounds, no therapeutic relevance was 
found in tumors with mutant or no P53 (Li & Lozano, 2013; Wade et al, 2013). JNJ-26854165 
(Kojima et al, 2010), HLI98 (Yang et al, 2005), MPD (Roxburgh et al, 2012) and MEL (Herman 
et al, 2011) are compounds that were designed to inhibit the E3 ubiquitin ligase function of 
MDM2. Treatment with these compounds in P53 wt cancers results in a decrease of MDM2 
mediated P53 proteasomal degradation, cell cycle arrest and apoptosis related gene 
expression. Remarkably, treatment with these compounds was also effective to some extent in 
P53 null systems.  
According to our work, the development of drugs which inhibit the MDM2 E3 ubiquitin ligase 
function or destabilize the whole protein will be of utmost interest. MDM2 interacts with EZH2 
and SUZ12 via a region in the first 300 amino acids of the protein but the P53-binding domain is 
dispensable for this interaction (cf. Figure 4-14 and Wienken et al, under review). Compounds 
that are based on the nutlins and benzodiazepinediones will therefore not target the MDM2-
PRC2 interaction and will not have any therapeutic relevance in cells with LOF P53.  
Apart from the mapping experiment we also know that MDM2 needs its E3 ubiquitin ligase 
function for gene repression. Experiments with MEFs expressing MDM2 that lacks E3 ubiquitin 





(cf. Figure 4-3 and Figure 4-18). Therefore, inhibitors such as JNJ-26854165 and HLI98 which 
are designed to target the ubiquitin ligase function may be able to not only target the p53 
regulation by MDM2 but also the repression of PRC2 target gene.  
As already mentioned in paragraph 5.5, the contributions of MDM2 regarding development of 
adipocytes and osteoblasts is mainly p53-independent. Since the cancer types that arise from 
these tissues (lipo- and osteosarcoma) are generally characterized by high levels of MDM2, 
patients suffering from esp. liposarcoma are included in MDM2 inhibitor clinical trials. During the 
8th International MDM2 workshop (New Orleans, 1.11.-4.11.2015) it was intensively discussed 
whether this could result in misleading conclusions in cases of substances targeting only the 
P53-MDM2 interaction. Inhibitor treatment could activate P53 to some extent but still ongoing 
p53-independent functions of MDM2 might be too extensive to drive cells into sufficient 
apoptosis. This would explain why several clinical trials were recently stopped due to a lack of 
treatment efficacy (Arnold J. Levine, personal communication) and would further support the 
idea to run clinical trials with compounds not only targeting the p53-dependent functions of the 
MDM proteins. 
In the context of therapeutic value it will be also important to discuss the role of P53. P53 is a 
positive regulator of MDM2 and tumors without wt P53 function are most probably characterized 
by low MDM2 expression (Wu et al, 1993). In the case of H3K27me3- and H2AK119ub1 
destabilization due to low MDM2 levels, treatment with EZH2/RING1B inhibitors may be more 
efficient in cells without wt P53 expression. Indirect evidence for this hypothesis was already 
given by Sasaki and colleagues as explained before in paragraph 5.5. According to their data, 
osteosarcomas, which are often characterized by high MDM2 levels, were less responsive 
towards PcG inhibition therapy (Sasaki et al, 2010). In this case, high MDM2 might have 
stabilized H3K27me3 and H2AK119ub1 levels, rendering inhibitor treatment ineffective. 
Furthermore, precautions have to be taken when using MDM2 inhibitors in a mutant P53 
system. In contrast to P53 loss of function, many tumors are characterized by P53 mutations 
that causes malignant gain of function (GOF) properties of P53 (Brosh & Rotter, 2009). In this 
case, malignant transformation is supported by P53 and MDM2 can act tumor suppressive 






5.9 How can MDM4 contribute to the MDM2/PRC2 gene regulation? 
Unfortunately, our knowledge about the relevance of MDM4 in the control of PcG target genes 
is limited. As described in Figure 4-25, loss of Mdm4 de-repressed an overlapping gene set in 
MEFs compared to Mdm2 and was also associated to some extent with loss of H3K27me3. 
MDM4 does not contain intrinsic E3 ubiquitin ligase function (Shvarts et al, 1997; Shvarts et al, 
1996). However, MDM4 can enhance MDM2 E3 function through heterodimerization and also 
stabilize the MDM2 protein via abrogation of its autoubiquitination (Linares et al, 2003). Due to 
the impact on MDM2, loss of MDM4 could indirectly regulate PRC2 target genes and thereby 
change its repressive chromatin state. So far we did not investigate whether MDM4 directly 
interacts with the PRC2; since it binds to MDM2 and forms dimers, the possibility is quite high 
though. It will be especially important to study these p53-independent MDM4 functions for 
potential drug design. Several studies indicated that high MDM4 levels can abrogate the 
outcome of MDM2 inhibitor therapy and it may be necessary to use compounds that can target 
both, MDM4 and MDM2 binding and enzymatic function to inhibit the Mdm-PcG gene regulatory 
network (Li & Lozano, 2013).  
Ko studies have revealed that Mdm4 and Mdm2 are functioning in a non-redundant pattern, 
which means that neither protein can substitute for the loss of the other (although 
supraphysiological Mdm2 levels were able to substitute loss of Mdm4, cf. paragraph 2.1.2). It 
could therefore also be plausible that Mdm4 does not share PRC2 co-regulatory functions that 
are beyond any indirect influences through Mdm2. We have to invest more time into this 
question in order to gain better insights. 
 
5.10  Concluding remarks and future perspectives 
In this study we have evaluated and discussed a novel function of MDM2 in the epigenetic 
regulation of PcG target genes. This gene regulatory function included enhancement of specific 
histone modifications and was responsible for stemness maintenance and cancer cell survival.  
One of the most interesting findings of the MDM2/PcG relationship was the interdependence of 
murine primary and human cell on both, RING1B and MDM2. We are now aiming to 
understand, whether the stabilization of H2AK119ub1 through MDM2 is indeed its major 
function. This would mean that destabilization of H3K27me3 is a bystander consequence and 
merely depends on H2AK119ub1 ubiquitination by MDM2 in the first place. Whether the 





different systems. Hereby, a mutual gene expression profile could be investigated through 
global gene expression studies. Accordingly, we have to test, whether the synthetic lethality and 
gene expression changes can be also observed in p53-/- Mdm2CA/CA MEFs. According to Figure 
4-23 D, MDM2 ubiquitinates H2AK119ub1 together with RING1B; from studies in MEFs we 
know that the enzymatic function of Mdm2 is crucial for gene repression (cf. Figure 4-3) and 
maintenance of H2AK119ub1 (cf. Figure 4-18). Taken together, loss of Ring1b in p53-/- 
Mdm2CA/CA MEFs should result in the same synthetic lethality as we observed it for complete 
loss of Mdm2.  
A similar question should be asked for MDM4. Unfortunately, we cannot say for sure how 
MDM4 is involved in the maintenance of H2AK119ub1. However, loss of it led to the 
deregulation of similar gene sets compared to MDM2 (cf. Table 4-1 and Table 4-3). Since 
MDM4 is necessary for the proper enzymatic function of MDM2 it could be plausible, that cells 
interdepend on RING1B and MDM4 as they do it for MDM2. 
Furthermore, we want to understand, whether the relationship between MDM2 and RING1B is 
unique or can be also determined for other proteins. In paragraph 5.3.1 the existence of other 
H2AK119 ubiquitin ligases such as BRCA1, TRIM37 and CRL4B was mentioned. It would be 
interesting to know whether a cell interdepends on TRIM37/CRL4B and MDM2 like it does for 
RING1B and MDM2. In a possible scenario, we would be able to determine a specific H2AK119 
ubiquitin ligase threshold which is needed for cellular survival. 
Analyzing whether Ring1b or any other H2AK119 ubiquitin ligase is able to cover up a possible 
phenotype in the p53-/- Mdm2-/- mouse would be a major breakthrough. Since the ko phenotypes 
of the Mdm2-/-- and the p53-/- Mdm2-/- mouse are apparently ruling out developmental functions 
for Mdm2 it will always be hard to completely understand the results of this project. Generation 
of a p53-/- Mdm2-/- mouse that carries an inducible and/or organ specific Ring1b ko could be an 
option to address this question. However, loss of Ring1b has already been associated with a 
massive loss of H2AK119ub1 and was also found to be embryonically lethal (Voncken et al, 
2003). This means that the majority of H2AK119 ubiquitination is carried out by Ring1b and not 
Mdm2. It could be hard to discriminate the additional consequences of the loss of Mdm2 in the 
Ring1b ko system.  
Apart from interaction with proteins of the PcG, MDM2 interacts with a multitude of different 
proteins (cf. Figure 2-5). Since several factors are known transcription factors or modulators of 





the PRC proteins and/or its stabilization of the H2AK119ub1 mark. Possible candidates include 
P53 (Momand et al, 1992), E2F1 (Zhang et al, 2005) and p300 (Grossman et al, 1998). Further 
analysis of this interactive network and the consideration of these results into drug design will 
improve the development of a targeted cancer therapy. 
Last but not least, we have to validate the therapeutic relevance of our findings. As outlined in 
paragraph 5.8, many different compounds have already been developed to target MDM2 or 
MDM4 but mainly in respect to P53 re-activation. We are especially interested in the 
compounds that inhibit E3 ubiquitin ligase function or lead to MDM2 degradation, since several 
of them were correlated with p53-independent functions of MDM2 leading to cell arrest and 
apoptosis. A possible experiment would include the treatment of p53 wt and p53 ko cells with an 
inhibitor like JNJ-26854165 or HLI98. Cells responsive towards treatment can be analyzed for 
PRC2 target gene expression as well as H3K27me3 and H2K119ub1 levels in order to validate 
whether the p53-independent effects of these compounds are based on the MDM2 epigenetic 
function described here. As a follow up, xenografts from p53 wt and -ko cells can be tested in an 
in vivo approach. 
 
The results of this project answered a few, and raised many new questions and I want to finish 
this thesis with a fitting quote from Sir David Lane:  
“Why have C. elegans and D. melanogaster evolved new ways to control p53 that nevertheless 
allow it to respond to the very same damage and developmental clues that the lost system of 
Mdm2-based control has perfected? How can such highly conserved genes be dispensable for 
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